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Abstract	  
 
Introduction: The endothelial mucosal cell adhesion molecule (MAdCAM-1) is 
considered to be critically important in recruiting lymphocytes expressing the α4β7 cell 
surface integrin. In addition to its well-characterised role in the normal gastrointestinal 
tract, there is emerging evidence of its role in liver and gastrointestinal inflammation.  The 
ability to detect MAdCAM-1 has thus far been challenging, hindering progress into studies 
to explore its modulation. 
Aims: (i) To characterise MAdCAM-1 in the liver and gut, (ii) establish an in vitro 
model system of MAdCAM-1 and (iii) investigate the factors leading to its expression 
and subsequent modulation. 
Methods: I have described novel methods of detecting MAdCAM-1 by: 
1. Characterising its presence in the human liver, gut and associated tissues e.g. pancreas. 
2. Developing a reverse transcriptase–polymerase chain reaction (RT-PCR) technique so as 
to detect MAdCAM-1 in the gastrointestinal system and thus quantify its expression using 
Real-Time RT-PCR analysis. 
3. Developing an in vitro cell culture system using the endothelial SVEC4-10 cells to express 
and subsequently modulate the expression of MAdCAM-1. 
Results: Using immunohistochemical methodology I found that in end stage chronic liver 
disease, MAdCAM-1 is expressed primarily on the peribiliary plexus and lymphoid 
aggregates, where it may facilitate lymphocyte egress.  MAdCAM-1’s constitutive 
expression was confirmed in histologically normal gut tissue and its upregulation was 
demonstrated in ulcerative colitis and Crohn’s disease, particularly localised to the venular 
endothelium of the lamina propria and follicular dendritic cells. MAdCAM-1 mRNA from 
human gut was measured by a RT-PCR technique in which a 94 base pair product 
consistent with human mucosal vascular MAdCAM-1 was detected in normal large bowel. 
Real Time analysis confirmed that MAdCAM-1 was upregulated in end stage liver 
disease. In a cell culture system MAdCAM-1 was shown to be upregulated by TNFα on 
SVEC4-10 using immunofluoresence studies and its expression was further modulated by 
steroids and anti-sense oligonucleotides. 
Conclusion: The importance of MAdCAM-1 in the gastrointestinal system is emphasised 
throughout. Our in vitro culture system utilising the SVEC endothelial cell line provides 
the basis for studying the modulation of MAdCAM-1 expression.  
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Synopsis	   	  
 
Chapter 1 acts a general introduction to adhesion molecules, leukocyte recirculation and 
the role of adhesion molecules in the pathogenesis of diseases affecting the closely 
related tissues of the liver and gut, which offer novel opportunities for treatment. The 
focus of attention is mucosal addressin cell adhesion molecule (MAdCAM-1) as this is 
now considered to be the major adhesion molecule involved in directing leukocytes to 
the gut and related tissues. 
 
Chapter 2 describes the detection of MAdCAM-1 in liver disease, inflammatory bowel 
disease (IBD) and pancreatic disease. The liver disease included primary sclerosing 
cholangitis and those unrelated to gut inflammation e.g.  primary  biliary cirrhosis, 
alcoholic liver disease and  hepatitis C. Immunohistochemistry was used to characterise 
the specific MAdCAM-1 immunoreactivity patterns in endothelium lined vessels and 
lymphoid aggregates. Blood vessel endothelium expresses MAdCAM-1 in immune 
mediated chronic cholestatic diseases (PBC and PSC). The expression of MAdCAM-1 
in vascular beds of the peribiliary plexus and lymphoid aggregates in end-stage liver 
cirrhosis of PSC and PBC may contribute to the localisation and recruitment of α4β7 
lymphocytes to the bile ducts during the pathogenesis of these conditions. Furthermore, 
there was lack of MAdCAM-1 in pre-cirrhotic liver tissues.  The differential expression 
of MAdCAM-1 in IBD unrelated to liver disease is also described, where the findings 
confirm the upregulation of MAdCAM-1 venules in IBD and shows Crohn’s disease to 
be characterised by MAdCAM-1 venules in the deeper layers of the intestinal tissue, 
reflecting the transmural nature of the inflammation. 
 
Chapter 3 describes the development of an in vitro model of MAdCAM-1 expression 
utilising the murine endothelial cell lines SVEC4-10 and bEND3 to investigate 
mechanisms leading to its upregulation and detection of expression using 
immunofluoresence. TNF-α stimulation caused MAdCAM-1 upregulation, 
demonstrated with a dose response curve and time course analysis. Maximal 
MAdCAM-1 expression occurred at 24 and 72 hours after stimulating bEND3 and 
SVEC4-10   cells respectively. 
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Chapter 4 describes the development of reverse transcriptase polymerase chain reaction 
(RT-PCR) of murine and human MAdCAM-1 in cell culture and tissues MAdCAM-1 
was present constitutively in histologically normal gut tissues. Real time RT-PCR 
allowed quantification of MAdCAM-1 mRNA and confirmed its upregulation in end 
stage cirrhotic liver tissues. Therefore, the ability to detect the presence of MAdCAM-1 
and quantify its expression could be useful in the diagnosis and management of other 
chronic inflammatory diseases e.g. IBD. 
 
 Chapter 5 studies the effect of modulating MAdCAM-1 using the SVEC 4-10 cell 
culture system (previously described in chapter 3).  The model allowed efficient testing 
of specifically designed strategies to modulate expression MAdCAM-1 in an in vitro 
setting. Such potential strategies include administration of anti-inflammatory cytokines 
such as IL-10, dexamethasone, and anti-sense oligonucleotide sequences targeted to 
MAdCAM-1. The principles underlying antisense therapies and their utility as potential 
therapeutic targets are described. 
 
Chapter 6 discusses the overall contribution of MAdCAM-1 to gastrointestinal 
inflammation thus far and the role of existing and newer agents to its modulation.  
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1.1	   	   Background	  
 
This chapter summarises the evidence that adhesion molecules (including MAdCAM-1) 
are critical in lymphocyte recirculation and pathogenesis of diseases affecting the 
closely related tissues of the liver and gut, which offer novel opportunities for 
modulation and treatment. 
 
1.1.1	  	  Leukocyte	  trafficking	  	  
 
Leukocytes continuously recirculate between the blood and tissues. They traffic to 
organs and subsequently leave the circulation via lymph nodes. Some are naïve, others 
have been programmed to recognise antigens and interact with endothelium and thus 
disseminate preferentially (i.e. “home”) to the site of original antigen exposure.  
 
In the absence of inflammation, circulating virgin leukocytes traffic preferentially in a 
physiological circulation to secondary lymphoid tissue e.g. lymph nodes, spleen and 
gut-associated lymphoid tissue (GALT), where requirements for effective antigen 
presentation and differentiation are fulfilled. The exit from the blood mainly takes place 
in unique post-capillary venules high endothelial venules (HEV) (Girard et al 1995). 
These are near-cuboidal cells displaying functional modifications to facilitate leukocyte 
extravasation. Migration through HEV’s appears to be very specific. Leukocytes 
circulating in the blood are able to discriminate between the HEV endothelium and 
endothelium lining non-lymphoid tissues. It has been estimated that approximately 1.4 x 
104 lymphocytes extravasate from blood into a single lymph node via HEV’s every 
second and that 25% of lymphocytes circulating in HEV’s will bind and emigrate 
(Butcher et al 1991).  If lymphocytes are presented with antigens, they proliferate by 
clonal expansion. Lymphocytes can exit from lymphoid tissues via efferent lymphatics 
to re-enter the systemic circulation. 
 
When tissues become inflamed, leukocytes including lymphocytes are recruited to those 
sites.  The mechanisms of recruitment involve combinations of molecules expressed on 
the leukocytes and on the endothelium.  Addressins are key partners in these processes, 
being tissue molecules that provide a unique molecular address, allowing leukocytes 
expressing the corresponding molecular ligands to target to particular organs (Vidal-
23 
 
Vanaclocha et al 1993) (Salmi et al 1998).  Granulocytes and monocytes also emigrate 
from the blood stream in response to molecular changes on the surface of blood vessels 
that signal injury or infection; they cannot recirculate. The processes governing 
emigration of cells from the circulation into tissues were first defined for neutrophils, 
but similar processes pertain for lymphocyte homing as well, although the latter process 
is more complex.  
 
1.1.2	   	   Adhesion	  molecules,	  cell	  trafficking	  &	  recruitment	  
 
Adhesion molecule is a general term for the molecules involved in the recruitment 
process, which are surface bound glycoprotein molecules expressed on leukocytes 
and/or endothelial cells. They share common characteristics acting as a molecular link 
between the external and internal milieu of the cell. They are all trans-membrane 
proteins with different domains, the largest of which is extracellular, attached to an 
intra-membranous segment linked to a cytoplasmic functional domain, through which 
they can influence cell function e.g. modulating the cytoskeleton of the cell and 
activating secondary messenger systems. 
 
The molecular mechanisms of leukocyte extravasation are well characterised in a 
“multistep paradigm” (Figure 1.1 and 1.2). This describes the overall process of 
extravasation as a three-step mechanism consisting of i) tethering and rolling of 
leukocytes on the endothelium ii) activation of integrins iii) firm adhesion and 
transmigration. 
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                              Leukocyte activation 
         
 
 
 
Fig	  1.1	  Transmigration of leukocytes through vascular endothelium.	  Normally,	  there	  is	  random	   contact	   between	   leukocytes	   and	   vascular	   endothelium.	   However,	   following	   vascular	  endothelium	  activation,	   leukocytes	  roll	  on	  to	   it,	  adhere	  and	  transmigrate	  between	  the	  endothelial	  cells	  to	  reach	  the	  areas	  of	  inflammation.	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The main classes of adhesion molecules are integrins, selectins, and cadherins. As 
already mentioned, endothelial adhesion molecules with a dominant role in tissue-
specific migration are often called “vascular addressins”; their counter-receptors on 
leukocytes are called “homing receptors”. Cells can express adhesion molecules 
constitutively (e.g. endothelial cells of the HEV in lymph nodes), or up-regulate them 
on exposure to cytokines, chemokines, or other pro-inflammatory molecules such as 
activated complement products and microbial metabolites.  There are several families of 
adhesion molecules, which participate variously in immune and inflammatory 
processes, based on structure, function, and location. 
 
1.1.2.1	   Tethering	  and	  rolling	  
 
Blood borne leukocytes are displaced from the central flow of the vessel, largely in 
regions of the microvasculature i.e. post-capillary venules. These tethering contacts lead 
to cells rolling at an estimated velocity of 10-50µm/s, slower than the erythrocyte which 
is typically 4000µm/s (Springer 1990). Adhesion molecules called selectins mediate 
these readily reversible contacts, controlling both tethering and rolling (Pachynski et al 
1998). These molecules are constitutively active and presented on the tip of microvillus 
projections, considerably higher than the planar surface, making them suitable 
candidates for initial contacts. The patterns of leukocyte recirculation depend upon the 
combinations of molecules expressed on the leukocyte and the combinations of 
addressins and other molecules providing individual tissues with a unique molecular 
address. 
 
1.1.2.2	   Activation	  of	  integrins	  
 
 The integrin activation step is thought to involve binding of chemotactic cytokines  
(called chemokines) immobilized by glycoaminoglycans on the endothelial glycocalyx 
(Gunn et al 1998).  Chemokines binding to specific G protein–coupled receptors on the 
lymphocyte trigger cytoskeletal rearrangement and thus activation of the leukocyte. The 
lymphocyte is therefore able to bind to the endothelium, resist the high shearing forces 
imposed on it and stop within the vessel (Berlin et al 1993).  
 
 
26 
 
 
                                                                              LEUKOCYTE 
 
 
 
 
 
 
 
 
 
 
 
           
    
 
 
 
 
 
 
 
 
 
 
 
Figure	  1.2 Adhesion molecules involved in leukocyte emigration 
         
 
    ROLLING 
 
FIRM 
ADHESION 
     
 
 
                          
 
ACTIVATION 
 
  TRANSMIGRATION 
27 
 
1.1.2.3	   Firm	  adhesion	  and	  migration	  
 
 The “stable” cell then seeks inter-endothelial cell junctions through which it can 
migrate within tissues and adhesion molecules expressed on the surface of endothelial 
cells ensure orderly sequence of cell-cell interactions. 
   
1.1.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Leukocyte	  migration	  into	  the	  liver	  and	  gut	  	  
 
The gut has a specialised immune system appropriate to its exposure to the major 
antigen challenge from the lumen, consisting of food products and bacteria. Antigen 
enters intestinal mucosa via ‘M’ (microfolded) cells, the specialised epithelium above 
the lymphoid follicles. Peyer’s patches represent organised lymphoid structures, 
appearing different from lymphoid follicles because they lack afferent lymphatics. 
Within Peyer’s patches the mucosal immune response is initiated by the uptake and 
processing of antigenic material by macrophages, follicular dendritic cells and its 
presentation to T and B cells. Here, lymphocytes bind to specialised HEV’s. If the naïve 
lymphocyte is not exposed to antigen it leaves Peyer’s patches and returns into the 
systemic circulation via efferent lymphatics. However, if the lymphocyte makes contact 
with its antigen it divides and differentiates into effector or memory cells. These 
immunoblasts are transported via the lymphatics into mesenteric lymph nodes and 
eventually into the blood with wide dispersion throughout the body.  
 
The liver shares a common embryological origin with the gut (from the endoderm), and 
it too has a distinct endothelial phenotype characterised by expression of several 
adhesion molecules. Furthermore, the liver like the gut epithelium is an important site of 
exposure to foreign antigens, particularly through the portal vein and thus needs to be 
able to respond efficiently to pathogens. Mechanisms by which the liver may modify 
gut-derived antigens range from conceptually simple filter functions of the reticulo-
endothelial system to complex processes such as induction of systemic tolerance.  
 
The resident leukocytes within normal liver include natural killer lymphocytes and a 
large number of functional memory/effector T cells which are removed from the 
circulation by the liver and continue to provide ongoing immune surveillance. Common 
mechanisms for leukocyte homing to both the gut and liver would make good sense in 
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evolutionary terms as the first port of call for the blood from the gut carrying nutrients 
(and potentially hazardous compounds), is the liver.  However, unlike the gut, 
lymphocyte recirculation in the liver is less well defined and the exact route of entry for 
lymphocytes into portal tracts remains unclear.   
 
There are three vascular routes by which T cells may enter the liver. Firstly, via portal 
vessels in the portal tracts; secondly, directly into the parenchyma from the hepatic 
sinusoids and finally via the central vein of the lobule. The sinusoids comprise a unique 
vascular bed which has a low velocity blood flow and which unlike other vascular beds 
does not require capture mediation by selectins. Lymphocytes are seen in portal tracts in 
the normal liver and heavy infiltration is observed in inflammatory liver diseases e.g. 
Hepatitis C.  The portal vessels empty into sinusoids but do not normally appear to have 
morphological evidence of post-capillary venules (high endothelial venules). However, 
the presence of new vessels at sites of lymphocytic infiltration is intriguing. These 
vessels appear to have phenotypic similarities with high endothelial venules; they have 
been described within portal tracts in chronic viral hepatitis where they could facilitate 
the recruitment of lymphocytes and may be important in regulating T-cell recirculation 
to the liver (Garcia-Monzon et al 1995). 
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1.2	  	   Classes	  of	  cell	  adhesion	  molecules	  in	  the	  liver	  and	  gut	  
 
1.2.1	  	  	   Selectins	  
 
The selectin family consists of three closely related cell-surface molecules: P-selectin, 
E-selctin and L-selectin The selectin family shares a common mosaic structure 
consisting of a lectin, carbohydrate and single epidermal growth factor-like domains, 
including a series of 2-9 short repeats similar to those found in complement regulatory 
proteins. The lectin domain is the central structure of the molecule concerned with 
receptor  binding because it interacts efficiently with molecules containing fucosylated, 
sialylated and related sulphated carbohydrate ligands (Lasky 1995). Selectin function is 
uniquely restricted to the vascular system and expression of individual selectins varies 
in the different inflammatory conditions summarised in Table 1.1  
 
The ligands for selectins are glycoproteins and   include P-selectin glycoprotein-1 
(PSGL-1), E-selectin ligand-1 (ESL-1) and CD44. Both ESL-1 and CD44 are ligands 
for E-selectin. Glycosylation-dependant cell adhesion molecule-1(GlyCAM-1) and 
CD34 are both members of the peripheral node addressin family (PNAd) which serve as 
ligands for L-selectin. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1),  a 
member of the immunoglobulin superfamily, may also serve as a ligand for L-selectin, 
when it is appropriately glycoslyated. Specifically,  PSGL-1 has the ability to  bind to 
all three selectins when appropriately glycosylated; binding of PSGL-1 to L-selectin 
(both expressed on leucocytes) can mediate a secondary tethering process, so that 
leucocytes expressing PSGL-1 can adhere to leukocytes already rolling on L-selectin.  
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Table	  1.1	  The  ligands,  localisation, expression and functions of the selectin family 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selectin 
(Receptor) 
 Ligand(s) 
Location        Expression           Functions 
E-selectin 
E-selectin 
ligand-1 
(ESL-1), 
CD44, 
cutaneous 
lymphocyte 
ligand (CLA) 
Vascular 
endothelial 
surface 
Transcriptionally 
induced by pro-
inflammatory 
mediators and LPS 
Eosinophils, neutrophils and monocyte 
adhesion during acute inflammation. 
Facilitates migration of T cells to skin 
P-selectin 
P-selectin 
glycoprotein-1 
(PSGL-1) 
Plateletα granules 
& endothelial cell 
Weibel-Palade 
bodies 
Granule/plasma 
membrane fusion in 
response to thrombin, 
histamine,substance P 
Eosinophils, neutrophils monocytes, 
adhesion during acute inflammation and 
thrombosis 
 
L-selectin 
Peripheral 
node 
addressin 
(PNAd), 
MAdCAM-1 
Leukocytes 
Expressed until 
leukocytes are 
activated, then shed 
Acute neutrophil mediated inflammation, 
peripheral lymph node homing 
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1.2.1.1	  	   E-­	  selectin	  (expressed	  on	  endothelial	  cells)	  
 
E-selectin is also known as endothelium leukocyte molecule ELAM-1 or CD62E. E-
selectin is barely expressed by the inactivate endothelium, but its expression is 
upregulated during inflammation when vascular endothelium becomes activated by pro-
inflammatory cytokines or lipopolysaccharides.  As well as facilitating the emigration 
of leukocytes into tissues, most notably neutrophils, it also promotes adhesion of resting 
CD4 memory cells to activated endothelium (Shimizu et al. 1991). Interferon γ (IFNγ) 
appears to stabilise E-selectin expression without prolonging its duration of synthesis 
(Doukas et al 1990). 
 
While the majority of endothelial cell surface E-selectin is thought to be removed from 
the cell surface by internalisation, some of it is shed in a circulating soluble form (Patel 
et al 1995). The expression of E-selectin as a circulating soluble adhesion molecule is 
up-regulated by transcription from TNF-α, IL-1 and LPS in inflammatory bowel disease 
(IBD).  
 
E-selectin is not expressed in the normal liver. (Bevilacqua et al. 1989). However, 
during endotoxaemia or septic shock its mRNA expression is seen in large vessel 
endothelial cells but also to a lesser degree on the sinusoidal lining (Adams et al 1994). 
Similar induction is found in liver from alcoholic hepatitis, primary biliary cirrhosis 
(PBC) and acute allograft rejection (Mueller et al. 1996) (Wong et al. 1997). 
 
1.2.1.2	  	   P-­selectin	  (expressed	  on	  endothelial	  cells	  and	  platelets)	  
 
P-selectin is stored in Weibel–Palade bodies of endothelial cells and produced by alpha 
granules of platelets (Diacovo 1996). It is released after activation of platelets with 
histamine or thrombin, during clotting and mediates adhesion between leukocytes and 
platelets. During inflammation, endothelial P-selectin acts to recruit leukocytes into 
postcapillary venules, while platelet associated P-selectin promotes aggregation of 
leukocytes with platelets to form thrombi. Endothelial cells can also synthesise and 
express P-Selectin in response to endotoxin or cytokines. However, important species 
differences have been observed in response to these stimuli. TNF α and endotoxin 
increase expression of P-selectin in murine endothelial cells, but do not do so in human 
                       Table 1.2.1A : The Selectin family                                         
 
. 
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endothelial cells (Gotsch et al. 1994). This differential response may be related to 
differences in the P-selectin promoter among species. (Weller et al 1992) 
 
1.2.1.3	  	   L-­selectin	  (expressed	  on	  leukocytes)	  
The majority of B cells, virgin T cells, most neutrophils, monocytes and eosinophils 
express L-selectin (also known as LECAM-1, LAM-1, Mel-14 antigen, gp90mel, and 
Leu8/TQ-1 antigen). L-selectins are the smallest of the vascular selectins and are 
important in lymphocyte homing and adhesion to high endothelial venules of peripheral 
lymph nodes contributing largely to the capture of leukocytes during the early phases of 
the cell adhesion cascade (Berg et al 1993) (Collett  et al 1999). The broad expression 
of L-selectin explains its critical role in the trafficking of all leukocyte lineages into 
secondary lymphoid tissues and peripheral sites of injury and inflammation.  Following 
capture, L-selectins are shed from the leukocyte surface after chemo-attractant 
stimulation, which limits the ability of these cells to roll on endothelial cells. They have 
been implicated in the binding and tethering of neutrophils to activated endothelium via 
different vascular adhesion molecules (Sitrin et al 2001). Interferon α is the only 
cytokine reported to increase surface density of L-selectin, correlating with increased m-
RNA levels (Evans et al 1993). 
	  
1.2.2	  	   	  	   The	  Immunoglobulin	  (Ig)	  Superfamily	   	   	  
	   	   	  
The Ig superfamilies are calcium independent transmembrane glycoproteins. Each Ig 
superfamily has extra-cellular domains, which contains several Ig-like disulphide 
bonded loops with condensed cysteine residues, a transmembrane and an intracellular 
domain, which interacts with the cytoskeleton. The Ig superfamily includes ICAM-1, 
ICAM-2, VCAM-1, and MAdCAM-1 (Table 1.2). All members of this family are 
expressed or inducible on vascular endothelium and only ICAM-1 and ICAM-2, very 
rarely VCAM (but not MAdCAM-1) may also be expressed by leukocytes. 
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ADHESION 
MOLECULE 
 
ALTERNATIVE 
NAME 
 
LOCALISATION CONSTITUTIVE INDUCIBLE LIGAND FUNCTION 
 
ICAM-1 
 
CD54 
 
Endothelium Yes Yes LFA-1 
Mac-1 
CD43 
Adherence/Emigration 
VCAM-1 CD106 Endothelium Very small Yes VLA-4 Adherence 
MAdCAM-1    Endothelium Yes (gut only) Yes Lselectin 
α4β7 
 
Adherence/Emigration 
Table	  1.2	  Adhesion super immunoglobulin glycoproteins involved in leukocyte-endothelial  
interactions in the liver 
 
 
 and gut 
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1.2.2.1	  	  	  	  	  	  	  	  	  	  	  	  	  Intercellular	  adhesion	  molecule-­1	  and	  2	  (ICAM-­1,	  ICAM-­2)	  
 
Both ICAM-1 and ICAM-2 are receptors for LFA-1. They are either constitutively 
present on capillary endothelium or may be induced by the cytokines TNFα, IL-1, IFN-
γ and LPS (Ayers et al 1993). ICAM-1 is also expressed on activated T cells, B cells, 
and monocytes. In these cells ICAM-1 contributes to the adhesion between interacting 
lymphocytes, and between lymphocytes and antigen presenting cells or other target 
cells. ICAM-1 may be up-regulated at sites of immune reaction where it controls the 
enhanced movement of lymphocytes into sites of inflammation. ICAM-1 binds to the β2 
integrins, lymphocyte function-associated antigen-1 (LFA) and also has a binding site 
for certain viruses e.g. rhinovirus (Tian et al 1997). 
 
1.2.2.2	  	  	  	  	  	  	  	  	  	  	  	  	  Vascular	  cell	  adhesion	  molecule-­1	  (VCAM-­1)	  
 
VCAM-1 appears to be important in controlling lymphocyte migration. VCAM-1 is less 
widely distributed than ICAM-1 and is expressed by germinal centre dendritic cells, 
interdigitating cells, Kupffer cells, synovial lining cells and renal proximal tubule cells. 
VCAM-1 is induced on the endothelium by cytokines with a similar time course to  E-
selectin  showing maximal transcript levels for both VCAM-1 and E-selectin  at 3-6 
hours with a decline to low, constitutive levels of expression at 48 hours (Fries et al 
1993). VCAM-1 is primarily involved in lymphocyte and monocyte-endothelial cell 
interactions and binds to an integrin of the VLA4 class expressed on all leukocytes 
except neutrophils. T cell activation leads to kinase-induced conformational changes of 
VLA-4, increasing the avidity of binding with VCAM-1.  
 
1.2.2.3	  	  	  	  	  	  	  	  	  	  	  	  Platelet	  endothelial	  cell	  adhesion	  molecule-­1(PECAM-­1)	  
 
PECAM-1 is found on platelets, leukocytes and endothelial cells. Its expression is 
stimulated by cytokines e.g. TNFα, IL-1 and IFN-γ (Bujan et al 1999). Endothelial cells 
express PECAM-1 on their lateral cell membranes. This distribution suggests three 
main functions involvement in endothelial cell junction, mediation of leukocyte 
movement between endothelial cells and binding of platelets to injured endothelium.  
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1.2.2.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Mucosal	  addressin	  cell	  adhesion	  molecule-­1	  (MAdCAM-­1)	  
 
Human MAdCAM-1 is a 60-kDa endothelial cell adhesion molecule, which combines 
two immunoglobulin-like domains and a mucin like region between Ig domain 2, and 
the endothelial surface (Figure 1.3) (Tan et al 1998) (Streeter et al 1988). It can bind 
two distinct lymphocyte receptors, L-selectin and the α4β7 integrin (Erle et al 1994). 
Thus, within Peyer’s patches MAdCAM-1 is covered with unique oligosaccharide 
determinants, which allow it to serve as a ligand to L-selectin and mediate rolling of 
naïve lymphocytes. This is in contrast to the vasculature of the lamina propria where 
initial rolling interactions between activated lymphocytes and endothelial cells are 
apparently mediated by binding of α4β7 and immunoglobulin like domains of 
MAdCAM-1 (Figure 1.3). 
 
In the study by Dando et al (2002) a dimeric form of MAdCAM-1 was observed created 
by two symmetry-related full-length molecules within the srystal lattice, through an 
extensive interface formed by residues from the edge of a B-sandwich in domain 1. 
Such edge-to-edge dimerisations of Ig domains have also been reported for human 
ICAM-1. In addition the fact that the two Ig domains of MAdCAM-1 project 
approximately 22nm away from the cell surface by an extended domain indicates that 
there are no steric restrictions for the formation of a dimmer.  It is interesting to note 
that the arginine (Arg)70 residue important for integrin recognition also contributes to 
the formation of the MAdCAM-1 via formation of bifurcated charged hydrogen bonds 
across the dimmer interface. (Figures 1.4 and 1.5). Mutational analysis experiments that 
identified the significance of (Arg)70 in integrin binding might suggest that the 
diminished integrin binding of the mutants could well be a consequence of dimeric 
structure discruption, thus suggesting that the arrangement of MAdCAM-1 in a dimeric 
form is essential for activity.  
 
MAdCAM-1’s important role is in regulating lymphocyte trafficking to both normal and 
inflamed mucosal tissues, specifically in the maintenance of mucosal immunity and the 
regulation of inflammation of the gastrointestinal tract (Briskin et al 1997). It has been 
shown to participate in directing lymphocyte traffic into the lamina propria of the small 
and large intestine, the inflamed pancreas and the lactating mammary gland. Its 
constitutive expression is restricted to endothelium lining a subset of blood vessels and 
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mucosal associated lymphoid tissue in stomach, small intestine, large bowel, pancreas, 
marginal zone of the spleen, inflamed choroid plexus and gall bladder (Auth et al 1993). 
 
1.2.2.4.1	  	  	  	  	  	  	  	  	  	  	  	  Expression	  of	  MAdCAM-­1	  during	  development	  
 
Up to 20% of thymocytes are CD4 or CD8, reacting with soluble MAdCAM-1, via 
α4β7. However, after birth soluble MAdCAM-1 reactive thymocytes are rapidly down 
regulated and MAdCAM-1 expression in thymic blood vessels disappears. In the 
developing gastrointestinal tract of rodents MAdCAM-1 is expressed widely in the 
venules of lamina propria and follicular dendritic cells in neonatal Peyer’s patches 
(Iizuka et al 2000). It is also expressed transiently in non-mucosal tissues during fetal 
life of rats e.g. vascular endothelial cells in the skin. Immune cell trafficking in utero 
and early human life is dominated by MAdCAM-1 (Salmi et al 2001a). During this 
period there are interestingly age dependant switches and species dependant class 
switches in the molecular mechanisms of lymphocyte migration MAdCAM-1 is widely 
expressed from week seven onwards of embryogenesis found to be present in  
microvessels of many extraintestinal  tissues e.g. peripheral lymph nodes, thymus, 
spleen, pancreas, skin, muscle, kidney. Gradually MAdCAM-1 becomes polarised to 
mucosal vessels after birth until adulthood, where it is the most tissue-specific 
endothelial adhesion molecule known. In utero MAdCAM-1 functionally governs 
lymphocyte adhesion to vessels both in the gut and peripheral lymph nodes binding to 
α4β7 integrin. MAdCAM-1-α4β7 pathways are fully operative in utero and MAdCAM-
1 mediated binding shows a more prevalent role both at the mucosal/non mucosal sites 
in utero and in newborns than in adults. Fetal MAdCAM-1 may be involved in the 
immigration of bone marrow T-lymphocytes precursors into thymus or in a population 
of splanchnic mesoderm during development. Induction of peripheral node addressin 
gradually starts to dominate the binding of lymphocytes to PLN during childhood. 
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Figure	   1.3	   Schematic diagram adapted from Briskin et al (1996) demonstrating 
murine & human MAdCAM-1 superimmunoglobulin protein structure. The	   encoded	  MAdCAM-­‐1	  protein	  is	  a	  40kDa	  protein,	  which	  is	  extensively	  post-­‐transcriptionally;	  modified	  in	  vivo,	  through	  0-­‐linked	  glycosylation	  leading	  to	  the	  formation	  of	  60kDa	  mature	  glycoprotein.	  MAdCAM-­‐1	  comprises	  two	  N-­‐terminal	   Ig	  domains	  of	  52	  and	  71	  amino	  acids	  and	  both	  separated	   from	  the	  cell	  surface	  by	  a	  mucin	   like	  region.	  Human	  MAdCAM-­‐1	   is	  made	  up	  of	  a	   transmembrane	  domain	  of	  20	  hydrophobic	   residues	   and	  a	  43	  amino	  acid	   tail,	  which	   is	   longer	   than	   the	  murine	  homologue.	  The	  extracellular	   domain	   of	   murine	   MAdCAM-­‐1	   contains	   an	   additional	   Ig	   domain,	   adjacent	   to	   the	  transmembrane	  segment	  that	  displays	  high	  homology	  to	  IgA1	  and	  is	  separated	  from	  the	  second	  Ig	  domain	  by	  a	  mucin-­‐like	   region.	   In	  humans	  MAdCAM-­‐1	  has	  compensated	   for	   the	   lack	  of	  a	   third	   Ig	  domain	   (present	   in	   murine	   and	   other	   species)	   by	   extending	   its	   mucin	   domain	   as	   two	   separate	  regions	   (major	  &	  minor	  domain)	   so	  as	   to	  hold	   the	   two	  N-­‐terminal	   ligand-­‐binding	  domains	  above	  the	  glycocalyx	  for	  presentation	  to	  αβ47.	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Figure	  1.4	  Ribbon representation of the N-terminal two-domain crystal structure of 
human MAdCAM-1	   (PDB	   id	   1GSM).	  The	   pivotal	   elements	   for	   α4β7	   integrin	   recognition	   and	  binding	  to	  human	  MACAM-­‐1	  are	  aspartate	  residue	  (Asp42)	  in	  the	  CD	  loop	  of	  domain	  1,	  a	  negatively	  charged	  B-­‐ribbon	   on	   the	  DE	   loop	   of	   domain	   2	  which	   actually	   stretches	   out	   far	   from	   the	   body	   of	  domain	   2	   and	   optimally	   orientates	   domains	   1	   and	   2	   for	   recognition	   of	   integrin	   and	   an	   arginine	  (Arg)70	   in	   domain	   2,	   critical	   for	   formation	   of	   a	   MAdCAM-­‐1	   dimeric	   	   form.	   This	   figure	   has	   been	  produced	  by	  UCSF	  CHIMERA	  package	  (Dando	  et	  al	  	  2002). 
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Figure	   1.5	   Surface structure of human MAdCAM-1 showing the relationship of 
aspartate residue (Asp42) in the CD loop of domain 1 and arginine (Arg70) in 
domain 2 (PDB	  id	  1GSM).	  	  	  The	  binding	  site	  for	  α4β7	  is	  buried	  in	  	  domain	  1	  surrounded	  by	  seven	  hydrophobic	  residues	  with	  no	  evidence	  of	  negatively	  charged	  residues	  in	  the	  vicinity	  to	  neutralise	  the	  strong	  positive	  charge	  critical	   for	   formation	  of	  a	  MAdCAM-­‐1	  dimeric	   	   form.	   In	  the	  monomeric	  form	  of	  MAdCAM-­‐1,	  this	  leaves	  the	  arginine	  surface	  accessible	  and	  potentially	  free	  to	  interact	  with	  ligand.	  This	  and	  other	  figures	  have	  been	  produced	  by	  UCSF	  CHIMERA	  package	  (Dando	  et	  al	  2002).	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1.2.2.4.2	  	  	   Regulation	  of	  MAdCAM-­1	  expression	  
 
The micro environmental factors which maintain preferential expression of MAdCAM-
1 on gut endothelial cells are elusive. Human microvasculature endothelial cell cultures 
(HIMEC) established from the small intestine appear to lose their expression of 
MAdCAM-1 within a few days in vitro (Haraldsen et al 1996). Two endothelial cell 
lines bEND.3 (brain) and SVEC (high endothelium) have been used to study the signal 
pathways which regulate MAdCAM-1 in response to TNFα (Takeuchi et al 1995), 
which induces MAdCAM-1 mRNA and protein in a dose and time-dependant manner 
(Oshima et al 2001a). This induction is tyrosine kinase (TK), p42/44, p38 mitogen-
activated protein kinase (MAPK) and nuclear factor (NF)-κB/poly-ADP ribose 
polymerase (PARP) dependent. MAdCAM-1 expression requires NF-κB translocation 
through both p42/44 and p38 MAPK pathways in high endothelial cells. 
 
MAdCAM-1 is induced in both gut and liver inflammation. In the gut, MAdCAM-1 is 
expressed in the flat walled endothelial vessels of the non-lymphoid tissues of the 
lamina propria and the follicular dendritic cells of the organised lymphoid tissues of 
Peyer’s patches and mesenteric lymph nodes. MAdCAM-1 has been found to be 
expressed in primary sclerosing cholangitis (PSC) in which portal inflammation may be 
a prominent feature (Hillan et al 1999) (Grant et al 2001). Its expression has been 
described to be  restricted to the portal vasculature, particularly the portal veins and the 
specialised but not exclusively the HEV’s as well as at sites of portal tract lymphoid 
follicle formation where it may be localised to dendritic cells, similar to its related super 
Ig family member VCAM-1. These observations suggest that MAdCAM-1 may be 
important in inflammation where it is involved in the recruitment of lymphocytes to the 
liver. 
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1.2.2.5	  	  	   Carcinoembryonic	  antigen-­related	  cell	  adhesion	  molecule	  
(CEACAM-­1)	  	  
 
 Carcinoembryonic antigen (CEA)  is a glycosyl phosphatidyl inositol (GPI)-cell surface 
anchored glycoprotein involved in cell adhesion. It is normally produced during fetal 
development with its production ceasing before birth. Therefore, it is not usually present 
in the blood of healthy adults, although levels are raised in heavy smokers. CEA  serves  
as a functional ligand for colon carcinoma L-selectin and E-selectin receptors which 
may be critical to the metastatic dissemination of colon carcinoma cells.  
 
Carcinoembryonic Antigen-related Cell Adhesion Molecule-1 (CEACAM-1),  formely 
known as CD66a and biliary glycoprotein-1 (BGP-I)  is a 115 kDa transmembrane 
glycoprotein. It is a member of the CEA family, which belongs to the immunoglobulin 
superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and 
the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long 
arm of chromosome 19. In humans, the CEA family consists of 29 genes, 18 of which 
are normally expressed. 
 
The CECAM-1 combines structural features of the immunoglobulin superfamily with 
functional properties of the cadherin adhesion molecules (section 1.2.4). CEACAM-1 is 
expressed in a variety of normal human tissues including epithelial, endothelial, and 
hematopoietic cells. CEACAM-1 mediates cell–cell adhesion and regulates cell 
proliferation, apoptosis, tumor growth,  differentiation/polarisation of epithelial cells, 
NK cell cytotoxicity, and T-cell-mediated immune response. CEACAM-1 has been 
suggested as putative tumor suppressor and its expression is reduced in malignant 
tissues as compared with corresponding normal tissues deriving from breast, prostate, 
colon and endometrium. These findings indicate that CEACAM-1 may play a role in 
suppression of carcinogenesis. In contrast, Thies et al (2007) recently provided evidence 
that CEACAM-1 expression in primary tumors of malignant melanoma patients is 
associated with subsequent development of metastatic relapse. This observation raised 
the possibility that CEACAM-1 might facilitate metastatic tumor spread. In endothelial 
cells, CEACAM1 exhibits properties of an angiogenic factor and acts as a major 
effector of VEGF, suggesting that CEACAM-1 expression may promote metastasis by 
the induction of angiogenesis. 
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1.2.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Integrins	  
 
Integrins form a diverse family of proteins which mediate cell-matrix and cell-cell 
interactions. Integrins are constitutively expressed molecules on un-stimulated 
lymphocytes (LFA-1, α4β1, VLA-4, α4β7, αEβ7) and/or up-regulated on rolling 
lymphocytes in response to chemokines on endothelial surfaces. They become activated 
to enhance rolling and lead to tethering of the cells. Integrins consist of two 
heterodimers, with non-covalently associated αβ chains and short cytoplasmic tails 
(Berman et al 2000).  They “integrate” the activation of the cytoskeleton with the 
extracellular matrix by transducing messages via classical signal pathways and are 
important in cellular processes e.g. proliferation, apoptosis and differentiation (Arao et 
al 2000) (Masumoto et al 1999).  
 
Naïve lymphocytes express low levels of α4β7 integrin but upon activation significant 
amount appears on the lymphocyte surface in a functionally active form. α4β7 
positivity defines a discrete subpopulation of memory T cells (CD4+, CD8+) and 
probably B cells involved in mucosal immunity (Schweighoffer et al 1993). 
Monoclonal antibodies to MAdCAM-1 or α4β7 effectively inhibit migration of gut-
derived thoracic duct blasts and memory/effector T cells to the intestine. Unlike naïve 
lymphocytes gut homing blasts and memory cells express very low levels of L-selectin 
or lack it completely and do not need L-selectin to home to Peyer’s patches or the 
appendix. Instead, they can bind directly to endothelium via an activated α4β7. Of 
interest, the principal function of α4β7 appears to be interaction with MAdCAM-1 
where it acts as a rolling receptor and mediates firm adhesion to endothelium (Wagner 
et al 1996). 
 
LFA-1 appears to be instrumental in the contact between cytotoxic T lymphocytes and 
target cells where it binds to ICAM-1 (Sigal et al 2000); in the gut (Peyer’s patches and 
the lamina propria) the combination of α4β7-MAdCAM-1 interaction and possibly LFA 
–1 ensure firm lymphocyte adhesion. 
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1.2.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  E-­Cadherin	  
 
E-cadherin is a member of the large cadherin superfamily. It is the predominant 
intercellular adhesion molecule expressed by intestinal epithelial cells. It is a calcium 
dependent transmembrane protein, which forms a key component of the zone adherens.  
E-cadherin molecules form dimers at the cell surface which interdigitate with other E-
cadherin molecules on adjacent epithelial cells. The functions of E-cadherin are 
mediated through actin cytoskeleton linkage via a number of cytoplasmic catenin plaque 
proteins, leading to signal transduction. E-cadherin gene knockout mice have confirmed 
(Schon et al 1999) its critical importance to normal development and tissue function. 
Low or absent levels of E-cadherin are associated with a variety of epithelial 
malignancies arising from mutations in the E-cadherin promoter (Palmer et al 2001). 
These abnormalities are accompanied with increased tumour invasion, metastasis and 
poor survival. Decreased membranous expression of E-cadherin molecules have been 
found in a number of gastrointestinal solid organ malignancies in humans e.g. gastric, 
oesophageal, pancreas, liver, colon as well as breast, bladder and prostate. Direct 
correlation between E-cadherin and grade of tumour differentiation has been observed 
in some gastric tumours e.g. in a multivariate retrospective study, E-cadherin positive 
tumours had significantly better survival rates than E-cadherin negative tumours 
(Grabsch et al 2001). 
 
E-cadherin is thought to be exclusively involved in cell-cell adhesion and hence cancer 
cell metastasis and invasion. However, evidence also suggests a heterophilic interaction 
with α4β7 integrin, which is on the surface of predominately intra-epithelial 
lymphocytes and only on a minority of circulating lymphocytes (Taraszka et al 2000). 
This receptor ligand interaction may therefore be important in mediating the retention of 
lymphocytes within the mucosal epithelium. 
 
1.2.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CD44	  
CD44 is a multifunctional adhesion proteoglycan molecule able to mediate lymphocyte 
rolling on hyaluronate and  activate LFA-1 (figure 1.2).  Lymphocyte binding to 
mucosal endothelium can be partially blocked by anti-CD44 antibodies in vitro 
(Shepley et al 1994); CD44 may not be central in the homing of lymphocytes to normal 
44 
 
mucosal sites as CD44 deficient mice do not  have abnormalities in their mucosa 
associated lymphatic tissues (Steeber et al 1996). 
 
1.2.6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vascular	  adhesion	  protein	  (VAP-­1)	  
 
VAP-1 was discovered in the early 1990’s (Salmi et al 1992). It is an inducible human 
endothelial protein, which supports shear-dependant lymphocyte binding to HEV in 
peripheral and mesenteric lymph nodes. It has a dual role as it has also been shown to 
act as a semicarbazide-sensitive mono-amine oxidase (SSAO) in addition to its adhesive 
function which  involves binding to an uncharacterised lymphocyte counter-receptor by 
the oligosaccharide moiety of VAP-1. It is interesting to note that as an enzyme, VAP-1 
can convert soluble primary amines into corresponding aldehydes and hydrogen 
peroxide, in a reaction that results in the formation of biologically active products 
(Kurkijarvi et al 2000). At high concentrations these compounds are cytotoxic and may 
contribute to the pathogenesis of different vasculopathies, as indicated by studies 
demonstrating that SSAO inhibition ameliorates the development of atherosclerotic 
lesions in diabetic models (Obata 2006). 
 
The molecular characterisation and cloning of VAP-1 shows it to be a homodimeric 
170-180 kDa glycoprotein, consisting of two 90-kDa subunits, held together by 
disulphide bonds (Salmi et al 1997). VAP-1 has a large extracellular domain, a single 
transmembrane domain, and a short cytoplasmic tail. The molecule has abundant sialic 
acid decorations that are essential to its adhesive function. In vivo studies support its 
involvement in rolling mechanisms on mesenteric vessels. 
 
VAP-1 has been found to be expressed constitutively in high concentrations on hepatic 
endothelium, which normally fails to express adhesion molecules such as selectins, and 
mediates capture of lymphocytes in the liver. The expression of VAP-1 under normal 
conditions is most prominent in endothelium of lymph nodes, although in the setting of 
chronic inflammation it is up-regulated in vessels from a variety of tissues including 
synovium, tonsil, gut and skin. Its constitutive expression in the liver (particularly the 
sinusoidal and vascular endothelia), as well as its absence or relatively low expression 
in other non-lymphoid sites, suggests that it could function as an addressin, to direct T 
cells onto hepatic endothelium, where in the absence of selectins and CD31, it may play 
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a specific role in lymphocyte recruitment. This has been confirmed from recent 
evidence which suggests that under conditions of physiological shear stress, VAP-1 
supports transendothelial migration, as well as lymphocyte adhesion across hepatic 
sinusoidal endothelial cells in directing T cell recirculation to the liver (Lalor et al 
2002).   
 
Although VAP-1 is only expressed at low concentrations within vessels in the non-
inflamed gut, it is also up-regulated in active IBD, which suggests that lymphocytes 
using VAP-1 to enter the liver (Kurkijarvi et al 1998) could also use VAP-1 to enter 
inflamed mesenteric vessels. Thus, a proportion of mucosal T cells as well as T cells 
activated in the liver also have the ability to migrate to the gut, thereby providing 
immune surveillance to both these sites. Interestingly, since prolonged VAP-1 blockade 
causes a significant decrease in the inflammatory response, e.g. in rat allograft rejection, 
this could be used for therapeutic benefit (Martelius et al 2004). Furthermore, due to the 
restricted tissue expression of VAP-1, targeting its expression may favour future 
possibilities for more liver-specific immunosuppression. 
 
1.3	  	   Chemokines	  
 
We have seen that whereas selectins are constitutively active,  integrins must be 
activated to mediate adhesion. Specifically, rolling T cells activate integrins when they 
receive signals from chemokines on endothelial surfaces. Chemokines are a family of 
small closely related chemotactic pro-inflammatory cytokine proteins secreted by cells. 
They share structural characteristics such as small size (they are all approximately 8-10 
kilodaltons in size) and the  presence of four cysteine residues in conserved locations 
are crucial  to their three dimensional morphology.  
 
  
There are more than 18 chemokine receptors and 50 chemokines  identified  and the 
family is rapidly increasing. There are four major groups of chemokines (CXC, CC, C 
and CX3C), based on the the number and spacing of conserved cysteine residues in the 
NH2-terminus.  
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Specifically, the CXC chemokine group are important in angiogenesis  and angiostasis 
e.g. wound healing and development. They are further subdivided into two subclasses 
based on the presence of the glutamic acid, leucine and  arginine group at the N-
terminus. These include CXCL8/1L-8, with  strong neutrophil chemoattractant 
properties i.e. chemotaxis. Absence of these specific amino acid related chemokines 
recruit mainly lymphocytes and exert angiostatic effects. 
 
The CC chemokines have two adjacent cysteines near their amino terminus. There have 
been at least 27 distinct members of this group reported for mammals,  namely CC 
chemokine ligands (CCL) 1 to 28.  Chemokines of this subfamily usually contain four 
cysteines (C4-CC chemokines) but a small number of CC chemokines possess six 
cysteines (C6-CC chemokines). The C6-CC chemokines include CCL1, CCL15, 
CCL21, CCL23 and CCL28. CC chemokines are known to induce the migration of 
monocytes and other cell types such as natural killer (NK)  cells and dendritic cells. The 
CC chemokine includes monocyte chemoattractant protein-1 (MCP-1) or CCL2. They  
stimulate  monocytes to enter the surrounding tissues from the bloodstream which 
transforms them into tissue macrophages. Another important member of the CC 
chemokine  subfamily is  CCL5 (or RANTES). They are known to interact with  
different cell types such as T cells, eosinophils and basophils that express the receptor 
CCR5. 
 
In the C chemokine group, lymphotactin attracts lymphocytes and NK cells but not 
monocytes. The chemokine fractalkine defines the CX3 . 
 
Activated endothelial cells, leukocytes and epithelial cells produce chemokines.  
Virtually any cell is capable of chemokine generation upon stimulation with 
lipopolysaccharide or pro-inflammatory cytokines. After secretion, chemokines can 
bind to heparin-like glycoaminoglycans on the cell surface, helping leukocytes to track 
down these ‘immobilised’ chemokines in a process named haptotaxis. The binding of 
chemokines to glycosaminoglycans not only prevents them from being washed away, 
but also maintains them in mono/dimeric forms, which increases their affinity for their 
individual receptors.  The immobilised chemokines can persist at high concentrations in 
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tissues for longer than freely diffusible chemokines, allowing them to exert their 
specific effects.   
 
Specifially, chemokines bind to precise G-protein receptors on the lymphocyte leading 
to cytoskeletal rearrangement and activation of integrins essential for lymphocyte 
recruitment.  The combination of such unique chemokines and adhesion molecule 
interactions within different tissues are comparable to postal addresses.  Thus, 
lymphocytes bearing the appropriate receptors are able to respond to such addresses. In 
addition to high concentrations of surface L-selectin essential for lymphocyte capture, 
naïve lymphocytes also express the chemokine receptor CCR7 thereby facilitating 
interaction with the L-selectin ligand PNAd and the chemokine SLC (CCL21), (both 
restricted to endothelium in secondary lymphoid tissues). CCL21 activates α4β7 
dependant adhesion to MAdCAM-1 and plays an important role in recruiting naïve 
lymphocytes to the Peyer’s patches of the gut (Pachynskil et al 1998). By contrast, 
surface L-selectin and CCR7 are reported to disappear from most memory lymphocytes, 
thereby preventing them from re-entering lymph nodes. The recruitment and 
localisation of memory T cells to the gut is also helped by two important chemokines 
with restricted expression at mucosal sites.  The gut associated chemokine CCL25 
(thymus-expressed chemokines ‘TECK’) is mainly concentrated to the small intestine, 
where it is expressed by endothelial, epithelial cells and the mucosal-associated 
epithelial chemokine (MEC) is identified at most mucosal sites including the colon 
(Kunkel et al 2000).  It is interesting that ligation of CCR9 by the chemokines ligand 
CCL25 promotes conformational changes in the α4β7 integrins and firm adhesion of 
MAdCAM-1 (figure 1.6). 
 
Chemokines can be divided into homeostatic and inflammatory types based on their 
functional properties. Inflammatory chemokines are up-regulated by inflammatory 
stimuli in inflamed tissues by resident and infiltrating immune cells, and mainly 
regulate the recruitment of neutrophil, moncytes, NK cells and effector lymphocytes 
into effector sites. Homeostatic chemokines are constitutively expressed at high levels 
in lymphoid organs as well as in non-lymphoid tissues such as skin and mucosa where 
they mediate the naïve and memory lymphocytes trafficking to lymphoid and effector 
tissues as well as their guidance to the correct microenvironment within the tissue. 
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Figure	  1.6	  Expression of CCL25 and human MAdCAM-1 by vascular endothelium 
promotes recruitment of gut-derived lymphocytes and binding of CCR9 and α4β7 
respectively	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1.4	  	  	   Regulation	  and	  synthesis	  of	  endothelial	  adhesion	  molecules	  	  
 
Stimuli such as lipopolysaccharide (LPS) and pro-inflammatory cytokines enhance 
expression of different endothelial cell adhesion molecules. For example, LPS and the 
cytokines TNF-α, IL-1β, Il-4 and IFN-γ can substantially enhance the transcription of 
genes for ICAM-1, V-CAM-1, P-selectin, E-selectin (Lidington et al 1999). P-and E-
selectin expression on HUVEC mono-layers and in vivo usually reach a maximal level 
at 3-5 hours in comparison to VCAM-1 which peaks at 6 hours and ICAM-1 at 12 hours 
after endothelial cell stimulation. E-selectin expression returned to basal values within a 
few hours after stimulation whereas P-selectin, VCAM-1 and ICAM-1 persisted for 24-
48 hours after a single stimulus.  
 
NF-κB transcription factors appear to be the most relevant in inflammatory bowel and 
liver diseases, as they are important in the regulation of endothelial cell adhesion 
molecules (Schreiber et al 1998). Unlike most transcription factors, NF-κB normally 
resides in the cytoplasm and must translocate into the nucleus to elicit a response. Many 
signals, including bacterial and viral pathogens and inflammatory cytokines elicit NF-
κB translocation. 
 
Binding sites for NF-κB have been identified in the promoter regions of the genes for 
VCAM-1, ICAM-1 and E-selectin. Activation of VCAM-1 requires two tandem binding 
sites for NF-κB, which are located on the basal VCAM-1 promoter. Of the four positive 
regulatory domains identified in the promoter region of the E-selectin gene, three 
require NF-κB binding for induction. 
 
The majority of the functional role of adhesion molecules arises from their surface 
expression, although a small amount is cleaved from sites of expression with a presense  
in biological fluids. This is probably by enzymatic action since mRNA encoding 
alternatively spliced soluble forms of adhesion molecules have not been reported in 
man. The first molecule to be recognised in soluble form was ICAM-1 and soluble 
forms of other molecules including E-selectin and VCAM-1 were later identified. The 
shed molecules may represent only a small proportion of the total expression of E-
selectin, as most of the molecules are internalised and subsequently degraded or 
recycled. The circulating isoforms of the adhesion molecules retain their ability to bind 
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to their respective ligands in spite of lacking transmembrane and intra-cytoplasmic 
domains, however little is known about their function.  
1.5	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  Adhesion	  molecules	  in	  gastrointestinal	  disease	  
 
Many different families of adhesion molecules are upregulated during inflammation in 
gastrointestinal and liver diseases accompanied by the coordinated recruitment of 
leukocytes. In the gastrointestinal tract, lymphocytes are localised in the lamina propria, 
Peyer’s patches, and are increased in number, particularly in the lamina propria and 
epithelial cells in ulcerative colitis, Crohn’s disease, coeliac disease and many other 
conditions. The liver has a massive population of leukocytes principally lymphocytes, 
which are recruited in response to insults such as injury, infection, and inflammation in 
viral hepatitis, primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and 
alcoholic liver diseases (ALD) in which the predominant infiltrating leukocyte is the 
neutrophil.  
 
The evidence discussed thus far suggests that recruitment of lymphocytes is identified 
by their critical ability to bind and subsequently migrate across the endothelium lining 
vessels within target tissues. The process involves a sequence of interactions with 
different adhesion molecules and chemokines which act synergistically to capture, bind 
and then direct the migration of the lymphocyte into tissues.  
 
1.5.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Gastrointestinal	  infection	  
 
Bacterial products initiate or amplify gastrointestinal inflammation with the recruitment 
and activation of leukocytes during inflammation of the colon (e.g. Clostridium 
difficile) and stomach (e.g. Helicobacter pylori). 
 
There is an accumulation of neutrophils in the lamina propria in response to an acute 
gastrointestinal infection with invasive bacteria (Huang et al 1996). Intestinal epithelial 
cells play an important role in the recruitment of these inflammatory cells to the site of 
infection through the secretion of adhesion molecules. ICAM-1 may function to 
maintain neutrophils, which have transmigrated through the epithelium in close contact 
with the intestinal epithelium, thereby reducing further invasion of colonic mucosa by 
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invading pathogens. Activation of the leukocyte adhesion glycoproteins LFA-1 and 
subsequent interaction with constitutively expressed endothelial ICAM-1 may help this, 
causing increased vascular permeability further aided by leukocyte-platelet aggregation. 
The infiltration of leukocytes caused by Clostridium difficile toxin A is protracted if the 
LFA-1 and P-selectin expression induced indirectly by the toxin is blocked. 
 
Penetration of the gut mucosa by pathogens expressing invasive genes occurs 
prominently through M cells, located in Peyer’s patches. However, alternative 
mechanisms exist for bacterial uptake in mucosal tissues such as that proposed by 
dendritic cells (Rescigno et al 2001).   Dendritic cells appear to open the tight junction 
between epithelial cells, send dendrites outside the epithelium and directly sample 
bacteria. This mechanism may involve interactions with the tight junctions, the 
transmembrane protein occludin and other cell adhesion related molecules including E-
cadherin and B-catenin. It will be of interest to know if similar mechanisms exist in the 
liver.  
 
1.5.2	  	  	  	  	  	  	  	  	  	  	  	  	  Coeliac	  Disease	  
 
In coeliac disease, a T-cell mediated response to dietary gluten causes chronic 
inflammation, increased epithelial cell proliferation and architectural distortion in the 
small upper bowel. Lymphocytes accumulate within the lamina propria, and also a 
distinct subpopulation within the epithelial cell layer. ICAM-1 and LFA-1 are expressed 
in the former site but not the latter in active disease, although on short term gluten 
challenge in treated coeliac patients ICAM-1 expression was not altered whilst VCAM-
1 and E-selectin expression increased over hours. (Sturgess et al 1990) (Kelleher D et al 
1994). 
 
1.5.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Radiation	  Enteritis	  
 
Radiation enterocolitis is a sequel to radiotherapy for pelvic and abdominal malignancy. 
Early changes after exposure include increased cell death, loss of villous height, and the 
extensive loss of intestinal function leading to fluid and electrolyte imbalance. Late 
complications develop from endarteritis obliterans leading to intestinal ischaemia and 
gangrene. 
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Cellular adhesion molecules may play an important role in the pathogenesis of radiation 
enteropathy. After gamma radiation, the nuclear transcription factor NFκB induces 
oxygen radicals causing endothelial cell activation and the release of inflammatory 
mediators. There follows up-regulation of CD11/CD18 on leucocytes accompanied by 
NF-κB dose dependent increase expression of ICAM-1 and E-selectin (Zouki et al 
2000). This increase occurs by binding p50 and p65 nuclear proteins, with release of 
proteases and reactive oxygen metabolites accounting for most of the neutrophil 
mediated radiation induced tissue damage (Handschel et al 1999). 
 
As a result of endothelial adhesion molecule upregulation there is recruitment of 
adherent and emigrating leucocytes in post-capillary venules. In vitro studies show 
cultured monolayers of endothelial cells respond to ionising radiation by increasing 
mRNA and cell surface expression of ICAM-1 and E-selectin (Panes et al 1995) 
(Heckmann et al 1998). Indeed, ICAM-1 may remain elevated as long as 10 days after 
one single dose of radiation.  
 
Medical therapy of radiation enteritis is limited. Antibiotics may be of use for bacterial 
overgrowth and local topical therapy to patients with proctitis. Anti-adhesion molecule 
therapy could have a therapeutic role in controlling the local inflammatory processes 
e.g. blocking LFA-1 and ICAM-1 has been shown to be beneficial in treating post 
irradiation syndrome in rats (Horie et al 1996). 
 
1.5.4	  	  	  	  	  	  	  	  	  	  	  	  	  Inflammatory	  Bowel	  Disease	  
 
Mucosal changes in ulcerative colitis (UC) and Crohn’s disease (CD) are characterised 
by the development of ulcerative lesions and prominent inflammatory infiltrates of 
leukocytes in the bowel wall consisting of B and T lymphocytes, macrophages, plasma 
cells and granulocytes. The aetiology is unknown but a failure to control mucosal 
immune responses to antigens in the lumen is likely to play a role.  Recruitment of cells 
to diseased gut mucosa appears essential to the initiation and perpetuation of IBD. The 
recruitment involves activation of a number of adhesion molecules and their ligands, on 
leukocytes and vascular endothelium. 
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MAdCAM-1 plays a central role in the aetiology of IBD through its ability to direct 
circulating lymphocytes to enter gut-associated lymphoid tissue and the gut interstitum. 
Furthermore, although MAdCAM-1 is constitutively expressed in some regions of the 
gut and mesenteric lymph nodes, the expression of MAdCAM-1 in these tissues is 
significantly increased during active colitis. Briskin et al (1997) reported that in small 
intestine and colon from patients with Crohn’s disease, the pattern of MAdCAM-1 
expression paralleled that found constitutively in normal intestinal tract, but the relative 
area of endothelium expressing MAdCAM-1was greater in IBD.  
 
In active IBD, ICAM-1 expression is increased on the cell membranes primarily by 
activated endothelial venular cells at the base of ulcerations with dense cellular 
infiltration. ICAM-1 is also expressed by infiltrating leukocytes and is upregulated in 
early lesions of CD e.g. aphthous ulcerations. The blocking of β2 integrins may initiate 
some intracellular mechanisms, which make neutrophils insensitive to ICAM-1, and 
these mechanisms seem to be impaired in UC in which integrins have also been shown 
to show inhibit ICAM-1 induced neutrophil locomotion (Nielsen  et al 2000). The 
chemotactic properties of ICAM-1 have been further explored in UC where the effect of 
prednisolone was shown to include both anti-chemotactic effects towards ICAM-1 and 
pro-chemokinetic properties, which might explain the rebound symptoms of UC during 
the tapering of prednisolone therapy.  
 
In IBD VCAM-1 is found to be membrane bound on endothelial cells, 
monocyte/macrophages, lymphoid and non-lymphoid tissues. VCAM-1 is functionally 
active in the chronic inflammation of UC and CD. It is important in the trafficking of 
recirculating lymphocytes into inflamed bowel mucosa but does not appear to be active 
in the acute inflammatory response. 
 
Expression of PECAM-1 is greater in normal colonic tissue than small intestine. A 
significant increase in PECAM-1 positive vessels is seen in active UC (Vainer et al  
2000) as compared with non inflamed areas adjacent to the inflamed tissue, indicating 
that PECAM-1 is involved in the earliest phases of IBD; its upregulation seems to a 
preconditioning for the development of inflammatory lesions.  It is significantly 
increased in mucosal vessels of uninvolved UC compared with healthy volunteers. 
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E-selectin may prove useful for in vivo detection and quantitation of disease activity in 
IBD as its expression is limited to activated endothelium. Interestingly, radiolabelled E-
selectin has been used to image IBD-affected bowel by scintigraphy, which appear to 
show good correlation with results of colonoscopy and barium studies (Bhatti et al 
1998). This study and others (Nielson et al 1996) also report a positive correlation 
between disease activity in IBD and serum levels of soluble, presumed shed E-selectin, 
although other studies (Goggins et al 2001) have not confirmed this relationship.  
 
There is the increasing appreciation of the role of E.coli  in IBD as  ‘mildly pathogenic’ 
by virtue of their possession of adhesion mechanisms and secretion of proteases. In 
Crohn’s disease E.coli probably invade the tissue, perhaps as a result of defective 
clearance by neutrophils, and chronically infect macrophages, where they may have a 
more superficial relationship with the mucosal surface in ulcerative colitis. There is 
already considerable interest on how uropathogenic Ecoli interact with epithelial cells 
and much of this may be relevant in the colon. This may include interaction with 
members of the CEACAM family that are present in the glycocalyx. 
 
1.6	   	  	  	  	  	  	  	  	  	  	  	  	  Entero-­hepatic	  recirculation	  &	  extra-­intestinal	  
manifestations	  of	  Inflammatory	  Bowel	  Disease	  	  
 
1.6.1	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  Extraintestinal	  intestinal	  manifestations	  of	  Inflammatory	  
Bowel	  Disease	  
 
Inflammatory bowel disease may be associated with a variety of extraintestinal 
manifestations. Some are transient and generally associated with active disease (e.g. 
joint, skin and eye inflammation). Other conditions may preceed or follow episodes of 
inflammation e.g liver involvment with sclerosing cholangitis.  
 
Grant et al (2002) proposed an attractive rationale for simultaneous expression of α4β7 
mediated responses in gut and liver which therefore allow the entero-hepatic 
recirculation of lymphocytes and provides surveillance to protect the liver against gut 
derived organisms; this pathway could well promote the development of liver 
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inflammation in association with IBD. Effector lymphocytes would have the capacity to 
migrate to both the gut and liver due to the common expression of adhesion molecules. 
T cell activation in the gut during episodes of IBD would thus lead to the production of 
primed lymphocytes, with the ability to bind both hepatic and mucosal endothelium.  
Furthermore, some of these cells will persist as long-lived memory T cells even after 
resolution of IBD. Such a mechanism could involve VAP-1 and/or MAdCAM-1 acting 
as common addressins shared by the liver and bowel. If hepatic inflammation 
subsequently develops in response to an appropriate insult or infection, these memory 
cells will be rapidly recruited via interactions with MAdCAM-1 or VAP-1 on portal 
endothelium and with VAP-1 on hepatic sinusoidal endothelium. If cross-reactive self 
antigens in the liver activate these cells, they could presumably survive and promote the 
development of chronic inflammation, in liver diseases such as primary sclerosing 
cholangitis (PSC) or autoimmune hepatitis.  
 
The involvement of long-lived memory T cells from the gut in the pathogenesis of PSC 
could explain why IBD and PSC do not always occur at the same time and why PSC 
can present for the first time in patients with quiescent UC and in people whose colons 
were removed many years before. However, although this model is attractive it still 
does not explain all the features of PSC i.e. why the activity of the PSC liver disease 
does not parallel bowel inflammation and indeed why the association is greater with UC 
than Crohn’s disease. It has been postulated that similar numbers of activated mucosal 
memory T cells are present in Crohn’s disease as in ulcerative colitis. Moreover, the fact 
that the association with Crohn’s disease is predominant in Crohn’s colitis suggests that 
colonic inflammation may be a critical factor. The explanation could lie in the nature of 
the auto antigens which activate mucosal lymphocytes in the PSC liver or the 
differences between the homing potential of colonic and small bowel memory T cells.  
 
Other extraintestinal complications may arise and in whom leucocytes may infiltrate 
organs e.g. eyes and joints. It is certainly apparent that the extraintestinal manifestations 
may occur during a flare of IBD, as circulating effector lymphocytes activated in the gut  
have been shown to express high concentrations of adhesion molecules e.g. VLA-4 and 
LFA-1, which subsequently promote recruitment of effector lymphocytes to tissues in 
which low concentrations of endothelial ligands VCAM-1 and ICAM-1 are expressed  
This mechanism could apply to the eye, a mucosal surface where increased expression 
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of ICAM-1 and VCAM-1 have been recorded in people with uveitis where VAP-1 have 
been detected in conjunctival follicle vessels. 
 
About 25% of IBD patients suffer from extraintestinal inflammatory complications, of 
which arthropathy is the commonest. The manifestations have been attributed to the 
presence of putative cross-reactive antigens between gut and liver, shared susceptibility 
genes, and to circulating immune complexes or lipopolysacharide. Leukocyte 
trafficking between gut and joints suggests an alternative mechanism. Salmi et al 
(2001b) showed that mucosal T cells bind to inflamed synovial high endothelial venules 
in vitro, an occurrence which is not just a result of inflammation because the same 
activated mucosal T cells bind poorly to inflamed peripheral lymph nodes. MAdCAM-1 
is absent from synovial vessels. Activated IBD gut immunoblasts may rely on VAP-1 
for synovial recognition, as blocking VAP-1 significantly inhibits binding of these 
leukocyte subsets to joint vessels (Salmi et al  2001). 
1.7	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Modulating	  adhesion	  molecule	  expression	  and	  
therapeutic	  applications	  of	  anti-­adhesion	  therapy	  in	  IBD	  
 
Interrupting inflammatory cell recruitment into IBD lesions is an important therapeutic 
aim. Several approaches have been used to probe the role of adhesion molecules in vivo, 
including blocking antibodies (Podolsky et al 1993) (Briskin et al 1997) chimeric 
selectin-immunoglobulin proteins (Dietsh et al 1993) and the study of human and 
animals with genetically determined cell adhesion deficiencies. These studies 
demonstrate that blocking one or more adhesion molecules can effectively inhibit 
inflammation; however, there appear to be clear differences in the adhesion 
requirements for particular types of inflammation. 
  
Anti-α4 monoclonal antibodies with recognition of α4β7 and α4β1 relieved gut 
inflammation and reduced leukocyte accumulation in a cotton-top tamarin model of 
inflammatory colitis (Podolsky et al 1993). Studies of transgenic mice have shown that 
α4 deficient transgenic mice are unable to recruit T-cells to Peyer’s patches and 
similarly, Peyer’s patches are absent in β7 integrin deficient animals, suggesting that 
both these integrins are essential for the formation of gut-associated lymphoid tissue. 
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Studies of other animal models of colitis have also shown intravenous administration of 
monoclonal antibodies to α4, or β7 integrin significantly attenuates colonic 
inflammation. (Picarella et al 1993). 
 
More recently, following the positive therapeutic effect of anti-α4 antibodies in 
experimental colitis, a trial of humanised monoclonal antibody to α4 integrin was 
performed. Although therapeutic efficacy was low there was evidence of interaction 
with endothelial VCAM-1 as shown by reduced serum soluble VCAM-1 concentrations 
after antibody blockade of α4 integrins (Gordon et al  2001) (Gordon et al 2002). 
 
In other approaches, antisense oligonucleotides (Anti-S) have been used to prevent the 
synthesis of adhesion molecule proteins in IBD patients. The concept of modulating 
gastrointestinal inflammation using Anti-S to therapeutic effect e.g. targeted to adhesion 
molecules and in particular MAdCAM-1 will be discussed in chapter 5. 
 
1.8	  	  	   	   Adhesion	  molecules	  in	  liver	  disease	  
 
Lymphocyte-endothelial interactions take place in sinusoidal vessels under conditions 
of low-velocity blood flow).  Normal liver sinusoids contain large granular 
lymphocytes, which are intimately associated with other sinusoidal (pit) cells. 
Lymphocyte interactions with sinusoidal endothelium differ from those involved with 
postcapillary venules in e.g. lymphoid tissue in some important aspects.  The 
characteristic rolling phase of primary adhesion seen in HEV is not observed, and 
adhesion to sinusoidal endothelium is unaffected in animals lacking endothelial 
selectins.  Retention of leukocytes in the hepatic sinusoids is however greatly reduced, 
although not abolished, in animals some lacking certain cellular adhesion molecules e.g. 
ICAM-1.  Inflammation in the liver causes portal vessels to express P-selectin, E-
selectin, VCAM-1 and high levels of ICAM-1. 
 
In some forms of chronic liver diseases particularly that associated with ductopenia 
such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), 
immunological mechanisms involving lymphocyte-mediated damage are important in 
the characteristic bile duct damage. The bile-duct damage characteristic of early PBC 
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mainly affects the septal and larger interlobular ducts, while the smaller interlobular 
ducts remain intact until later. The epithelium of the affected ducts becomes irregular 
and is infiltrated with lymphocytes. The basement membrane becomes disrupted and the 
duct may rupture. An inflammatory infiltrate is seen around the ducts which may form 
lymphcytes aggregates or follicles. Elsewhere, there are a mixture of plasma cells, 
eosinophils and neutrophils. The eosionphils contribute to bile duct damage and  
granuoloma formation by releasing mediators which are located with in their granules.  
With progressive PBC the disease extends beyond the confines of the portal tracts and 
there is increasing fibrosis and alteration of the acinar architecture. There is ductular 
reaction and progressive fall in duct numbers. 
 
Primary sclerosing cholangitis is characterised by inflammation, strictures and saccular 
dilatations in the biliary tree. The features on liver biopsy depend in part on the location 
of strictures in relation to the biopsy site. There is periductal oedema, concentric 
fibrosis, ductular proliferation, portal inflammation, atrophy or disappearance of the 
ducts. Loss of the ducts is the common finding in the smallest portal tracts, while 
periductal fibrosis is typical of medium-sized tracts. 
 
Primary biliary cirrhosis closely resembles PSC in the more later stages. Notably,  the 
typical granulomatous cholangitis of PBC is not a feature of PSC. Substantive chronic 
inflammation of the portal tracts with or without lymphoid follicles favours PBC. 
Conversely, fibrous obliteration of ducts is characteristic of PSC, with dense portal 
fibrosis and  relatively little inflammation.  
 
PSC and PBC are both characterised by the relative increase in cytotoxic T-
lymphocytes compared to healthy adults. (Lindor et al 1987) (Whiteside  et al 1985) 
(Yamada et al 1985). The possibility however that T cells mediate biliary epithelial cell 
injury in PSC by a direct cytotoxic effect appears less likely in view of the observations 
showing the inability to detect any normal cytotoxic activity among liver derived T 
lymphocytes from these patients (Bo et al 2001).   In both PBC and PSC there is 
increased expression of class II antigens.  Infiltrating T cells have been shown to be 
closely associated with areas of bile duct destruction in both diseases. Recent studies 
have revealed enhanced T helper type 17 (Th17) response and weakened T regulatory 
cell (Treg) response in some autoimmune diseases such as PBC; thus indicating a role of 
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Th17/Treg imbalance in the pathogenesis of autoimmunity and its potential function  in 
the breakdown of immune self-tolerance, with  Interleukin-23  characterising  the 
disproportionate cytokine profile pivotal in Th17-related human autoimmunity (Rong et 
al 2009). 
 
ICAM-1 is strongly expressed on inflammatory interlobular bile ducts in PSC and PBC, 
in contrast to bile ducts in normal livers, which do not express ICAM-1 (Adams et al 
1991) (Volpes et al 1990) (Bloom et al 1995). In PBC, medium sized ducts, which are 
spared by the disease, do not express ICAM-1. Whether ICAM-1 expression on biliary 
epithelia cells is an early event in the pathogenesis of bile-duct damage or a secondary 
response to inflammation is not clear. This is highlighted by Bloom et al (1995) who 
showed ICAM-1 expression only in advanced PSC making a primary role for ICAM-1 
in early disease less likely. 
 
 A soluble isoform of ICAM-1 can be detected in the bile as well as sera of normal 
subjects with greatly elevated levels detected in chronic liver disease (Adams et al 
1992).  Soluble ICAM-1 from bile samples may arise as a result of increased production 
by hepatocytes, bile epithelial cells or from changes in ICAM-1 elimination. The use of 
soluble isoforms of ICAM-1, as systemic markers of endothelial cell ICAM-1 
expression from work on murine and human endothelial cells has been proposed, but 
suggest that they may not be directly related. Messenger RNA which specifically 
encodes soluble isoforms of ICAM-1  in mouse plasma after TNFα administration may 
be dissociated from ICAM-1 expression on endothelial cells of lung , intestine and other 
organs. Serum ICAM-1  levels are  increased in intra and extra hepatic cholestasis 
(Polzien et al 1996). The rise appears to be  dependant on the degree of disease. Serum 
ICAM-1  concentrations  in advanced PBC  seems to be more reliably correlated to the 
histologically proven degree of intrahepatic cholestatsis  than any of the other classical 
parameters of cholestasis. 
 
In alcoholic cirrhosis, there is activation of the immune response with increased 
expression of adhesion  molecules e.g ICAM-1 , LFA-3 and MAC-1, on the surface of 
circulating lymphocytes which is more intense in patients with advanced disease (Luna-
Casada et al 1997). 
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There is emerging evidence of  MAdCAM-1’s role in inflammatory liver disease.  Grant 
et al 2001 demonstrated, using adhesion assays, that leukocytes would specifically 
adhere via α4β7 receptors to human PSC liver, and that α4β7 lymphocytes could be 
demonstrated adjacent to MAdCAM-1 on portal vessels. These findings indicate that 
the MAdCAM-1/α4β7 system is likely to be of functional significance in the 
inflammatory pathophsiology of PSC. 
1.9	  	  	   	  	  	  	  	  	  	  	  	  	  Liver	  allograft	  rejection	  	  
Acute (cellular) rejection, the most common form of rejection, is a cell-mediated 
immune injury. The characteristic histological triad of cellular rejection includes portal 
inflammation, bile duct damage and endothelialitis, although the latter is not present in 
all cases. During acute liver allograft rejection there is upregulation of ICAM-1 
expression on bile ducts, endothelium and perivenular hepatocytes compared to donor 
livers, patients with stable transplants, or those with non-rejection complications 
(Adams et al 1989). The tissue distribution of ICAM-1 during rejection resembles that 
seen for HLA-DR although ICAM-1 expression rather than MHC antigen expression 
seems more specific for rejection. The upregulation of ICAM-1 on tissues may be an 
important step in the development of acute rejection determining which cells are the 
targets of immune damage. Most patients with acute cellular rejection will respond to 
treatment with high dose immunosuppression but approximately 15% do not and 
progress to chronic irreversible rejection. On the other hand, whilst VCAM-1 is 
constitutively expressed on kupffer cells with extremely week portal vein endothelia 
expression in the normal liver, acute rejection is associated with up regulation of 
VCAM-1 on most portal venous and arterial vessels, mainly in infiltrated portal tracts.  
 
 
Chronic (ductopenic) rejection (“vanishing bile duct syndrome”) is defined as 
obliterative vasculopathy and loss of bile ducts occurring 60 days or longer after 
transplantation. The expression of VCAM-1 is upregulated on central vein endothelia in 
chronic rejection and additional focal expression on hepatocytes, whilst the expression 
of ICAM-1 on bile ducts and hepatocytes is greatest in chronic, irreversible rejection. 
Persistent expression of VCAM-1 and ICAM-1 may promote a continuing 
inflammatory response resulting in their destruction. However, why these patients fail to 
respond to immunosuppression is unknown and the reduction of VCAM-1 and ICAM-1 
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expression seen after successful treatment with high-dose corticosteroids suggests that 
the action of these drugs may in part be mediated by their regulation.  
1.10	   	   Ischaemia/Reperfusion	  	  
 
Ischaemia/Reperfusion (I/R) has been implicated in the pathogenesis of a number of 
gastrointestinal disorders such as IBD and necrotising enterocolitis.  Leukocytes are key 
mediators of I/R injury in several splanchnic organs, including stomach, intestine, liver, 
and pancreas (Dulkanchainum et al 1998). Leukocytes accumulate in the post ischaemic 
gut, and I/R induced inflammatory responses (leukocyte adhesion, increased vascular 
permeability) may be mimicked in vitro by exposing endothelial cell monolayers to 
hypoxia and oxygenation. I/R also results in the upregulation and activation of the 
P65/P50 heterodimer of NF-κB in endothelial monolayers. The firm adhesion and 
emigration of leukocytes elicited by I/R involves an interaction between Mac-1 on 
leucocytes and ICAM-1 on endothelial cells. Antibody blocking studies show that P-
selectin contributes to the rapid rolling of leukocytes. There is a biphasic response that 
peaks at 30 minutes with a second peak in surface expression at 4-6hrs after 
reoxygenation. A similar biphasic response occurs with very rapid increase in E-
selectin. Several chemical mediators have been implicated in the increased expression 
of P and E-selectin, with leukotrienes, histamine and reactive oxygen metabolites all 
postulated mediators. 
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1.11	  	  	  	  	  	   Aims	  of	  the	  Study	  
 
MAdCAM-1 is now thought to be the major adhesion molecule linking liver and gut, 
providing the main route by which lymphocytes gain access to the normal and inflamed 
gut. The lymphocyte integrin α4β7 is the major ligand receptor for MAdCAM-1, which 
is thus critically placed to mediate the homing of these lymphocytes to mucosal organs. 
Modulation of other adhesion molecules has been used for therapeutic advantage.   
The overall aim of this project was to determine the expression of MAdCAM-1 in 
tissues/cell culture systems and investigate effects of modulating MAdCAM-1 
expression.  
 
In order to achieve this, we have followed the following sequence: 
a) To characterise the expression of MAdCAM-1 using immunohistochemical analysis. 
• The first chapter deals with the broad concept of adhesion molecules including 
MAdCAM-1.   
• The second chapter describes the detection of MAdCAM-1 in liver, gut and related 
tissues e.g. pancreas in a variety of diseases using immunohistochemical analysis. 
 b) To develop an in vitro model of MAdCAM-1 as a basis of investigating its 
expression.  
• The third and fourth chapters deal with further characterisation of MAdCAM-1 with 
detection and quantification of MAdCAM-1 in tissues and cell culture.  
c) To modulate MAdCAM-1 using an in vitro model.  
• The fifth chapter deals with investigating the effects of modulating MAdCAM-1 
using a variety of strategies including Anti-S. In principle the results of this work 
could then be applied to animal models of MAdCAM-1 expression to determine 
which agents have effective modulatory capabilities on MAdCAM-1 expression, 
thereby attenuating inflammatory and immune mediated diseases associated with 
MAdCAM-1.  
• The sixth and final chapter summarises the  findings  from characterising MAdCAM-
1 and  the effect of modulating its expression including the  role of existing and 
newer agents 
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Chapter	  2	  
 
MAdCAM-­1	  expression	  in	  the	  liver,	  gut	  
and	  associated	  tissues	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2.1	  	   Overview	  of	  MAdCAM-­1	  expression	  in	  the	  
gastrointestinal	  tract	  
 
We have seen from chapter 1 that the recruitment of leukocytes from the circulation is a 
pivotal step in inflammation. The ligand-receptor interactions mediating the emigration 
of specific cell-types into individual organs affected by inflammation are crucial to our 
understanding of gastrointestinal disease. Such interactions are important as they have 
the potential ability to act as targets for therapeutic gain. The critical role of one such 
interaction in the gut is MAdCAM-1 and its ligand, the lymphocyte integrin α4β7. 
 
MAdCAM-1 was first recognised on murine endothelial cells in the gut lamina propria, 
mesenteric nodes, mammary gland, and on follicular dendritic cells of mucosal 
lymphoid organs (Peyer’s patches) but not peripheral lymph nodes. The expression of 
MAdCAM-1 in experimental gut inflammation increases (Kato et al 2000) and α4β7 is 
therefore decisively placed to mediate the homing of these lymphocytes to mucosal 
organs. 
  
The intriguing concept that lymphocytes programmed to home to the gut may also home 
to the liver constitutes an attractive hypothesis linking chronic IBD with liver associated 
inflammation affecting medium to large bile ducts e.g. primary sclerosing cholangitis.  
Grant et al (2002) proposed an interesting hypothesis involving the entero-hepatic 
recirculation of lymphocytes, providing surveillance to protect the liver against gut 
derived organisms, a pathway which may help the development of liver inflammation in 
association with IBD.  
 
In this part of the work we have therefore set out to characterise the 
immunohistochemical expression of MAdCAM-1 in gastrointestinal tissues, liver and 
related organs e.g. pancreas. The ability to detect the presence of MAdCAM-1 and 
ultimately quantify its expression could be potentially useful in the diagnosis and 
subsequent management of chronic inflammatory diseases affecting these organs. 
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2.2	   	  	  	  	  	  Experiment	  1:	  Morphological	  survey	  of	  MAdCAM-­1	  
expression	  in	  the	  human	  liver	  
 
2.2.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Background	  
 
Immunological mechanisms are important in the development of liver cirrhosis. In this 
regard, recruitment and regulation of lymphocytes entering from the circulation into 
areas of inflammation are crucial. Lymphocyte trafficking is dependent on the 
interaction of ligands on cell surfaces and adhesion molecules on the surface of blood 
and lymphatic vessels. The endothelium thus provides a molecular address which is 
recognised by T lymhocytes subsets.  The liver, placed astride the portal venous 
circulation, plays a major role in modifying the systemic immune response to gut-
derived antigens, by mechanisms ranging from conceptually simple filter functions of 
the reticulo-endothelial system to complex processes such as induction of systemic 
tolerance (Sumpter et al 2007). 
 
In the human gut, MAdCAM-1 is predominantly expressed on vascular endothelium in 
the lamina propria, high endothelial venules in lymphoid aggregates and follicular 
dendritic cells in lymphoid follicles (Briskin et al 1997). Potential functions in these 
sites are the recruitment of antigen-specific cells (Waidmann et al 2002), recruitment of 
naïve lymphocytes, antigen presentation/processing, (Feuerer et al 2004) modulation of 
maturation of antibody responses (van der Feltz et al 2001) and provision of growth and 
survival signals to B cells (Krtaz et al 1996). 
 
2.2.2	  	   	   Hypothesis	  and	  Aims	  
 
Our hypothesis is that inflammatory processes within the liver upregulate local 
MAdCAM-1 expression to enhance those functions and in particular, the regional 
vascular distribution of MAdCAM-1 upregulation is related to distribution of disease 
within the liver lobule/portal tract. Since the expression of MAdCAM-1 in the liver 
remains poorly characterised the aim of this study was to compare semi-quantitatively 
compare the expression of MAdCAM-1 in normal liver, in relation to inflammation in a 
variety of liver disease.  
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It is already established that the peribiliary vascular plexus supplies the intrahepatic bile 
ducts; around the larger ducts the plexus is two layered with a rich inner subepithelia 
layer of fine capillaries and an outer capillary venous network which receives blood 
from the inner layer (Burt  et al 2007) (Koda et al 2000). Small bile ducts have only a 
single layer of fine capillaries. Specifically, our object was to define the fine structure of 
vascular plexuses and lymphatics in the portal tract, particularly the peribiliary plexus, 
and the bile ducts in liver on which MAdCAM-1 may be expressed and to determine the 
presence/distribution of MAdCAM-1 in normal, mild, moderate and severely affected 
livers in a range of immune and non-immune mediated liver disease, with and without 
co-existing gut inflammation i.e. to compare the expression of MAdCAM-1 in a variety 
of liver diseases, so as to better understand its role in the liver. 
 
2.2.3	   	   Material	  and	  Methods	  
MAdCAM-1 expression was determined by immunohistochemistry on human liver 
from a total of 29 patients with chronic liver disease who underwent orthotopic liver 
transplant (OLT): 9 patients (5 male, 4 female, age range 22-57, median 53 yrs) with 
PSC, 7 female subjects (age range 36-51, median 50 yrs) with PBC; 7 explants with 
alcoholic liver disease (ALD 5 males and 2 females) age range 33-64 yrs, median 48 
yrs, 5 with chronic hepatitis C virus infection (all males, age range 44-57, median 51 
yrs) 3 liver biopsies from chronic rejection after OLT,  normal liver tissue obtained 
from 3 liver biopsy, 4 partial hepatectomies performed for colorectal metastasis with 
wide resection margins and 4 sections of extra hepatic biliary obstruction were obtained 
from trucut liver biopsies during staging laparoscopy for pancreatic adenocarcinoma 
associated with obstructive jaundice. The diagnoses of PBC, PSC, ALD, HCV, HBV 
and chronic ductopenic rejection   were made on established criteria (Lefkowitch 2010). 
Pre-cirrhotic liver tissues were taken from needle biopsy specimens of PBC stages 1-2 
(5 females), HCV stages 1-2 (3males, 2 females), and explants from hepatitis B 
fulminant liver failure (2 males). There were 2 specimens  of non cirrhotic portal 
hypertension obtained from  transjugular liver biopsies; the first was from a  48 year 
man on long term azathioprine therapy for Crohn’s disease and the second from a  52 
year lady with myeloproliferative disease and portal venous thrombosis. The controls 
for MAdCAM-1 expression were taken from samples of normal colon tissue, which 
constitutively expresses MAdCAM-1. 
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All tissues were fixed in 10% buffered formalin and embedded in paraffin. Four micron 
sections were cut on to APES (3-aminopropy triethoxysiline) coated slides, one section 
being stained with haematoxylin and eosin.  Two methods of immunohistochemical 
staining were used (i) three stage immuno-alkaline phosphatase (APAAP) (ii) three 
stage immunoperoxidase techniques, whilst also comparing antigen retrieval methods 
using Trilogy, an EDTA based solution with EDTA only 
 
2.2.3.1	  	   Alkaline	  Phosphatase	  Anti-­Alkaline	  Phosphatase	  (APAAP)	  
methodology	  
 
Sections were deparaffinised in xylene, dehydrated in alcohol, re-hydrated in water, and 
immersed in 15% acetic acid for 20mins to block endogenous alkaline phosphatase. 
They were then treated for target antigen retrieval using 1mmol/L EDTA (pH 8) in a 
pressure cooker followed by cooling in running water. After rinsing in TRIS buffered 
saline (TBS) pH 7.6, slides were incubated in 10% normal goat serum (Dako) for 
20minutes followed by polyclonal rabbit anti-human MAdCAM-1 (2µg/ml, a gift from 
Genetech, San Francisco, USA) overnight at 40C. Sections were then thoroughly 
washed in TBS, and incubated with alkaline phosphatase conjugated goat anti-rabbit 
IgG antibody (1:50 Sigma Aldrich, Poole, UK) for 1 hour at room temperature. The 
sections were washed with TBS again and   incubated with fast red substrate (diazotised 
5-nitroanisidine 1-5-naphthalene disulphonate, Dako, UK) for 30 minutes, followed by 
brief counter staining with Mayer’s hematoxylin (Sigma Aldrich, Poole, UK). The 
slides were mounted in DPX (ProSciTech) and observed using light microscopy.  
 
2.2.3.2	  	   Trilogy	  methodology	  as	  a	  form	  of	  antigen	  retrieval	   	  
 
Trilogy (Cell Marque, Rocklin, CA, USA) is a commercial EDTA based solution  used 
by laboratories as a universal solution to unmask antibodies and  has the apparent 
advantages of lack of refrigeration, expiry and dilution not being required as compared 
to EDTA on its own.  
 
 
The sections were deparaffinised and re-hydrated as before. They were rinsed in 
distilled water twice for 5 minutes each. Antigen retrieval included preheating with 
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Trilogy (pH 8) at 990C for 30 minutes in a water bath. The sections were transferred to 
new preheated Triology for another 30minutes at 990 C and rinsed with PBS for 
5minutes. Endogenous peroxidase activity was quenched with KPL Blocking Solution 
and diluted concentrate at 1:10 in hydrogen peroxide at room temperature for 4minutes. 
The slides were then rinsed with PBS for a further 5minutes, followed by blocking with 
avidin biotin with Vector Avidin Biotin Kit and rinsed with PBS for 5 minutes. The 
endogenous immunoglobulin binding sites were blocked with 10% normal goat serum 
in 3% BSA/PBS for 30 minutes and then the sections were incubated with primary 
antibody rabbit-antihuman MAdCAM-1 (concentration 2ug/ml) in blocking serum for 
30 minutes at room temperature. A negative control in which primary antibody was 
replaced by mouse IgG antibody (DAKO; Code X0931) was performed for each tissue 
specimen to assess non specific staining. Dilution of antibodies and duration of 
incubation at individual stages of the test were adjusted experimentally in laboratory 
conditions (dilution of anti-mouse MT antibodies, 1:100; incubation duration, 30 
minutes).  The slides were washed twice with PBS for 5 minutes and then  incubated 
with  diluted biotinolated goat-ant-rabbit IgG diluted 1:200 in blocking serum for 30 
minutes at room temperature. This was followed by an ABC reagent for 30 minutes and 
further rinsing with PBS. The sections were further incubated with Pierece Metal 
Enhanced DAB for 5mins, rinsed with tap water and   counterstained with Mayer’s 
hematoxlin for 1 minute and finally washed in distilled water. They were dehydrated, 
cleared and mounted in synthetic mounting media. 
 
2.2.3.3	   	  	  Immunoperoxidase	  staining	  	  
 
After dewaxing, the slides were incubated in 0.3% hydrogen peroxide in methanol 
followed by microwave treatment in citrate buffer for 5 minutes. They were then 
incubated in Normal Goat serum (1:10 dilution) for 20 minutes, followed by anti-human 
MAdCAM-1 for 1 hour. The sections were washed with PBS and incubated with 
biotinylated goat anti-rabbit IgG (1:200 dilution) for 30 minutes and washed again with 
PBS. They were then incubated with PAP complex for 30 minutes and washed 
repeatedly with PBS. DAB substrate was added and left for 10 minutes, washed again 
with PBS, counterstained with haematoxylin, mounted and visualized by light 
microscopy. 
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2.2.3.4	   	  	  Dendritic	  cell	  and	  lymphatic	  vessel	  staining	  
 
A panel of adjacent serial sections from tissue were also immunostained for a subset of 
dendritic   cells, including CD21, CD68 and S100 to elucidate the site of the 
MAdCAM-1 immunoreactivity in the lymphoid aggregates using the APAAP 
methodology as described above.  
 
Monoclonal antibodies to CD21 were used to identify follicular dendritic cells, CD68 
stains to recognise monocyte/macrophage and dendritic cell. Antibody to S100 proteins 
stains antigen presenting cells such as interdigitating dendritic cells. 
 
Sections were incubated with primary antibody for one hour. Blocking was performed 
with normal goat serum (1:10, DAKO UK Ltd) followed by incubation with rabbit anti-
mouse antibody (1:25, DAKO UK Ltd) for 45 minutes and then with alkaline 
phosphatase-conjugated mouse anti-alkaline phosphatase (1:50, DAKO UK Ltd) for a 
further 45 minutes. 
 
Some sections were stained to demonstrate lymphatic endothelium using anti-
podoplanin (a gift from Dr Kershaki, Austria). Microwave pre-treatment was followed 
by labeling with rabbit anti-human podoplanin IgG for 60 minutes at room temperature 
and washing in PBS biotinylated goat anti-rabbit antibodies (Vector). The staining was 
visualised using a streptavidin–peroxidase complex (Vector), diamino-benzidine and 
H2O2. Sections incubated without primary antibodies were used as negative controls. 
 
2.2.3.5	   	  Immunofluoresence	  Microscopy	  
 
After pre-treatment, sections were incubated with anti-human MAdCAM-1 (1:150) and 
antiCD34 (1:100) primary antibodies. They were then washed in PBS and incubated 
with secondary antibody (goat anti-rabbit FITC and goat anti-mouse Texas Red, both 
1:50 in PBS) for 1 hour at room temperature, and examined by fluorescence 
microscopy. 
 
Representative sections were incubated with anti-CD21(1:100), anti-CD68(1:50),  anti-
S100(1:50) and anti-human MAdCAM-1(1:150) primary antibodies. They were 
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subsequently washed in PBS and incubated with secondary antibody (goat ant-rabbit 
FITC and goat anti-rabbit FITC and goat anti-mouse  Texas Red, both 1:50 in PBS) for 
1 hour at room temperature and examined by flouorescence microscopy. 
2.2.3.6	   Immunohistochemical	  Assessment	  
 
Two observers (Aftab Ala and Richard Standish) independently assessed the sections 
semi-quantitatively and scored the staining on a scale of 0-3 according to the intensity 
of MAdCAM-1 immunoreactivity (0-no staining, 1-mild staining, 2- moderate staining 
and 3 marked staining). The staining methods were repeated twice to validate the 
scoring system. Particular attention was paid to areas of lymphoid aggregation and 
vascular endothelium, specifically in the vessels of the PBP. The sections were also 
examined for staining of hepatocytes, biliary epithelium and sinusoid lining cells. The 
bile ducts were analysed in three categories according to size: proliferating bile ductules 
(the smallest duct branches with a generally inconspicuous lumen, usually confined to 
marginal zones in portal areas), interlobular ducts (small ducts, diameter 20-100um), 
and large ducts of greater than 100um in diameter, usually septal or trabecular ducts.  
 
2.2.4	   Results	  
 
Both APAAP and immunoperoxidase techniques showed similar levels of MAdCAM-1 
immunostaining, but immunoperoxidase gave rather higher background staining than 
APAAP as did using the Triology method of antigen retrieval. MAdCAM-1 
immunoreactivity was seen in all cirrhotic sections of explant liver tissue expression 
being localised primarily to septal areas mainly within the (i) endothelium of the 
peribiliary vascular plexus and (ii) septal-hepatic lymphoid aggregates.  
 
The sections taken from normal livers and non cirrhotic portal hypertension  failed to 
demonstrate any immunoreactivity to MAdCAM-1.Positive ontrols were taken from 
sections of normal colonic tissue, which demonstrated MAdCAM-1 expression on 
vascular endothelium within the lamina propria and submucosa.  
 
2.2.4.1	  	  	  	  	  	  	  	  	  	  	  	  	  Peribiliary	  vascular	  plexus	  	  (fig 2.1, tables 2.1-2.4)	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Around the large to medium bile ducts, 2 layers of vessels showed MAdCAM-1 
immunoreactivity representing the inner and outer layers of peribiliary vascular plexus 
(PBP). MAdCAM-1 expression was seen in vessels around large to medium sized ducts 
in PSC.  In PSC most (7/9) showed MAdCAM-1 expression in vessels around medium 
sized bile ducts; 3 showed moderate staining of the PBP and in the remaining 4 staining 
was weaker. Overall. moderate staining  in the PBP appeared to be more frequently  
present arounds ducts in PSC, compared to the other disease states. In PBC, over half of 
MAdCAM-1 expressing PBP vessels showed only weak immunoreactivity (4/6) with 
the remainder (2/6) showing moderate staining. Double staining with anti-MAdCAM-1 
and anti-CD34 demonstrated co-localisation of CD-34 and MAdCAM-1 in structures 
resembling PBP capillaries (figure 2.4). 
 
There were similar levels of MAdCAM-1 immunoreactivity of the PBP in other 
cirrhotic liver sections.  
 
2.2.4.2	  	   Intrahepatic	  lymphoid	  aggregates (figure 2.1, tables 2.1 to 2.4) 
 
Most patients expressed MAdCAM-1 within septal lymphoid aggregates (6/9 PSC and 
all 7 PBC cases). This appeared as 2 distinct forms, (i) away from the aggregate centre 
in a “peripheral” pattern (3/9 PSC and 6/7 PBC) or (ii) in vessel endothelium - “central” 
pattern of MAdCAM-1 staining (6/7 PSC and 3/9 PBC). 4 of 7 had moderate to marked 
MAdCAM-1 staining intensity conforming to the “peripheral” pattern compared to only 
2/7 in a central pattern of similar intensity. Most of the PSC cases had light MAdCAM-
1 immunoreactivity (5/9) and only one had moderate staining to MAdCAM-1. 
Localisation of MAdCAM-1 to lymphoid aggregates in PSC and PBC was confirmed 
by immunofluoresence microscopy, which showed both the “peripheral” and “central” 
staining patterns.   
 
Focal staining was seen with S100, CD68 and CD21 antibodies but these did not 
correspond to the observed pattern of MAdCAM-1 immunoreactivity. Dual 
immunostaining was also performed with anti-MAdCAM-1 and anti-S100, CD68 and 
CD21,  but these did not co-localise with MAdCAM-1. An example of this has been 
illustrated with CD21 in figure 2.3(G-I). 
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We explored the possibility that the ‘central’ cells within lymphoid aggregates were CD 
34 positive. There was focal staining evident with CD34 that matched the ‘central’ 
pattern of MAdCAM-1 staining in lymphoid aggregates.  
 
All the sections taken from Hepatitis C showed similar immunoreactivity. 
 
2.2.4.3	  	   Lymphatic	   endothelium	   and	   podoplanin	   localisation	   in	  
lymphoid	  aggregates	  and	  the	  peribiliary	  vascular	  plexus	  (figures 2.2 to 2.4)	  
 
Podoplanin was located in vessels with morphological features of lymphatic channels 
that were surrounding, immediately adjacent to, and separate from lymphoid aggregates. 
These vessels were characterised by flattened endothelium without evidence of 
erythrocytes within their lumen and were spatially distinct from vessels expressing 
MAdCAM-1, including the PBP. Co-localisation of CD34 and MAdCAM-1 with a 
different pattern of staining than the podoplanin suggests that the vessels are capillaries 
of the PBP.  
 
There was no evidence of MAdCAM-1 expression in hepatocytes, biliary epithelium, 
hepatic artery, septal connective tissue or sinusoids from any of the liver sections. Only 
one patient with PSC had weak staining of two small vessels at the edge of parenchymal 
nodules. 
2.2.4.4	  	   Negative	  controls	  
 
MAdCAM-1 was not present in normal liver, specimens from extra-hepatic duct 
obstruction, or chronic rejection after liver transplantation. Negative controls incubated 
without primary antibody or with isotype matched anti-IgG were included in all 
experiments. 
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Figure 2.1 (A-E) MAdCAM-1 immunoreactivity patterns in vessels and lymphoid 
aggregates from cirrhotic liver explants of PSC and PBC. Plate	  A	  and	  B	  show	  MAdCAM-­‐1	  immunostaining	   of	   vessels	   around	   	   peribiliary	   glands,	   adjacent	   to	   a	   lymphoid	   aggregate(arrow	  head).	  These	  vessels	  represent	  the	  inner	  (continous	  	  arrow)	  and	  outer	  layers	  (broken	  arrow)of	  the	  peribiliary	   plexus	   (Plate	   B	   higher	   magnification	   x10	   objective). The pattern of staining of the 
lymphoid aggregate (plate C) appears to correspond to follicular dendritic cells. The	   lymphoid	  aggregates	   have	   two	   main	   MAdCAM-­‐1	   immunoreactivity	   patterns:	   “peripheral”	   (plate	   C)	   	   and	  “central”	  (plate	  D).	  The	  high	  endothelial	  venules	  are	  MAdCAM-­‐1	  immunoreactive	  vessels	  (plate	  E)	  within	   lymphoid	   aggregates,	   which	   are	   likely	   to	   represent	   areas	   of	   lymphocyte	   egress.	   (Alkaline	  phosphatase/Fast	  Red	  immunostaining:	  Magnification	  x5	  objective	  A;	  x10	  objective	  B,	  C	  and	  D;	  x20	  objective	  E). 
	   	  
 
74 
 
 
 
 
    Figure	   2.2	   (A-D) Immunohistochemical localisation of the lymphatic phenotypic 
marker    podoplanin in PSC and PBC. Plates	   A	   and	   B	   demonstrate	   podoplanin	   staining	  patterns	   of	   vessels	   around	   a	   lymphoid	   aggregate,	   but	   not	   conforming	   to	   	   “peripheral”	   or	   “central”	  	  MAdCAM-­‐1	   immunoreactivity.	   Note	   the	   portal	   vein	   (single	   arrow)	   containing	   red	   blood	   cells	   	   is	  identifiable,	   as	   is	   the	   muscular	   wall	   of	   the	   hepatic	   artery	   (double	   arrow),	   and	   neither	   shows	  podoplanin	   immunoreactivity.	   Plates	   C	   and	   D	   show	   podoplanin	   staining	   into	   lymphatic	   channels,	  which	  extend	  a	  short	  distance	  into	  the	  parenchyma	  from	  porto-­‐septal	  areas,	  both	  in	  the	  presence	  and	  absence	   of	   inflammatory	   cells.	   (Alkaline	  phosphatase	   immunostaining:	  Magnification	   x10	  objective	  A&B,	  x20	  Objective	  C&D)	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Figure 2.3(A-I) Dual immunofluoresence micrographs showing representations of 
MAdCAM-1 (Panel A and D –green),  CD34 (Panel B and E-red) and CD 21(Panel H-
red) immunoreactivity. Panel A demonstrates MAdCAM-1 immunofluoresence of a peribiliary plexus 
around a large sized bile duct. Panel B  confirms the presence of CD34 immunoreactive vessels around these 
ducts. Panel	  C	  shows	  dual	  colour	  co-­‐localisation	  (yellow)	  of	  MAdCAM-­‐1	  and	  CD34	  fluorescence	  within	  the	  peribiliary	   plexus.	   Plate	   D-­‐F	   shows	   a	   lymphoid	   aggregate	   with	   a	   ‘peripheral’	   pattern	   of	   MAdCAM-­‐1	  immunolocalisation	  (Panel	  D	  maked	  with	  single	  arrow)	  which	  	  fails	  to	  co-­‐localise	  	  with	  CD34	  	  (Panel	  E)	  in	  double	   staining	   (Panel	   F)	   but	   colocalises	   an	   adjacent	   vessel	   endothelium	   (yellow-­‐marked	   with	   double	  arrow).	  Panels	  G-­‐I	  shows	  a	  different	  lymphoid	  aggregate	  from	  the	  same	  tissue	  with	  a	  ‘peripheral’	  pattern	  of	   MAdCAM-­‐1	   immunoreactivity	   (Panel	   G),	   Focal staining was performed  to exclude a dendritic cell 
morphology e.g  CD21(Panel H) but did not correspond to the observed pattern of MAdCAM-1 
immunoreactivity. Dual immunostaining with anti-MAdCAM-1 did not  co-localise with anti-CD21(Panel I) (Magnification	  x20	  objective). 
 
G H I 
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Table	  2.1	  (Primary sclerosing cholangitis: n=9) MAdCAM-1 immunostaining score 
 
 
 
 
MAdCAM-1 Immunostaining score 
No staining  0 
Light staining  1+ 
Moderate staining   2+ 
Marked staining   3+ 
 
 
 
 PATIENT	  	    AGE	    HISTOLOGY	   	  	  	  	  	  	  	  LYMPHOID	  AGGREGATE	  	  	  	  	  	  	  STAINING	  PATTERN	  
 
‘Peripheral’             ‘Central’ 
 PERIBILIARY PLEXUS-                          
BILE DUCT SIZE                    
 
   Large            Medium             Small          
1M 22 Cirrhosis 2+ 1+ 0     0 
 
0  
2F 47 Cirrhosis 2+ 1+ 0 
 
1+ 0  
3F 28 Cirrhosis 0 0 0 
 
2+ 0  
4F 35 Cirrhosis 1+ 1+ 0 
 
2+ 0  
5M 38 Cirrhosis 0 1+ 0 
 
2+ 0  
6F 47 Cirrhosis 1+ 1+ 1+ 1+ 
 
2+  
7M 50 Cirrhosis 0 0 0 
 
0 
 
0  
8M 43 Cirrhosis 3+ 3+ 2+ 1+ 1+ 
 
 
9M 34 Cirrhosis 0 0 0 
 
1+ 
 
0   
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Table	  2.2	  (Primary Biliary Cirrhosis: n=12) MAdCAM-1 immunostaining score	  
 
   
 
 
MAdCAM-1 immunostaining score  
No staining    0         
Light staining   1+ 
Moderate staining   2+ 
Marked   staining   3+  
 
Large ducts were not present in the needle biopsy sprecimens. They are classified as a 
N/A 
 
 
PATIENT AGE HISTOLOGY LYMPHOID 
AGGREGATE 
STAINING 
PATTERN 
‘Peripheral’ 
 
 
 
 
‘Central’ 
PERIBILIARY 
PLEXUS-                          
BILE DUCT 
SIZE                     
 Large 
 
 
 
 
Medium 
 
 
 
 
Small 
1F 61 Cirrhosis 1+ 2+ 0 1+ 1+ 
2F 57 Cirrhosis 2+ 3+ 0 1+ 1+ 
3F 51 Cirrhosis 1+ 0 0 1+ 0 
4F 57 Cirrhosis 2+ 0 0 1+ 0 
5F 36 Cirrhosis 0 1+ 0 2+ 0 
6F 57 Cirrhosis 3+ 0 0 0 0 
7F 47 Cirrhosis 2+ 0 0 1+ 0 
8F 49 Stage1 0 0 N/A 0 0 
9F 52 Stage2 0 1+ N/A 0 0 
10F 49 Stage2 0 0 N/A 0 0 
11F 59 Stage1 0 0 N/A 0 0 
12F 61 Stage1 0 0 N/A 0 0 
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Table	  2.3	  (Alcohol liver disease: n=7) MAdCAM-1 immunostaining score	  
 
 
 
MAdCAM-1 immunostaining score  
No staining               0+ 
Light staining           1+ 
Moderate staining   2+ 
Marked staining      3+ 
 
 
 
 
 
 
 
PATIENT	   AGE	  
HISTOLOGY            PERIBILIARY PLEXUS- 
                 BILE DUCT SIZE                    
 
      Large            Medium                Small 
             
1M 61 Cirrhosis 0 
 
1+ 0  
2F 57 Cirrhosis 0 1+ 0  
 
3M 51 Cirrhosis 0 1+ 0  
 
4F 57 Cirrhosis 0 1+ 0  
 
5M 36 Cirrhosis 0 1+ 1+  
 
6M 48 Cirrhosis 0 1+ 
 
0 
7M 57 Cirrhosis 0 0 0 
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Table 2.4 (Hepatitis C: n=10) MAdCAM-1 immunostaining score.  
 
 
	  
MAdCAM-1 immunostaining score  
No staining   0                        
Light staining   1+           
Moderate staining  2+    
Marked staining  3+    
 
Large ducts were not present in the needle biopsy sprecimens. They are classified as a 
N/A 
 
PATIENT	   AGE	  
HISTOLOGY 
LYMPHOID	  AGGREGATE	  
STAINING	  PATTERN	  
‘Peripheral’   ‘Central’ 
            PERIBILIARY PLEXUS- 
BILE DUCT SIZE 
 
 
 
  Large            Medium            Small 
 
1M 51 Cirrhosis 1+ 2+ 0 
 
1+ 1+  
2M 52 Cirrhosis 2+ 1+ 0 1+ 0  
 
3M 49 Cirrhosis 1+ 2+ 0 1+ 0  
 
4M 
 
5M 
 
6M 
 
7F 
 
8M 
 
9M 
 
10F 
 
 
55 
 
48 
 
48 
 
54 
 
52 
 
53 
 
48 
Cirrhosis 
 
Cirrhosis 
 
Stage2 
 
Stage2 
 
Stage2 
 
Stage1 
 
Stage1 
1+ 
 
1+ 
 
0 
 
0 
 
0 
 
0 
 
0 
0 
 
1+ 
 
0 
 
1+ 
 
0 
 
0 
 
0 
0 
 
0 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
1+ 
 
1+ 
 
0 
 
0 
 
0 
 
0 
 
0 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
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2.2.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Discussion	  
 
My results have demonstrated significant up-regulation of MAdCAM-1 expression in 
chronic liver disease i.e. cirrhosis. Specifically, I found MAdCAM-1 to be localised to 
septal areas primarily within: i) endothelium of the PBP and ii) intra-hepatic (septal) 
lymphoid aggregates. I confirmed the presence of MAdCAM-1 expression in liver 
disease characterised by portal inflammation e.g. PSC and PBC and extended these 
observations to show its presence  in a number of other chronic liver diseases which are  
not necessarily associated with portal inflammation e.g. ALD,  as well as those which 
are unrelated to gastrointestinal inflammation e.g. HCV. 
 
The peribiliary plexus (PBP) is a network of delicate small vessels surrounding the 
intrahepatic bile ducts supplied by branches of the hepatic artery, which drain into 
hepatic sinusoids or branches of the portal vein (Kobatashi et al 1994). The PBP is the 
main vascular supply of the biliary epithelium (Takasaki S et al 2001). It functions in 
supporting the secretory and absorptive properties of the biliary epithelium. I found 
MAdCAM-1 to be expressed in the PBP in a range of bile duct sizes in PSC and PBC 
explants. The specificity of MAdCAM-1 staining is indicated by the fact that bile ducts 
are not stained. The vascular endothelial nature of these structures was confirmed by 
dual immunofluoresence with MAdCAM-1 and CD34.   The distribution of MAdCAM-
1 around the bile ducts differed between PSC and PBC. The smaller single capillary 
layer ducts showed similar levels in both conditions but only large sized bile ducts 
expressed MAdCAM-1 in PSC, an observation which is particularly interesting since 
PSC involves large ducts than PBC i.e. the absence of large duct inflammation in PBC 
and lack of MAdCAM-1 expression around these ducts may reflect regional distribution 
of disease, which was further supported by MAdCAM-1 staining around its small bile 
ducts. In addition, MAdCAM-1 expression on the PBP around medium and large ducts 
is increased in the cirrhotic PSC and PBC liver. Moreover, moderate staining appeared 
more frequently in the PBP of the cirrhotic PSC liver  compared to the other disease 
states. These vessels of the PBP might represent transformed high-endothelial venules 
which in other sites are well characterised for their role in leukocyte trafficking 
(Miyasaka et al 2004) (Hayasaka H et al 2010). That is, there is some evidence to 
suggest that  HEV neogenesis and the  development of the high endothelial venules 
which may mediate lymphocyte trafficking can appear ectopically for instance in 
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chronically inflamed tissues.  
 
There is little previous evidence on the expression of vascular adhesion molecules on 
the PBP. Yasoshima et al (1995) showed some of these vessels to express ICAM-1 in 
PBC but did not study MAdCAM-1. The vascular endothelium can secrete 
proinflammatory cytokines e.g. TNFα and this is a likely amplification step leading to 
the upregulation of adhesion molecules on the endothelium of the peribiliary vascular 
plexus. 
 
The presence of MAdCAM-1 on the endothelium of the PBP is presumptive of a role in 
lymphocyte emigration and recruitment, suggesting MAdCAM-1 acts as a local 
addressin at these sites, using the endothelium of the PBP for egress and as a 
recirculatory pathway to areas of inflammation such as those around bile ducts. The 
possibility that this egress occurs in capillaries is exciting because this lymphocyte-
endothelium interaction could occur in low velocity flow states. The functional 
significance of the expression of MAdCAM-1 on the PBP is uncertain as they are also 
present in cases of HCV and ALD cirrhosis, where bile duct injurt is not a major 
feature. It is possible that the structures immunoeactive to MAdCAM-1 on the PBP are 
functionally post-capillary sinuses which are ideal sites for lymphocyte egress. 
 
Whether MAdCAM-1 upregulation is a late event in the pathogenesis of chronic liver 
disease or a secondary response to inflammation is not known. Cholestasis alone is 
unlikely to be responsible for MAdCAM-1 upregulation due to the lack of expression in 
extrahepatic obstruction. We studied early stage specimens (pre-cirrhotic) in other 
biliary tract diseases e.g. PBC, and non-biliary tract liver disease, unrelated to 
gastrointestinal inflammation such as. HCV, and acute fulminant hepatitis B, to 
characterise the time course of MAdCAM-1 and assess its expression in relation to 
degree of inflammation and bile duct loss. In PBC other adhesion molecules such as 
ICAM-1 appear to be expressed commensurate with the level of inflammation (Adams 
et al 1991). Interestingly, there was minimal evidence of MAdCAM-1 expression in any 
pre-cirrhotic specimens, (PBC, HCV). I detected MAdCAM-1 in nearly all cirrhotic 
liver but not in non cirrhotic liver (non-cirrhotic portal hypertension and normal liver). 
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It therefore follows that the upregulation of MAdCAM-1 was not due to the effects of 
portal hypertension. 
 
The observation that the majority of MAdCAM-1 was upregulated on cirrhotic liver 
suggests that its upregulation might be related to the fibrogenesis or neovascularisation 
of cirrhosis. Certainly, TNFα activation of fibroblasts reportedly induces expression of 
MAdCAM-1 (Leung et al 2003). The possibility that some of the endothelium-lined 
vessels showing immunoreactivity to MAdCAM-1 were actually lymphatic in origin 
was considered using the novel endothelial cell-surface glycoprotein podoplanin, 
originally observed in rat and human kidney as a marker for the endothelium of 
lymphatic vessels (Breitender-Geleff et al 1997). I have demonstrated podoplanin 
expression on vessels with morphological features of lymphatic vasculature, subjacent 
to and separate from lymphoid aggregates but these were morphologically distinct from 
vessels expressing MAdCAM-1. They were characterised by a single layer of flattened 
endothelium without erythrocytes and with intraluminal lymphocytes. There were 
occasional thin-walled branches originating from larger lymphatic vessel in portal-
septal areas extending a short distance between hepatocyte plates. Thus, those areas that 
express MAdCAM-1 in and around septal lymphoid aggregates appear not to be 
lymphatic channels.  
 
There appeared to be two populations of MAdCAM-1 positive cells in the lymphoid 
aggregates. I described the pattern of MAdCAM-1 expression in lymphoid aggregates 
as  “peripheral” or “central” with immunoreactivity in vessel endothelium likely to be 
the HEV. Although definitive conclusions could not be made from our experiments 
regarding the nature of the peripheral staining pattern, it may represent MAdCAM-1 
expression on the specialised dendritic cells e.g. interdigitating reticular cells, follicular 
dendritic cells (FDC) (Szabo et al 1997), or macrophages (Stagg et al 2002).  
 
We explored the possibility that the ‘central’ cells within lymphoid aggregates were CD 
34 positive. There was focal staining evident with CD34 that matched the ‘central’ 
pattern of MAdCAM-1 staining in lymphoid aggregates.  Dual immunostaining with 
MAdCAM-1 and CD 34 to extend these experiments would have been useful  to 
confirm whether these cells were  vascular endothelial  in origin e.g. HEV.  
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The inflammatory processes within the liver may up-regulate MAdCAM-1 locally, 
enhancing recruitment of antigen specific cells. Although there was focal staining seen 
with  S100, CD68 and CD21 antibodies,  surprisingly this did not correspond to the 
pattern seen for MAdCAM-1.  Dual immunostaining was also performed with anti-
MAdCAM-1 and anti-S100, CD68, CD21 but these did not co-localise with MAdCAM-
1.The morphology of some of the lymphoid MAdCAM-1 staining pattern appeared 
similar to dendritic cells e.g. FDC present in Peyer’s patch and also resembled VCAM-1 
immunoreactivity in lymphoid aggregates from end stage viral hepatitis (García-
Monzón et al 1995) and ICAM-1 (Koopman et al 1991), through which they can 
support antigen presentation to α4β1 and LFA-1 expressing B cells, respectively in 
germinal centres, thus leading to their maturation and differentiation into memory cells. 
Hepatic expression of MAdCAM-1 on dendritic  cells could serve as a signal for 
retention of α4β7 lymphocytes in the liver.  The possibility of HEV within lymphoid 
aggregates raises the further possibility of its importance in lymphocyte egress and 
effective recirculation to areas of inflammation. Unfortunately, the dendritic cell 
markers used in our study did not appear to give any comparable immunoreactivity.  
Certainly more extensive dual staining using specific markers for further dendritic cell 
subsets is required to define exactly where MAdCAM-1 protein is expressed. If 
MAdCAM-1 appears to be expressed in dendritic cells within the liver then this would 
suggest that it has a more extensive role then acting as an addressin in chronic liver 
disease.  
 
The activation of α4β7 mucosal lymphocytes recruited from the gut to the PSC liver is a 
possible mechanism by which hepatic inflammation is maintained in some patients with 
IBD. The concept that lymphocytes programmed to home to the gut may also home to 
the liver constitutes an attractive hypothesis linking chronic IBD with liver 
inflammation.  These results concur with those by Grant et al (2001) confirming 
MAdCAM-1 expression in liver cirrhosis secondary to PSC. We have extended these 
observations to demonstrate MAdCAM-1 in other cirrhotic liver diseases e.g. PBC, 
(where we see similar patterns of MAdCAM-1 expression in the vascular beds of the 
PBP) as well as ALD and HCV. We did not see MAdCAM-1 expression in normal 
liver, extra-hepatic biliary obstruction and very little in the way of pre-cirrhotic stages 
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of liver disease. In all cases the isotype-matched control used displayed no reactivity, 
suggesting that the stain with anti-MAdCAM-1 was real.  
 
In conclusion, we have provided evidence to suggest that MAdCAM-1 may contribute 
to the pathogenesis of end stage immune mediated liver disease. Furthermore these 
observations have been extended to include other non-cholestatic bile duct chronic liver 
diseases. Further investigation of the expression and modulation of MAdCAM-1 
expression could lead to improved understanding of the pathophysiology of end-stage 
liver disease and provide the basis for the development of new therapeutic modalities. 
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2.3	   Experiment	  2:	  Expression	  of	  MAdCAM-­1	  in	  inflammatory	  
bowel	  disease	  	  
	  2.3.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  Background	  
 
Crohn’s disease (CD) and ulcerative colitis (UC) comprise chronic inflammatory bowel 
disease, the aetiology of which still remains unclear. Crohn’s disease is characterised by 
non caseating granulomas, lymphoid aggregates and extension of inflammation through 
all layers of the bowel wall. Ulcerative Colitis is characterised by mucosal inflammation 
and extensive formation of ulcers which are usually confined to the submucosa.  
 
Briskin et al (1997) report a ubiquitous over expression of MAdCAM-1 in venules in 
mucosal inflammation sites in CD and UC. However, differences in immunological 
backgrounds suggest different expression patterns of cell adhesion molecules between 
UC and CD. Cytokine analysis in CD demonstrates an increased expression of IL-2, 
IFN-y and IL-12 (produced by antigen presenting cells), which suggests the 
predominance of the T-helper type 1 (Th1)response. Ulcerative colitis seems to be an 
atypical Th2 disorder, in which the Tcell-profile has been more difficult to characterise. 
This disease was considered to have Th2 profile but the concentrations of 1L-4 and IL-5 
which are normally elevated in Th2 mediated diseases have been variable in UC tissues. 
2.3.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  Hypothesis	  and	  Aims	  
 
Our hypothesis is that there are regional differences in MAdCAM-1 expression between 
Crohn’s disease and ulcerative colitis and this reflects the distribution of the disease. 
With this in mind, we set out to characterise the expression of MAdCAM-1 in 
inflammatory bowel disease by immunohistochemical analysis. 
 
2.3.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Methods	  
 
Surgically resected tissue specimens were prospectively obtained immediately after 
removal from seven patients with Crohn’s disease (five men and two women, median 
age 34.1 years) and six with ulcerative colitis (four men and two women, median age 
29.7 years). The patients with Crohn’s disease included four ileocolitis and   three with 
terminal ileal diseases. Patients with ulcerative colitis included four with pancolitis and 
two with left sided disease. All the patients were treated with corticosteroids before the 
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operation. Control tissue consisting normal appearing colon and small intestine tissue 
was obtained from 5 patients with colorectal carcinoma. Tissue samples were collected 
from either macrospically uninvolved areas at a distance of 2-4 cms from the inflamed 
area or from centres of severely affected tissue. The indications for surgery included 
disease refractory to treatment, chronic stenosis or both in Crohn’s disease, long 
standing pancolitis or those individuals with left sided colitis in UC. In all cases, 
diagnosis was confirmed by histopathological examination of the resected specimen. 
 
2.3.3.1	  	  	  	  	  	  	  	  	  	  	  	  	  Immunohistochemistry	  
 
The tissue samples were collected immediately after elective surgical resection and 
formalin fixed. Immunohistochemistry was performed as described earlier in this 
chapter. The negative control consisted replacement of the primary antibody with 
isotype-matched negative control antibodies (DAKO UK). 
 
2.3.3.2	  	  	  	  	  	  	  	  	  	  	  	  	  Morphometric	  analysis	  
 
Two observers (Aftab Ala and Richard Standish) independently assessed the sections 
semiquantively and scored the staining on a scale of 0-3 according to the degree of 
MAdCAM-1 immunoreactivity (0-no staining, 1-mild staining, 2-moderate staining and 
3- marked staining, without knowledge of the histological diagnosis. The staining 
methods were repeated twice to validate the scoring system.  To quantify the expression 
of MAdCAM-1 whole areas of the ulcer base and active inflammation from each slide 
in 5 representative fields per high power field (at a magnification of x40 objective) were 
studied. The average numbers of vessels immunoreactive to MAdCAM-1 were 
calculated in the lamina propria, submucosa or mucosa.  Five visual fields within the 
mucosa, submucosa and muscularis mucosa  were chosen randomly from each section 
for semi-quantitative light microscopic analysis (x40 objective) so as to assess the 
extent of the endothelial expression of MAdCAM-1 positive vessels and then quantify 
the number of MAdCAM-1 positive vessels on a section serial stained for CD34. The 
percentage of CD34 positive vessels that co-expressed MAdCAM-1 vessels was 
estimated and the results were expressed as semi-quantitative scores. Only tissues 
without histological signs of inflammation were included as ‘uninvolved’. There was no 
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relationship between the presence of granuloma formation in CD and associated nearby 
or focal MAdCAM-1 immunoreactivity upregulation or intensity of staining. 
 The	   distinction	   between	   capillaries	   and	   venules	   were	   made	   on	   the	   following	  criteria:	   capillaries consist of a single layer of endothelial cells; they have a luminal 
diameter from 4-10 µm; they do not have a tunica media and little or no tunica 
adventitia; they are predominantly localised to the lamina propria. Venules are initially 
formed by the confluence of a number of capillaries. These are distinguished by size 
from capillaries,  being 20-30 µm in diameter with a muscular wall. 
 
Comparisons between groups were made using the Mann-Whitney two tailed test for 
unpaired samples. Correlations were tested using Spearman’s rank correlation test. 
2.3.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	  
2.3.4.1	  	  	  	  	  	  	  	  	  	  	  	  	  Control	  mucosal	  tissues	  (Figure	  2.4	  i	  to	  ii)	  
 
MAdCAM-1 was expressed sporadically in the endothelial cells of venules in the 
lamina propria and submucosa compared to relative paucity in the subserosa or 
muscularis mucosa in control large intestine. There was absence of immunoreactivity on 
arteries and very little on arterioles and veins. MAdCAM-1 immunoreactivity in an 
individual vessel usually was either very strong or could not be detected at all; only few 
vessels showed weak staining.  
 
2.3.4.2	  	  	  	  	  	  	  	  	  	  	  	  	  MAdCAM-­1	  in	  the	  uninvolved	  gut	  adjacent	  to	  inflammation	  	  	  	  
(Figure 2.5 to 2.7, table 2.5) 
 
In the uninvolved area of CD and UC, MAdCAM-1 showed distribution patterns and 
staining intensity similar to those seen in the normal gut. As in controls 
immunoreactivity for MAdCAM-1 was restricted to venules and a few veins, but was 
not detected on arterial vessels. Vascular endothelium was more often MadCAM-1 
positive in the mucosa and submucosa than in the serosa or muscularis  propria. 
Evaluation of semiquantitative analysis showed no significant differences between 
uninvolved areas of IBD and the normal gut (Table 2.5, figure 2.6 to 2.8). 
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2.3.4.3	  	  	  	  	  	  	  	  	  	  	  	  	  MAdCAM-­1	  in	  the	  inflamed	  gut	  (Figures 2.4iii to iv& 2.5 to 2.8, 
table 2.5) 
 
In highly inflamed areas of CD and UC, there was  upregulation of MAdCAM-1.  
MAdCAM-1 expression was multi-focal i.e. localised to both the luminal and ab-
luminal aspect of venular endothelial cells, within the lamina propria but only partially 
encircled the venular endothelial surface. In CD, MAdCAM-1 was expressed in venular 
endothelial and gut associated lymphoid tissue (figure 2.4iii); there were consistent 
MAdCAM-1 immunoreactivity patterns on the venular endothelium within the tunica 
muscularis and serosa in all cases of highly inflamed CD, consistent with the pattern of 
disease i.e. immunoreactivity was observed in all layers of the intestinal wall.  There 
were no clear differences between the intensity of staining patterns in CD and UC in the 
venular endothelium or the lymphoid aggregates. However, taking into account the ratio 
of MAdCAM-1  venules to  CD34+ vessels in comparison with normal bowel, inflamed 
colon lesions of Crohn’s disease showed a significant  increase in MAdCAM-1 
immunoreactivity score on venules (p<0.001). In ulcerative colitis,  the significance 
between inflamed colon lesions and the normal bowel or uninvolved gut  reached a 
level of p<0.01. Overall, comparing active Crohn’s disease with ulcerative colitis the 
level of signifiance was p<0.05 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   (i)                          (ii)                           
 
 
 
 
 
 
±±±±±±±±± 
 
 
 
 
 
 
 
 
 
 
 
 
 
  (iii)                (iv) 
 
 
Figure	  2.4	  Immunohistochemical localisation of MAdCAM-1 in the gastrointestinal 
tract and inflammatory bowel disease. MAdCAM-­‐1	  immunoreactivity	  (red)	  in	  Formalin	  fixed	  tissue	  sections	  of	  vascular	  endothelium	   	   from	  colon	  explants	  of	  histologically	  normal	   large	  bowel	  tissue(i	  and	   ii),	  where	  MAdCAM-­‐1	   is	   	   localised	  to	  endothelial	   lined	  venules	  of	   the	   	   lamina	  propria	  and	   submuosa	   	   (iii)	   gut	   associated	   lymphoid	   tissue,	  with	  differential	   expression	  of	  MAdCAM-­‐1	   in	  venules	  within	   lymphoid	  aggregates	   	  of	   the	  submucosa,	   compared	   to	  sub-­‐serosa,	   suggesting	   	   that	  gut	   associated	   tissues	   are	   more	   abundantly	   involved	   in	   Crohn’s	   disease	   than	   ulcerative	  colitis.(iv)advanced	  Crohn’s	  disease,	  where	  MAdCAM-­‐1	  was	  observed	  in	  all	   layers	  of	  the	  intestinal	  wall	   and	   no	   relationship	   between	   MAdCAM-­‐1	   immunoreactivity,	   granulomas	   or	   neighbouring	  	  	  blood	  vessels.	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Figure 2.5 MAdCAM-1 immunoreactivity in inflamed colonic mucosa from a patient with advanced 
Crohns disease taken from a high power view of figure 2.4 (iv). MAdCAM-1 immunolocalisation  to 
both the luminal and abluminal aspect of venular endothelial cells in the lamina propria and submucosa. 
The abluminal aspect refers to the side away from the lumen of the venular endothelial cells. MAdCAM-1 
expression was multifocal,  in that there was variation in the distribition of  MAdCAM-1 in venular 
endothelium and did not always encircle the entire venular endothelium.  
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Table	  2.5	  Differential MAdCAM-1 expressions in Crohn’s disease, ulcerative colitis 
and normal colon tissues. MAdCAM-­‐1	   immunoreactivity	   on	   vascular	   endothelium	   in	   normal	  colon	  (n=5),	  un-­‐involved	  (n=7)	  and	  highly	  inflamed	  (n=7)	  gut	  in	  Crohn’s	  disease,	  uninvolved	  (n=6)	  and	  highly	  inflamed	  gut	  (n=6)	  in	  Ulcerative	  Colitis.	  A=artery,	  As=arteriole,	  Vein=vein,	  Ven=venule,	  Cap=capillary.	  Only tissues without histological signs of inflammation were included as ‘uninvolved’. There	   is	   upregulation	   of	   MAdCAM-­‐1	   in	   highly	   inflamed	   CD	   and	   UC.	   There	   was	   consistant	  immunoreactivity	  on	  the	  venular	  endothelium	  within	  all	  layers	  of	  the	  intestinal	  wall	  in	  CD.  
	  
 
MAdCAM-1 
immunoreactivity 
score 
Normal 
 Colon 
 (n=5) 
Uninvolved  
CROHN’S DISEASE 
(n=7) 
Highly inflamed 
 CROHN’S DISEASE 
(n=7) 
 A As Vein Ven Cap A As Vein Ven Cap A As Vein Ven Ca 
3+ 0 0 0 0 0 0 0 0 1 0 0 0 2 4 0 
2+ 0 0 1 1 0 0 0 1 1 0 0 0 0 2 0 
1+ 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
Nil  5 5 4 3 5 7 7 6 5 7 7 7 5 1 7 
 
 
MAdCAM-1 
immunoreactivity 
score 
Normal 
 Colon 
 (n=5) 
Uninvolved 
 ULCERATIVE COLITIS 
(n=6) 
Highly inflamed  
ULCERATIVE COLITIS 
(n=6) 
  A As Vein Ven Cap A As Vein Ven Cap A As Vein Ven Ca 
3+ 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 
2+ 0 0 1 1 0 0 0 1 0 0 0 0 0 1 0 
1+ 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 
Nil  5 5 4 3 5 6 6 5 5 6 6 6 5 3 6 
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Figure  2.6 MAdCAM-1 immunoreactivity 
 in venules in normal colon(n=5),  
uninvolved(n=7) and highly inflamed gut in 
Crohn’s disease(CD)(n=7). In comparison with 
normal colon(+), inflamed lesions of Crohn’s 
disease (+++) showed a significant increase in 
MAdCAM-1 immunoreactivity scores(p=0.001). 
Figure  2.7 MAdCAM-1 
immunoreactivity in venules in normal 
colon(n=5),  uninvolved(n=6) and highly 
inflamed ulcerative colitis (UC) (n=6). 
MAdCAM-1 expression was upregulated 
in active ulcerative colitis (***)compared 
with normal colon(*) and uninvolved 
colon(**). 
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Figure	  2.8	  Percentage	  of	  CD34	  positive	  vessels	  co-­expressing	  MAdCAM-­1	  in	  IBD	  There	   is	  differential	   expression	   	  MAdCAM-­‐1	   in	  venules	   in	  ulcer	  bases	  of	  Crohn’s	  disease	  and	  ulcerative	  colitis	  .	  The	  vertical	  axis	  represents	  the	  ratio	  of	  MAdCAM-­‐1	  venules	  to	  CD34	  total	   vessels(box-­‐whisker	   plots).	   Neg=normal	   bowel,	   Neu=unaffected	   gut,	   positive	  inflamed	  gut.	   	  MAdCAM-­‐1	  venules	  appeared	  to	  be	  	  more	  frequently	  observed	  in	  the	  ulcer	  base	   in	   Crohn’s	   disease	   than	   normal	   or	   unaffected	   gut	   tissue	   as	   demonstrated	   by	   the	  difference	   in	   the	   ratio	   of	   of	   MAdCAM-­‐1	   venules	   to	   CD34(p<0.001).	   	   The	   differences	   in	  ulcerative	  colitis	  compared	  to	  normal	  and	  unaffected	  tissues	  were	  relatively	  less	  apparent	  at	  p<0.01.	  There	  was	  an	   increased	  expression	  of	  Crohn’s	  MAdCAM-­‐1	  venules	   to	  CD34	   in	  comparison	  to	  ulcerative	  colitis	  at	  p<0.05	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2.3.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Discussion	  
 
Our results demonstrates upregulation of endothelial expression of MAdCAM-1 in CD 
and UC, where significant MAdCAM-1 expression was found within inflamed areas of 
colonic IBD, compared to histologically normal mucosa in confirmation of preliminary 
findings by Briskin et al (1997) and Souza et al (1999), which suggests that MAdCAM-
1 may participate in the recruitment of circulating inflammatory cells into inflammatory 
lesions.  
 
MAdCAM-1 venules were abundant in inflamed mucosa in both UC and CD. There 
were however important differences noted between UC and CD. We found 
immunolocalisation within inflammatory areas at the ulcer base, where MAdCAM-1 
venules appeared to be predominant in CD, and interestingly favoring venules within 
the deeper layers of the intestinal tissue, mainly in lymphoid aggregates. These 
observations demonstrate  a more extensive expression of MAdCAM-1 in CD, which  
could therefore  contribute to transmural inflammation as well as mucosal 
inflammation, suggesting that MAdCAM-1 is involved not only in the initial phase of 
inflammation at the mucosal level, but also in the progression phase of CD, towards 
transmural inflammation and inflammatory reactions in ulcer bases. It is possible that 
also our observations demonstrating the higher occurrence of   MAdCAM-1 laden 
venules in the submucosa lymphoid aggregates than subserosa suggests that 
MAdCAM,-1 expression may be upregulated by bacteria in the intestinal tissues or 
enhancing entry of dietary antigens.  Our observations accord with the more extensive 
nature of MAdCAM-1 immunoreactivity in CD as noted in parallel by Arihiro et al 
(2002). However, these workers used different sets of MAdCAM-1 antibodies i.e 
monoclonal, different antigen retrieval methodology and tissue samples which had been 
fixed frozen compared to our formalin fixed materials. It is interesting to note that when 
taking in account the  ratio of MAdCAM-1 venules to CD34+ there is also significant 
MAdCAM-1 expression in ulcerative colitis  with  normal/uninvolved tissues (figure 
2.8). Dual immunostaining as a method of co-localisation may have been useful as a 
method of confirming colocalisation of CD34 with MAdCAM-1 in our tissue samples. 
Our observations on ulcerative colitis contrasts with those from figure 2.7 where the 
significance was less apparent. A possible reason for this difference may relate to the 
active  angiogenesis and related pre-angiogenic factors critical in ulcer  healing  in 
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ulcerative colitis leading to new vessel formation and  therefore an increase in the 
MAdCAM-1 venules to CD34+ ratios (Danese et al 2008). 
 
In IBD, perhaps surprisingly, there was no evidence of significant up-regulation of 
MAdCAM-1 in histologically non-inflamed tissues, adjacent to inflamed lesions. Given 
the susceptibility of any segment of the gastrointestinal tract to be affected by CD and 
the continuous spread of UC, areas in the vicinity of inflammation will probably 
become inflamed in the later course of disease and thus be regarded as ‘early’ lesions. 
MAdCAM-1 expression therefore appears to follow the onset of inflammation. Of 
course, that may be a very low level expression in uninvolved gut, which may not be 
detected by immunohistochemistry. Alternatively, as these tissues were all previously 
exposed to corticosteroids,  it is possible that the lack of expression is a modulatory 
effect of  corticosteroids on MAdCAM-1. This has been studied in an invitro setting in 
chapter 5. 
 
 We found that three out of the four specimens taken from ileo-caecal CD had 
granulomas that initially appeared to have extremely high expression of MAdCAM-1.  
We tested the hypothesis that MAdCAM-1 is important in the pathogenesis of 
granulomas in CD but there was no consistent pattern between granulomas and 
associated immunoreactive venules. Furthermore, when these sections were stained 
without the primary antibody there was similar focal concentration of fast red 
immunoreactivity indicating this was likely to be non-specific, possibly due to FcR 
expression by granulocytes/macrophages. 
 
The upregulation of MAdCAM-1 during gut inflammation has been suggested to be 
responsible for the establishment of chronic inflammation via the recruitment of α4β7 
lymphocytes. The functional significance of MAdCAM-1 in IBD has been highlighted 
by studies where immunoneutralisation of either MAdCAM-1 or α4β7 intergrin 
attenuate inflammation in animal models as well as patients with IBD, which we have 
already discussed in Chapter 1. Numerous animal models of colitis have been used to 
study the mechanisms for the development of chronic IBD. As we have observed in 
normal colon human MAdCAM-1 is constitutively expressed on the venular 
endothelium of the lamina  propria and submucosa, where as in murine experimental 
colitis models MAdCAM-1 is induced on colonic vascular and on the vessels within 
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serosa and muscularis propria when compared to control animals. (Viney et al 1996). 
One elegant and important  study by Soriano et al (2000) using mice from the age of 4 
weeks to 40 weeks showed that blockade with MAdCAM-1 antibodies alone during 
established inflammation was less effective than the combined synergistic blockade of 
MAdCAM-1 and VCAM-1  (which is also strongly expressed in the SAMP/Yit  mice 
with spontaneous ileitis). Futheremore, since the simultaneous blockade of both cellular 
adhesion molecules significantly attenuated T-lymphocyte binding to microvessels in 
the ileal mucosa, it is possible that pathways independent of the α4β7/MAdCAM-1 can 
also mediate trafficking to inflamed intestine (Matsuazaki et al 2005). Furthermore, 
prophylactic blockade of MAdCAM-1 prevented the development of ileitis, whereas the 
early administration of VCAM-1 antibodies had no effect supporting the earlier concept 
that the contribution of MAdCAM-1 is likely to be most pronounced during the early 
phases of IBD. Thus, it is likely that MAdCAM-1 affects ileal inflammation locally not 
only in the mucosa but also in the mesenteric lymph node (MLN), as significant 
amelioration of acute and chronic infiltrates have been observed when both MAdCAM-
1 and L-selectin are blocked. 
2.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Experiment	  3:	  	  Expression	  of	  MAdCAM-­1	  in	  the	  human	  
pancreas.	  	  
 
2.4.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  Background	  
 
The pancreas is an intriguing organ with a rich blood supply, facilitating the recruitment 
of lymphocytes. It is already known to express some adhesion molecules constitutively 
e.g. ICAM-1 and VCAM-1, which are known to be important for lymphocyte 
recruitment (Komatsu et al 2000). MAdCAM-1 is the main vascular addressin 
responsible for homing of lymphocytes laden with α4β7 to emigrate into the gut and 
gut-associated lymphatic tissues. However, the expression of MAdCAM-1 in 
extraintestinal tissues such as the human pancreas has not been fully characterised. We 
have seen that lymphocyte homing to mucosal associated lymphoid tissue (MALT) such 
as Peyer’s patches and the lamina propria of the intestine is critically dependant on 
MAdCAM-1. The restricted expression of MAdCAM-1 is acquired during embryonic 
development.  This is supported by early fetal expression (7-17 weeks gestation) of 
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MAdCAM-1 in the micro vessels of many extraintestinal tissues e.g. peripheral lymph 
nodes, skin, muscle, spleen and also the pancreas (Salmi et al 2001). 
 
Our earliest observations confirm the significant upregulation of MAdCAM-1 in active 
inflammatory bowel disease, where we have confirmed expression to be localised on 
endothelia cells in lamina propria of the gastrointestinal tract. It has been reported that 
MAdCAM-1 becomes expressed on islet cells of non obese diabetic (NOD) mice at a 
relatively early phase during lymphocyte accumulation (Hänninen et al 1998). The 
NOD mouse is an appropriate model for insulin-dependent diabetes mellitus, since it 
itself results from destruction of pancreatic beta cells by mononuclear cells infiltrating 
the islets of Langerhans. As it is well known that MAdCAM-1 preferentially mediates 
the homing of mucosal lymphocytes, it is conceivable that islet associated MAdCAM-1 
favours the accumulation of such mucosal lymphocytes into pancreatic islets, 
suggesting that MAdCAM-1 may have a role in the pathogenesis of chronic 
pancreatitis.  
 
The aim of this part of the study was to identify and localise the expression of 
MAdCAM-1 in the human pancreas.  
 
2.4.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Methods	  
 
MAdCAM-1 expression was determined by immunohistochemistry on human pancreas 
from a total of 7 patients with chronic pancreatitis (5male, 2 female, age range to 46-64, 
median 53 yrs) with chronic pancreatitis associated with pancreatic adenocarcinoma.  
For comparison, we used 4 samples of normal pancreatic tissue, two samples from type 
I diabetes with chronic pancreatitis and six with pancreatic adenocarcinoma only during 
staging laparoscopy. 
 
Negative controls included sections without primary antibody and also isotype matched 
purified IgG.  
 
Positive controls for MAdCAM-1 expression were taken from samples of normal colon 
tissue, which constitutively expresses MAdCAM-1(as previously described in section 
2.2.3). The tissue samples were taken from resection on those patients undergoing 
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pancreatectomy for pancreatic adenocarcinoma. All these patients had a history of 
chronic excess alcohol consumption. However, it was impossible to be certain that 
chronic pancreatitis preceded carcinoma.  
 
All pancreatic tissues were fixed in 10% buffered formalin and embedded in paraffin. 
Sections were cut at four micron thickness on to APES (3-aminopropy triethoxysiline) 
coated slides and one section was stained with haematoxylin and eosin. For comparison 
immunohistochemistry was carried out using both three stage immuno-alkaline 
phosphatase (APAAP) and three stage immunoperoxidase techniques as described 
earlier in this chapter. 
 
2.4.2.1	  	  	  	  	  	  	  	  	  	  	  	  	  Morphological	  analysis	  
 
Two observers (Aftab Ala and Richard Standish) independently assessed the sections 
semiquantitativley and scored on a scale of 0-3+ according to the intensity of 
MAdCAM-1 immunoreactivity: grade 0 did not exhibit staining, grade 1+: light, grade 
2+: moderate, grade 3+: marked staining, without knowledge of the histological 
diagnosis.  Particular attention was paid to areas of lymphoid aggregation and vascular 
endothelium in relationship to the pancreatic islets and acinar cells. The staining 
methods were repeated twice to validate the scoring system.  
 
2.4.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	  (Table 2.6, Figure 2.6 to 2.7) 
 
There was very weak constitutive staining of periductal and intracinar capillary vessels 
in normal pancreas. Intensity of MAdCAM-1 immunoreactivity increased in all cases of 
chronic pancreatitis, compared to normal and pancreatic carcinoma. On the whole the 
islets were devoid of immunoreactivity in the normal pancreas. Focal immunostaining 
of lymphoid aggregates was seen for S100, CD68 and CD21 but the staining pattern did 
not correspond to the pattern of MAdCAM-1 immunoreactivity 
 
Positive controls: These were taken from sections of normal colonic tissue, which 
demonstrated MAdCAM-1 expression on vascular endothelium within the lamina 
propria and submucosa. 
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Negative controls: MAdCAM-1 was not present in negative controls incubated without 
primary antibody or with isotope matched anti-IgG.  
 
Characteristic features of chronic pancreatitis with advanced peri- and intralobular 
fibrosis of pancreatic parenchyma were observed in all study cases. Exocrine acinar 
cells appeared atrophic. The presence of fibrous connective tissue was observed both in 
exocrine texture and pancreatic islets. The ducts were dilated and focally proliferated, 
and some were filled with partially calcified protein plugs. The duct epithelium adjacent 
to these plugs was flattened or destroyed. In the areas of inflammatory cell infiltration 
and fibrosis there were lymphoid aggregates with MAdCAM-1 immunoreactivity. 
  
We found MAdCAM-1 upregulation in chronic pancreatitis, compared to slightly 
weaker evidence of expression in pancreatic carcinoma. MAdCAM-1 expression was 
immunolocalised to the periductal and intracinar capillary vessels.  
 
In the majority of cases, the islets were devoid of immunoreactivity. Interestingly, in 
two cases of type 1 diabetes mellitus, there was staining of perineural capillaries in 
association with inflammatory cell infiltration, adjacent to islets and in one case only 
there appeared to be immunoreactive capillary vessels within a single islet.  
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Table	  2.6	  MAdCAM-1 immunoreactivity in normal pancreas, pancreatic carcinoma 
and chronic pancreatits  The	  sections	  were	  assessed	  semiquantitativley	  and	  scored	  on	  a	  scale	  of	  0-­‐3+	  according	  to	  the	  intensity	  of	  MAdCAM-­‐1	  immunoreactivity:	  grade	  0	  did	  not	  exhibit	  staining,	  grade	  1+:	  light,	  grade	  2+:	  moderate,	  grade	  3+:	  marked	  staining.   
 
PANCREATIC 
CARCINOMA 
PATIENT 5 1+ 0 0 
PATIENT 6 1+ 0 0 
PATIENT 7 1+ 0 0 
PATIENT 8 0 0 0 
PATIENT 9 0 0 0 
PATIENT 10 1+ 0 0 
CHRONIC 
PANCREATITIS 
PATIENT 11 1+ 0 1+ 
PATIENT 12 3+ 1+ 2+ 
PATIENT 13 1+ 0 0 
PATIENT 14 1+ 0 1+ 
PATIENT 15 2+ 1+ 0 
PATIENT 16 2+ 0 0 
PATIENT 17 1+ 0 1+ 
 
 
 
 
NORMAL 
PANCREAS 
MAdCAM-1 
immunoreactivity in 
Acinar Cells 
MAdCAM-1 
immunoreactivity in 
Pancreatic Islets 
MAdCAM-1 
 in lymphoid aggregates 
PATIENT 1 0 0 0 
PATIENT 2 1+ 0 0 
PATIENT 3 0 0 0 
PATIENT 4 1+ 0 0 
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(A) 
 
(B) 
Figure	   2.9	   MAdCAM-1 staining patterns in periductal and intra acinar capillary 
vessels of human pancreas using peroxidase methodology. Plate	  A	  and	  B	  shows	  groups	  of	  
of islet cells lying within a lymphocytic infiltrate including lymphoid aggregates. Although in the 
majority of chronic pancreatitis cases the islets were devoid of MAdCAM-1 immunoreactivity, 
MAdCAM-1 staining within the islet cell lymphoid aggregate is typical of the staining as a whole.	  (Plate	  A	  magnification	  x5	  objective,	  Plate	  B	  x20	  objective). 
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(A) 
 
(B) 
 
Figure	   2.10	   APAAP methodology of immunostaining demonstrating islet capillaries 
and islet cells. Although	  there	  is	  relatively	  weak	  expression	  within	  normal	  islet	  cells,	  strong	  focal	  MAdCAM-­‐1	   expression	   is	   found	   localised	   to	   high	   endothelial	   venules	   (mainly	   in	   a	   ‘ring	   pattern’)	  within	   focal	   areas	   of	   chronic	   inflammation.	   (Plate	   A	   magnification	   x5	   objective,	   Plate	   B	   x20	  objective). 
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2.4.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  Discussion	  
 
Our study shows upregulation of MAdCAM-1 expression in chronic pancreatitis 
compared to controls from normal and pancreatic carcinoma tissues. Specifically, 
MAdCAM-1 immunolocalises to the periductal and intra-acinar capillary vessels in the 
human pancreas with increased intensity of staining in chronic pancreatitis. This 
observation suggests that endothelial MAdCAM-1 is involved in lymphocyte entry into 
the tissues of chronic pancreatitis. Chronic pancreatitis is histologically characterized by 
extended fibrosis and infiltration of leukocytes. Cellular infiltrates are present already in 
early stages of chronic pancreatitis, but the mechanisms responsible for their 
recruitment into human pancreas are unknown.  
 
The differences which we have observed in restricted immunolocalisation of 
MAdCAM-1 in the pancreas suggest a mechanism for controlling cellular traffic in the 
pancreas.  The differential MAdCAM-1 expression in pancreatic parenchyma and 
infiltrates from patients with chronic pancreatitis strongly suggests an involvement in 
the initiation and perpetuation of disease. In support of these conclusions it is interesting 
to note that from our two cases of type I diabetes mellitus and chronic pancreatitis,   
there was MAdCAM-1 immunoreactivity of vessels, in association with inflammatory 
cell infiltration, adjacent to islets and in one case there appeared to be MAdCAM-1 
immunoreactive capillary vessels within a single islet. The staining of the periductal and 
intraductal capillary vessels appeared uniform, compared to the differential staining 
pattern of the venules seen in the colonic tissues described earlier in the chapter. 
Typically there are groups of islet cells lying within a lymphocytic infiltrate including 
lymphoid aggregates. Although in the majority of chronic pancreatitis cases the islets 
were devoid of MAdCAM-1 immunoreactivity, MAdCAM-1 staining within the islet 
cell lymphoid aggregate is typical of the staining as a whole.  In the inflamed pancreas 
of non-obese diabetic mice, elevated levels of MAdCAM-1 in high endothelial like 
vessels of the Langerhans is also observed.  
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There is evidence to suggest these mice develop autoimmune-mediated lymphocytic 
inflammation of pancreatic islets (insulitis), which leads to beta-cell destruction, and 
development of diabetes (Xang et al 1997). Inflamed islets of these animals show the 
expression of lymphocyte α4β7 integrin and endothelial MAdCAM-1 adhesion 
molecules involved in tissue-selective migration of lymphocytes to mucosal lymphoid 
tissues. The tissue samples used in our study were taken from resection on those 
patients undergoing pancreatectomy for pancreatic adenocarcinoma. All these patients 
had a history of chronic excess alcohol consumption. However, it was impossible to be 
certain that chronic pancreatitis preceded carcinoma. Other aetiologies of chronic 
pancreatitis include inherited genetic predisposition (hereditary pancreatitis), or 
autoimmune pancreatitis. In our series, the chronic pancreatitis may have been 
associated with duct obstruction secondary to the pancreatic adenocarcinoma, which 
limits the interpretations from the results.  
  
 
The modest but clear presence of MAdCAM-1 in our samples from pancreatic tumour 
and the recent observations linking Tregulatory cells and MAdCAM-1 in pancreatic 
carcinoma may be significant. (Nummer et al 2007). The data demonstrate a previously 
unrecognised role of tumour endothelium for the selective recruitment of Treg cells. 
Such recruitment involves selective interactions between Treg cells and the tumor 
vasculature mediated by adhesion molecules and respective ligands e.g. α4β7. These 
findings suggest that the development of new therapeutic strategies based on targeted 
endothelial blockade could have merit in therapy.  
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Chapter	  3	  
 
Establishing an in vitro model to  
Investigate MAdCAM-1 expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
3.1	   Overview	  
 
In chapter 2 we demonstrated that MAdCAM-1 is expressed constitutively in the gut, 
and is upregulated in liver and gastrointestinal inflammation. Specifically, we have 
shown that MAdCAM-1 is upregulated in the inflamed colonic mucosa of humans with 
UC and CD, with increased expression in deeper layers of the bowel wall in surgically 
resected Crohn’s tissues.  MAdCAM-1 also seems to play critical roles in several 
chronic immune and inflammatory conditions e.g. chronic pancreatitis. We 
hypothesised that MAdCAM-1 acts as a local addressin in the gut and liver concerned 
with the recirculation and homing of lymphocytes to these organs during inflammatory 
processes.  
 
As we have discussed earlier, the expression of other cell adhesion molecules ICAM-1 
and E-selectin on endothelial cells have been well characterised. In marked contrast, the 
mechanisms underlying the regulation of MAdCAM-1 expression and the effect of 
MAdCAM-1 modulation from therapies related to IBD have been ill defined, in large 
part because of the lack of a suitable in vitro endothelial cell culture system in which 
this organ specific adhesion molecule is expressed. Since the original report on 
MAdCAM-1 regulation by Sikoski et al (1993), few other studies have examined the 
regulation of MAdCAM-1, particularly within high endothelial venules, which are most 
relevant to chronic gut inflammation and inflammatory bowel disease. Since the entry 
of lymphocytes into specialised venules appears to regulate chronic gut inflammation an 
improved understanding of the factors which promote MAdCAM-1 expression will 
inform modalities for the modulation of MAdCAM-1. 
 
MAdCAM-1 expression in vitro has previously been reported in high endothelial 
venules and brain capillary cell lines (Steffen et al 1996). Most experimental studies on 
MAdCAM-1 expression thus far, have been obtained using an endothelioma cell line 
bEnd.3, originally derived from brain microvessels. However, bEnd.3-based models do 
not accurately model high endothelial venules and therefore would not appear to be an 
attractive model of MAdCAM-1 in this regard. We show in this chapter that a relatively 
recently characterised endothelial cell line (SVEC4-10) from high endothelial venules 
of mice may provide the basis for such a model. 
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3.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Developing	  an	  in	  vitro	  model	  of	  MAdCAM-­1	  expression	  
in	  an	  8-­chamber	  well	  system	  	  
 
3.2.1	   	  	  	  	  	  	  	  	  	  	  	  	  Background	  
 
SVEC are endothelial cell lines derived by simian virus SV40 (strain 4A) 
transformation of  high endothelial venules cells from axillary lymph node vessels of 
adult male C3H/HeJ mouse (H-2k). These fully transformed, small vessel murine 
endothelial cells were first cloned in 1987. They grow indefinitely and are well 
differentiated, responding like normal endothelial cells to some interleukins and to 
extracellular matrix signals for tube-like differentiation.  
 
The mouse brain endothelial cell line bEnd.3 (strain BALB/c) was transformed by 
infection with NTKmT retrovirus vector that expresses polyomavirus middle T antigen. 
The endothelial nature of these cells has been confirmed by the observed expression of 
von Willebrand factor and uptake of fluorescently labelled low density lipoprotein. 
 
Tumour necrosis factor (TNFα) is one of most potent cytokines capable of stimulating 
MAdCAM-1 both in vivo and in vitro.  Expression of MAdCAM-1 on endothelial cells 
and in the colon of mice has been reported after TNFα administration. TNFα also 
induces the expression of several other adhesion molecules including ICAM-1, VCAM-
1 and E-selectin.  
 
3.2.2	   	  	  	  	  	  	  	  	  	  	  	  	  	  Aims	  
 
To develop: 
(i) An in vitro model cell culture system of MAdCAM-1 expression  
(ii) Semi-quantitative analysis of MAdCAM-1 expression in this model 
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3.2.3	   	  	  	  	  	  	  	  	  	  	  	  	  	  Methods	  
3.2.3.1	   SVEC4-­10,	  bEnd.3	  cells	  and	  Culture	  Medium	  	  
 
SVEC4-10 (ATCC catalogue number CRL-2181) and bEnd.3 (ATCC catalogue number 
CRL-2299) were maintained in freshly made culture medium consisting of Dulbecco’s 
modified Essential medium containing 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 
4.5 g/L glucose, 1 mM sodium pyruvate, heat inactivated 10% fetal bovine serum, 
100U/ml penicillin/streptomycin. 
 
The frozen cells were thawed quickly in a 370C water bath. The ampoule was in 70% 
ethanol at room temperature and each 0.5ml cell suspension was diluted slowly over 5 
minutes with 1ml s of filtered HBSS and followed by 2mls of HBSS for a further 
5minutes. This was then di1uted with 5 mls of culture medium in a 75 mls flask and 
incubated at 370C in 10 % CO2/air atmosphere. 
 
3.2.3.2	   Subculture	  procedure	  and	  trypsinising	  cells	  
 
The SVEC and bEnd.3 cells were maintained in culture with the medium replenished 
every 48  hours. When cells reached 70-80% confluence, the monolayer was detached 
from the flask by trypsinising the cells. Ideally, at this confluence the cells are not piled 
up or aggregated, but appear in single sheet uniform cells. The culture medium was 
discarded from the flask and the cells immediately washed three times with warm Ca2+ 
/Mg2+ free HBSS to remove residual serum which would inhibit the action of trypsin. 
One ml warm trypsin (0.25%)–EDTA (0.03%) was filtered-sterilised through a 0.2 µm 
filter (Minisart, Sartorius) into the flask at room temperature until the cells detached; 
typically about 5 minutes. The cells were transferred rapidly to warm complete DMEM 
to inhibit further action of the trypsin and centrifuged at 1200 rpm (300g) at room 
temperature for 3 minutes. The supernatant was discarded and the resulting pellet 
resuspended in an appropriate volume of DMEM (175 cm2 flask, 5mls and 80 cm2 flask, 
2mls) with gentle syringing using a sterile 21G needle to disaggregate cell clumps.  
 
Cell yield and viability were determined by trypan blue exclusion and haemocytometer 
counting. 20µl of trypan blue solution, 160 µl of HBSS and 20 µl of the cell suspension 
were mixed sequentially and after 2 minutes the cells were counted in a Neubauer 
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haemocytometer. Intact membranes of viable cells exclude trypan blue, whereas trypan 
blue stains dead or injured cells due to loss of membrane integrity. An appropriate cell 
density was reseeded into fresh flasks for the next cell passage, frozen for storage in a 
liquid nitrogen cell bank, or used for experimental procedures. 
 
3.2.3.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  Immunofluoresence	  staining	  of	  MAdCAM-­1	  
 
Fresh culture medium were added, aspirated and dispensed into new culture flasks with 
a subculture ratio of 1:4 to 1:6. The cells were seeded on to 8 well FalconR Culture 
Chambers each consisting of Polystyrene Vessel Treated Glass slides (Becton 
Dickinson Labware - Catalogue no 354118). Falcon Culture Slides are comprised of a 
glass slide treated to provide a consistent surface (0.69 cm2 for cell growth) and 
compartmentalized chamber molded from medical grade polystyrene. A hydrophobic 
mask on the slide delineates the location of cells and prevents adhesive from remaining 
on the Culture Slide after chamber removal.  
 
At 70%-80 % confluence these cells were stimulated by incubating with 20 ng/ml 
mouse Recombinant TNFα (SigmaAldrich, Poole, UK) in the 8 chamber well slides, 
initially for 24hours. Thereafter, each chamber well was rinsed carefully three times 
with 0.5 mls of phosphate buffer saline (PBS) followed by 10 minute incubation with 
equal volume of Formalin fixative, with further rinsing using 0.5 mls PBS.  The cells 
were incubated at 40C overnight  with primary antibody using  functional grade purified 
Rat anti-mouse MAdCAM-1 monoclonal antibody-10µg/ml MECA 367 (eBioscience, 
UK  Cat No 16-5997), in 1% Bovine serum albumin in PBS.  
 
Each chamber was rinsed three times with PBS and further incubated for one hour with 
secondary antibody Goat Anti-Rat IgG (whole molecule) FITC conjugate at 10µg/ml 
(SigmaAldrich, Poole, UK), followed by further washing three times in PBS. 
VECTASHIELDR Mounting Medium (Cat No H-100, Vector Laboratories, UK) was 
applied to prevent rapid photo bleaching. After removal of the chamber wells cover 
slips were applied.  
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3.2.3.4	  	  	  	  	  	  	  	  	  	  	  	  MAdCAM-­1	  and	  time	  course	  of	  its	  expression	  on	  SVEC	  and	  Bend.3	  
monolayer	  
 
A time course experiment was performed where cells were exposed to TNFα for 2, 5, 9, 
23, 48, and 72 hours (SVEC) and 2, 5, 9 and 20 hours (bEnd.3). At the end of the time 
course cells were fixed with formalin and immunostained for MAdCAM-1 the 
technique described. Each experiment was repeated three times.  
 
3.2.3.5	  	  	  	  	  	  	  	  	  	  	  	  Image	  Analysis	  	  
 
Slides were initially examined by phase contrast imaging to demonstrate the 
morphology of the two cell types. They were then examined on a Nikon microscope and 
images captured using a Nikon Coolpix 990 digital camera; the images taken were 
representative of 2 to 4 fields observed for each time point in each experiment. They 
were analysed using image analysis software (NIH Image, Bethesda, Maryland, USA) 
and the mean pixel intensity was measured for each field and a mean ± standard 
deviation calculated. The time 0 control was subtracted from the other time point values 
to give a value minus the background fluorescence intensity. 
 
3.2.3.6	  	  	  	  	  	  	  	  	  	  	  	  Statistical	  analysis	  
 
The results are displayed as the mean ± standard deviation of the sample means (µ ± 
SDn-1). Statistical analysis carried out using the two tailed t-test and significance 
determined if p<0.05      
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3.2.4	   	  	  	  	  	  	  	  	  	  	  	  Results	  (figure	  3.1	  to	  3.5)	  
	  
3.2.4.1	   Cell	  viability	  
 
There was an estimated  greater than 98% in cell viability in  all experiments which 
were performed. 
3.2.4.2	  	  	  	  	  	  	  	  	  	  	  	  Morphology	  and	  immunofluoresence	  
 
SVEC cells formed branching tube-like networks. They divided slowly forming sheets 
of flattened polygonal cells (figure 3.1a), which ceased division at confluence. At near 
confluence both cell types remained in a monolayer. The monolayer morphology of 
SVEC cells forms ‘nests’ of polygonal cells surrounded by elongated bands. 
Immunofluoresence localisation of MAdCAM-1 in SVEC4-10 endothelial cells showed 
that TNFα (20 ng/ml) stimulation induced a marked increase in the immunofluoresence 
localisation of MAdCAM-1 on the surface of SVEC cells (figure 3.2). TNFα 
stimulation also induced a cell surface expression of MAdCAM-1 on bEnd.3 although 
there appeared to be less junctional localisation than the SVEC cells(figure 3.3).  
 
Compared to the SVEC cells, the bEnd.3 cells appeared relatively more elongated and 
‘spindly’ at near confluency (figure 3.1b and 3.3). In the control experiments, 
MAdCAM-1 expression was only faintly detected in the non-stimulated cells and 
primary antibody deficient controls were consistently negative. 
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Figure 3.1a Phase contrast image analysis of SVEC4-10 endothelial cells at near 
confluence prior to stimulation with TNFα . The monolayer of cells form a ‘nest’ of polygonal 
like structures (100x and 200x magnification respectively). 
          
 
          
Figure 3.1b Phase contrast image of bEnd.3 endothelial cells at near confluence, 
prior to stimulation with TNFα . The monolayer of cells appears elongated and ‘spindly’ (100x 
and 200x magnification respectively). 
. 
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9 hours  
 
                                                               
 
 
 
 
 
Figure 3.2 Immunofluorescent staining of MAdCAM-1 on SVEC cells demonstrating 
MAdCAM-1 surface expression after 0-48 hours incubation with TNFα . Following	  stimulation,	   there	   was	   marked	   MAdCAM-­‐1	   immunostaining	   expressed	   on	   the	   surface	   of	   the	   cells	  
particularly	  at	  the	  junctions	  (200xmagnifiation)	  
 
	  
	  
	  
 2 hours  9 hours 
 23 hours  48 hours 
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9 hours  
 
	  
Figure	   3.3	    Immunofluorescent staining of  MAdCAM-1 on bEnd.3 cells 
demonstrating surface expression after 0-20 hours incubation with TNFα . The cells 
appear  typically elongated at near confluence (200x magnification). 	  
 
 
 9 hours 
 20 hours 
 5 hours 
 2 hours 
 0 hours  2 hours 
 9 hours 
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3.2.4.3	   Time	  course	  of	  MAdCAM-­1	  immunofluoresence	  induction	  by	  
20ng/ml	  TNFα 	  
 
In the bEnd.3 cells,  the time course experiment was only carried out for 20 hours with 
maximum stimulation after 20ng/ml TNFα stimulation (figure 3.4). 
 
Cell surface expression of MAdCAM-1 is increased on SVEC high endothelial cells 
stimulated  by 20ng/ml TNFα.  Significant MAdCAM-1 fluorescence occured at 
23hrs(p<0.01),  which was  further sustained up to 72 hrs (figure 3.5). This contrasted 
with the control experiments without TNFα stimulation where MAdCAM-1 was only 
faintly detected. 
 
The maximal  mean pixel intensity following TNFα stimulation of SVEC cells was 
higher than that achieved with bEnd.3 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 hours 
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Figure	  3.4	  Surface expression and time course of MAdCAM-1 after 20ng/ml TNF α 
stimulation of Bend.3 cells in an 8 chamber system. Significant	   MAdCAM-­‐1	  fluoresence(marked	   as	   *)	   occured	   at	   20hrs	   (p<0.05),	   	   contrasted	   with	   the	   control	  experiments	  without	  TNFα	  stimulation	  where	  MAdCAM-­‐1	  was	  only	  faintly	  detected.	  Each	  cohort	  was	  performed	  in	  triplicate.	  (n=9) 
 
        
Figure	  3.5	  Surface expression and time course of MAdCAM-1 after 20ng/ml TNFα  
stimulation of SVEC cells in an 8 chamber system. Significant	  MAdCAM-­‐1	  fluoresence	  (marked	  as	  *)	  occured	  at	  23hrs(p<0.01),	   	  which	   is	   sustained	  at	  48hrs(p<0.01	  marked	  as	  **)	  and	  maintained	  up	  to	  72	  hrs(p<0.01,	  marked	  as	  ***).	  This	  contrasted	  with	  the	  control	  experiments	  without	  TNFα	  stimulation	  where	  MAdCAM-­‐1	  was	  only	  faintly	  detected.	  Each	  cohort	  was	  performed	  in	  triplicate.	  (n=9)	  
 
 
 
 
 
 
 
  
* 
* ** *** 
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3.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Developing	  an	  in	  vitro	  model	  of	  MAdCAM-­1	  expression	  
in	  a	  96	  well	  plate	  system	  
 
3.3.1	   	  	  	  	  	  	  	  	  	  	  	  	  	  Background	  	  
 
In the previous experiments we have demonstrated the constitutive surface expression 
of MAdCAM-1, albeit at low levels, on 2 different types of endothelial cells. Using an 
in vitro 8 chamber well system we showed this level of expression to be influenced by 
TNFα. Specifically, TNFα in a dose and time dependant manner causes the upregulation 
of MAdCAM-1 as measured quantitatively.  It would therefore make therapeutic sense 
to quantify MAdCAM-1 expression since this would enable us to accurately study 
factors governing this expression.  
 
We focused our attention to SVEC 4-10 cells because of its similarities to HEV and the 
consistent and optimal MAdCAM-1 upregulation with TNFα. Nevertheless, there 
appeared to be inherent limitations to further use of the 8 chamber well system. The 
number of experiments, which could be performed at any one time clearly restricted its 
use. Moreover, there were also severe limitations in the number of variables i.e. 
experimental conditons which could be designed at a given time point. Finally, there 
were the innate quantitation biases of image analysis in an 8 chamber system. That is, 
the quantifiable flouresence value was based on mean pixel intensity following 
subjective representation of 2 to 4 fields. This inevitably contributed to delayed readings 
and possible inaccuracies in the final fluorescence and henceforth MAdCAM-1 signal. 
 
A possible solution to overcome these pertinent disadvantages of the 8 chamber system 
were the introduction of a 96 well plate system. Our ability to stimulate surface 
expression of MAdCAM-1 in this in vitro model will be used to investigate a number of 
factors which will be used to modulate its expression. This work is described in Chapter 
5.  
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3.3.2	   	   Aims	  
 
1. To develop a reproducible in vitro model of MAdCAM-1 expression using 
SVEC 4-10 cells   
2. To quantify the level of MAdCAM-1 expression in the in vitro model using a 96 
well plate reader system 
 
3.3.3	   	  	  	  	  	  	  	  	  	  	  	  	  Method	  
 
SVEC4-10 cells in fresh DMEM taken at time of subculture were seeded at a ratio 1:4 
to 1:6 on to gelatin coated 96 Falcon™ 96-well flexible polyvinyl chloride (PVC) 
plates.  
 
The plated cells were incubated as previously until they were 70%-80 % confluent and 
stimulated by incubating with 20 ng/ml mouse Recombinant TNFα (SigmaAldrich, 
Poole, UK) in for 24hours. Thereafter, each chamber well was washed carefully three 
times with 0.2 mls of phosphate buffer saline (PBS) followed by ten-minute incubation 
with equal volume of Formalin fixative, followed by further rinsing with PBS.  The 
cells were incubated overnight at 40C functional grade purified Rat anti-mouse 
MAdCAM-1 monoclonal antibody-10µg/ml MECA 367 (eBioscience, UK Cat No 16-
5997) in 1% Bovine serum albumin/PBS.  Each chamber well was washed 3x with PBS 
and further incubated for one hour at room temperature with Goat Anti-Rat IgG (whole 
molecule) FITC conjugate at 10µg/ml (SigmaAldrich, Poole, UK), followed by a further 
3 washes with PBS.   
 
3.3.3.1	   Image	  Analysis	  	  
 
The surface expression of MAdCAM-1 was detected and analysed using the Fluorescent 
CytofluorR 4000 reader at 485/20(excitation) and 530/25(emission).  The value for the 
time 0 (background control) was subtracted from that of the other time points. The value 
for each time point and TNFα concentration was the mean ± standard error of 6 
observations. 
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3.3.4	   	   Results	  (figure	  3.6)	  
 
The SVEC4-10 cells showed maximal fluorescence intensity following 20ng/ml 
stimulation with TNFα (p<0.01). There was generally a dose dependant increase in 
surface MAdCAM-1 expression with increasing doses of TNFα (0 to 20ng/ml) but a 
relative fall in fluorescence intensity at higher doses e.g.  with 30 ng/ml TNFα	  (p<0.05) 
 
 
 
P<0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  3.6	  Surface expression of MAdCAM-1 from SVEC4-10 cells after 24 hours 
stimulation with varying doses of TNFα in a 96 well plate	   (n=9). Maximal	   peak	  expression	   occurred	  with	   20ng/ml	   TNFα	  with	   a	   relative	   fall	   	   in	   fluorescence	   intensity	   at	   higher	  doses	  (30ng/ml)	  
• 	  *	  	  	  p<0.01	  compared	  to	  control	  (without	  TNFα)	  	  	  	  
• **	  	  p<0.05	  compared	  to	  control	  (without	  TNFα)	  	  	   
	  
	  
* 
 
** 
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3.3.5	   	   	  Discussion	  
 
Following the 8 well system studies, in this chapter I have optimised the expression of 
MAdCAM-1 in SVEC 4-10 cells using immunofluoresence studies,  so as to develop a 
robust in vitro mouse model of MAdCAM-1 in a 96 well plate system.  
 
My  results related to the time course of MAdCAM-1 appear to be different to the 
parallel work by Oshima et al (also in 2001) using the same SVEC cell line. This group 
demonstrated maximal MAdCAM-1 expression (later confirmed by Western Blot 
methodology),  also occurred at 24 hours following TNF-α stimulation, although a 
further time course analysis beyond 24 hours was not included. Like these workers, I 
wished to confirm the presence of MAdCAM-1 protein from the SVEC 4-10 cells and 
carried out Western analysis but were unfortunately unable to detect any signal. This 
could be due to antibody non-specificities or technology failure. We could not detect a 
signal on multiple occasions for unknown reasons.  
 
My initial results used 8 chamber well slides as opposed to conventional glass slides to 
assess the morphological characteristics of the endothelial cells. The observed 
distribution of MAdCAM-1 on the cell surface was interesting, showing that TNFα 
induced MAdCAM-1 appeared to be concentrated at cell-cell junction, although this 
junctional appearance of MAdCAM-1 was not uniform on all cells. This could be 
explained by (i) cell alterations induced by transformation (ii) direct TNFα 
heterogeneous stimulatory effects on the endothelium or, (iii) the degree of confluence 
of the culture. It still remains, that the role of MAdCAM-1 at endothelial junctions is ill-
defined.  
 
Although bEnd.3-based models are clearly useful, these cells derived from brain 
capillaries do not accurately model high endothelial venules. The SVEC cells appear to 
be useful in this regard and could provide a more realistic and relevant model in the 
investigation of the mechanisms involved in human IBD. It is for this reason that I 
chose to pursue further experiments with SVEC 4-10 cells rather than bEnd.3   
 
 
 
121 
 
The 96 well system had advantages over the 8 well system. It allowed in one sitting  (i) 
larger numbers of experiments to be performed (ii) greater number of variables and 
experimental conditions to be adjusted in a consistent manner and (iii) quicker 
acquistion of results by using a plate reader. Certainly,  the 96 well system allowed 
consistent levels of fluorescence and  appeared to be a more reproducible model without 
the inherent risks of bias associated with mean pixel intensities and subjective 
representations  from areas of maximal fluorescence associated within the 8 well 
system. This inevitably led to delays and possibilities of inaccuracies in the final 
fluorescence and therefore MAdCAM-1 signal from the 8 well systems.  
 
From my quantitative immunofluoresence data I have confirmed the ability of this 
model to demonstrate a TNFα dose dependent increase in MAdCAM-1 expression 
which was quantifiable by direct measurement of the fluorescence (figure 3.6). This 
experiment showed a significant maximal fluorescence intensity following 20ng/ml 
TNFα (p<0.01). Although there was a relative fall in fluorescence intensity at higher 
TNFα doses,  this still  remained significant, albeit at a level of signifiance of p<0.05. I 
therefore choase 20ng TNF/ml as the concentration of choice in future experiements on 
MAdCAM-1 modulation.   
 
Using the 96 well system, I repeated the time course series of experiements which I had 
initially performed in an 8 chamber sytem  with 20ng/ml of TNFα. I confirmed  
MAdCAM-1 expression at 23 hrs which was  sustained at 72 hours. My  in vitro model 
system was reproducible enabling MAdCAM-1 expression to be formally quantified 
after endothelial cell activation.  
 
Our ability to stimulate surface expression of MAdCAM-1 in this in vitro model will be 
used to investigate factors, which will be used to modulate its expression. This work is 
described in Chapter 5.    
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Chapter	  4	  
 
 
 
Qualitative	  and	  Quantitative	  measurement	  of	  MAdCAM-­1	  
expression	  in	  cells	  and	  tissues	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4.1	   	  	  	  	  	  	  	  	  	  	  	  Experiment	   1:	   Development	   of	   a	   Reverse	  
Transcriptase-­Polymerase	   Chain	   Reaction	   	   	   (RT-­PCR)	   assay	   to	  
assess	  MAdCAM-­1	  expression	  in	  gastrointestinal	  tissues	  	  
 
4.1.1	   	  	  	  	  	  	  	  	  	  	  	  	  	  Background	  
 
Previously, we have semiquantitativley characterised human MAdCAM-1 in 
gastrointestinal tissues, liver and pancreas by immunohistochemical analysis. The 
ability to quantitatively assess MAdCAM-1 expression in these tissues may provide not 
only an assessment critical in evaluating disease activity but also study the response and 
effect of treatment. The most commonly used methodology to do this is the estimation 
of MAdCAM-1 mRNA by quantitative RT-PCR (qPCR), although of course this 
technique provides information at the RNA (gene transcription) rather than the protein 
level. 
 
Elevated levels of circulating soluble adhesion molecules have been essential in the 
understanding the pathology of disease. In support of this, there has been an elevated 
level of soluble ICAM-1 and VCAM-1 in observed malignancy, infection and 
inflammation. Leung et al. showed for the first time the ability of MAdCAM-1 to be 
secreted as a soluble molecule into serum, urine and other biological fluids. The average 
level of MAdCAM-1 detected in the serum was 237ng/ml(180-317 ng/mls). These 
levels are similar to those of ICAM-1 in the serum and levels of soluble MAdCAM-1 in 
urine ranging from 20-123ng/ml.  
 
4.1.1.1	   Human	  and	  Mouse	  MAdCAM-­1	  
 
The human MAdCAM-1 gene is localised to p13.3 on chromosome 19 in close 
proximity to the ICAM-1 and ICAM-3 genes (p13.2-13.3).  This region is homologous 
to a region on mouse chromosome 10. Of note, the overall nucleotide protein identity 
between human and murine MAdCAM-1 is poor (42% and 38%) respectively, although 
the first Ig domains are highly conserved (59% and 65% respectively).  
 
The coding sequences of the  human MAdCAM-1 gene is contained in five exons, 
under the control of a 717bp 5’flanking promoter region; the signal peptide and the  two 
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Ig and mucin domains (major and minor) are encoded by separate exons (Butcher et al 
1996), although the transmembrane domain,  cytoplasmic domain and 3’untranslated 
region are themselves encoded on exon 5.  The mucin domain contains 8 repeats which 
are subject to alternative splicing, an observation which has been confirmed by human 
and mouse cDNA analysis; this inevitably leads to the generation of splice variants 
which lack all or part of the second Ig domain and all or parts of the mucin domain. 
 
The genomic organisation of the MAdCAM-1 gene correlates well with the subdomain 
structure of the encoded protein (Grimwood J et al 2004). The 5’UTR and the signal 
peptide are encoded by exon 1; the two N-terminal Ig domains and mucin-like domain 
are encoded by exons 2, 3 and 4 respectively, and finally the transmembrane and 
cytoplasmic domains and 3’UTR are combined on exon 5. Several potential 
transcriptional regulatory elements, including NF-κβ, SP1, AP2, PEA3, NF-E1, Adh1, 
MYOd, E2A, ENKCRE, IRS sites and a GC box have been identified in the promoter 
region of the gene. A potential TATA box, 2 NF-κβ sites and one SP1 have been found 
in the mouse MAdCAM-1 gene promoter region and conserved in position (Leung et al 
1997).  These transcription factor-binding sites including NF-Kb docking may explain 
the upregulation of MAdCAM-1 following stimulation with cytokines such as TNF-α, 
which activate NF-KB. DNA methylation occurs naturally in both prokaryotic and 
eukaryotic organisms. In higher eukaryotes, DNA methylation has been proven to play 
a central role in a number of biological processes such as X chromosome gene slincing, 
embryonic development, gene imprinting and cell cycle regulation. DNA methylation 
usually occurs in CpG islands which are often located around the promoters of 
housekeeping or other genes frequently expressed in the cell. Human MAdCAM-1 is 
encoded by a gene on chromosome 19p13. Of note, chromosome 19, which contains the 
human MAdCAM-1 gene has the highest densities of all human chromosomes and its 
high G+C content and density of CpG islands and repetitive DNA sequences indicate a 
chromosome rich in biological and evolutionary significance. The density of CpG 
islands on this chromosome suggests that MAdCAM-1 gene may be a candidate for 
regulation by methylation. 
 
Several features of MAdCAM-1 have been conserved between humans and mice 
including the structure of the Ig ligand-binding domains.  Nonetheless, the 3’ region 
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remains relatively divergent between the species. Comparison of the human gene 
sequence with the mouse homologue shows that the differences in organisation of the 3’ 
region are not simply due to splice variants (Sampaio et al 1995). As a consequence, the 
human MAdCAM-1 gene does not contain sequence equivalents to the 3rd Ig-A 
homologous domain of mouse MAdCAM-1 adjoining the 3’end of the mucin domain. 
Certainly, despite this major difference in structure, other regions of the human and 
mouse MAdCAM-1 remain highly conserved, including positions at three of the four 
intron-exon splice junctions, further supporting the close evolutionary relationship 
between these molecules. Alignment of the human and mouse MAdCAM-1 gene shows 
three of the four intron-exon junctions separating the signal peptide and Ig domain 
sequences, MAdCAM-1 mucin-like domains and intron-exon splice sites separating the 
mucin and transmembrane sequences are not conserved between species. For example, 
in humans, the splice site is nine amino acids N-terminal to the boundary of the 
extracellular and transmembrane domains, whereas in mouse it is only three amino 
acids N-terminal.   
 
Sequence and genomic organisation of the human MAdCAM-1 gene provides further 
evidence that previously isolated MAdCAM-1 cDNA encode human MAdCAM-1 
(Leung E et al 1997). The identification of an additional cDNA splice variant serves to 
emphasise that the functions of MAdCAM-1 are likely to be extensively altered by 
rearrangement of its multi domain structure. At least seven alternatively spliced variants 
of the human MAdCAM-1 gene have been identified that encode different protein 
isoforms e.g. Variation 1: lacking major and minor mucin domains, variation 2: lacking 
entire mucin domain and domain 2, variation 3: lacking some of the major mucin 
repeats and second immunoglobulin domain. It must be noted that the full –length 
nature of some variants have not been determined.  
 
Despite the absence of a human counterpart of the third IgA-homologous domain and 
lack of sequence of conservation of the mucin domain, the genomic organisations of the 
human and mouse MAdCAM-1 are very similar. An alternatively spliced human 
MAdCAM-1 variant exists which lacks exon 4, encoding the whole mucin domain; 
therefore this shorter MAdCAM-1 would be unable to accept and present 
carbohydrate modifiactions and as a result would have a reduced capacity to support 
lymphocyte adhesion through binding to L-selectin.    
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Figure	   4.1	   Schematic diagram representing genomic organisation of the Human 
MAdCAM-1 gene and comparisons with the mouse homologue on Chromosome 19 
(p13.3) close to ICAM-1/3 genes (p13.2-p13.3). The	  MAdCAM-­‐1	  subdomains	  encoded	  by	  the	  MAdCAM-­‐1	  cDNA	  sequence,	  organisation	  of	  exons	  and	  their	  relationship	  to	  the	  cDNA	  sequence	  are	  described.	   The	   human	   MAdCAM-­‐1	   gene	   contains	   five	   exons	   where	   the	   signal	   peptide,	   two	  immunoglobulin	   domains	   and	   mucin	   domains	   are	   each	   encoded	   by	   separate	   exons.	   The	  transmembrane	  domain,	  cytoplasmic	  domain	  and	  the	  3’’	  untranslated	  region	  are	  encoded	  together	  on	  exon	  5.	  The	  mucin	  domain	  contains	  eight	  repeats	  in	  total	  which	  are	  subject	  to	  alternate	  splicing.  
 
 
 
 
 
 
 
 
 
 
 
 
Signal 
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5’translated 
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VCAM-1 
Super Ig domain 1 
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8 repeats -
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domain 
3’untranslated 
         EXON  1             EXON  2              EXON  3          EXON 4              EXON 5 
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ccacgcgtcc gtcacaagac agaggcaggc atggaatcca tcctggccct cctgctggcc  
 
ctggccctag taccctacca gctcagcaga ggacagtcct tccaggtgaa cccccctgag   
 
tctgaggtag ctgtggccat gggcacatcc ctccagatca cctgcagcat gtcctgtgac 
 
gagggtgtag cccgggtgca ctggcgtggt cgggacacca gcttgggcag tgtacagacc 
 
ctcccaggca gcagtatcct ctctgtacgg ggcatgctgt cagacacagg cactcctgtg 
 
tgtgtgggct cctgcgggag tcgaagcttc cagcactccg tgaagatcct TGTGTATGCC 
 
TTCCCAGACC agctggtggt gtccccggag ttccttgtac ctggacagga ccaggtggtg    
 
tcctgcacgg cccacaacat ctggcctgca gaccCGAACA GTCTCTCCTT TGCCctgcta 
 
ctgggagagc agagactgga gggtgcccaa gccctggaac cagagcaaga agaggagata 
 
caagaggctg agggcacacc actgttccga atgacacaac gctggcggtt accctccctg 
 
gggacccctg cccctcctgc ccttcactgc caggtcacca tgcagctgcc caaactggtg 
 
ctgacccata gaaaggagat tccagtacta cagagccaga cctcacctaa gccccccaac   
 
acgacctctg ctgagcccta catcctgacc tcatcaagta ctgctgaggc agtctccact 
 
gggctcaaca tcaccaccct accttctgcc cctccatacc ccaagcttag ccctaggact 
 
ctgagctctg agggaccttg ccgcccgaaa atccaccagg acctggaggc aggctgggag 
 
ctactctgtg aagcatcctg tgggcccgga gttactgtgc gctggacctt ggctcctggc 
 
gacctggcaa cctaccacaa gagggaggct ggggcccagg catggctaag cgtgctgccc 
 
ccaggtccca tggtagaggg ctggttccag tgccgccagg accctggcgg ggaggtgacc 
 
aatctgtatg ttcctggcca ggtgaccccg aattcctcct ccaccgtcgt cctatggatt   
 
ggcagcttgg tgctggggct gcttgcactg gtcttccttg cctaccgcct gtggaaatgc 
 
taccggccag gtcctcgccc agacactagc tcatgtacac acctatgaag ctccattatg 
 
ccagactaaa ggaggcagag agtgaccagc tgcaggattt ggggcatcaa gatgatagtg 
 
tggcctcttt ccttggtggt cagcacatct ataagtttct cctgacttct gggcttttct 
 
gcctgctggc ccagagctaa ataaaagccc cgtatct 
 
Figure	  4.2	  	  	  Human MAdCMA-1 cDNA	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4.1.1.2	   Polymerase	  chain	  reaction	  
 
The development of the polymerase chain reaction (PCR) technique in the 1980’s has 
allowed rapid advances in the field of molecular biology. It is an indispensable tool in 
medical and biological research and diagnostics. The methodology uses thermostable 
DNA polymerase to replicate a piece of DNA initiated from synthetic oligonucleotides 
primers complementary to sequences flanking the region of interest recruiting free 
dNTP's (deoxy-nucleotide-triphosphates) from the reaction mixture. The resulting DNA 
then becomes a template for further replication and in this way a few copies of target 
DNA can be exponentially amplified to millions of copies by cycles of denaturation, 
primer annealing and DNA extension. 
 
In order to utilise PCR for estimation of MAdCAM-1 expression in cells and tissues 
cDNA is generated which is complimentary to the mRNA of interest. This is carried out 
by reverse transcription with the aid of reverse transcriptase, an enzyme utilised by 
certain RNA viruses to convert their genomic RNA to DNA within the host cell. In in 
vitro reverse transcription the enzyme catalyses the synthesis of a single strand of 
cDNA initiated from oligo dT, sequence specific oligonucleotides primers or random 
hexamers which anneal to the mRNA.    
 
4.1.2	   	  	  	  	  	  	  	  	  	  	  	  Aim	  
 
To assess the expression of MAdCAM-1 in human tissues by reverse transcription – 
polymerase chain reaction. 
 
4.1.3	   	  	  	  	  	  	  	  	  	  Methods	  
 
A 100 µg fresh tissue of histologically normal colon tissue (samples 1 and samples 2) 
was snap frozen in liquid nitrogen and cryopreserved at –80oC until RNA extraction. 
TRIzolR Reagent (Invitrogen) was used for isolation of total RNA following 
manufacturer’s instructions. Briefly, 100µg of tissue was homogenised in 2ml TRIzolR, 
400 µl of chloroform was added to 1ml of homogenate (in TRIzolR) and centrifuged for 
10 minutes at 12,000rpm in a microcentrifuge. The RNA partitions in the aqueous phase 
which is removed and RNA recovered by precipitation with an equal volume of 
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isopropanol incubated at –200C for 30 minutes and centrifuged for 15 minutes at 
12,000rpm. The supernatant was removed and the pellet was washed with excess 70% 
ethanol and centrifuged at 12,000rpm for another ten minutes. The RNA pellet was then 
resuspended in 100µl RNase free H2O. The total RNA was reverse transcribed to 
complementary DNA in a 50 µl reaction, allowing transcription top proceed at 370C for 
2 hours. These experiments were carried out on 3 occasions using different  normal 
colon tissue samples to confirm  reproducibility.  
 
4.1.3.1	   Reverse	  Transcription	  
10 picomole of oligo dT primer was added to 20µl of RNA (DNase treated) and 
incubated at 65oC for 5 minutes. This was then added to the reverse transcription mix as 
detailed below and incubated at 37 oC for 60 minutes. 
                                                                                             
                                  Volume  
1st Strand Buffer           10    
          
Moloney Murine leukaemia virus (MMLV) reverse transcriptase  4.0 
Oligo d(T) Primer (10picomol)                      1.0 
dNTP (10mM)        2.5  
RNase FreeH2O        12.5 
RNA          20 
          50 µl 
 
The reaction was terminated by heating to 70 oC for 15 minutes and the cDNA stored at 
20oC until use. 
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4.1.3.2	   Polymerase	  Chain	  Reaction	  
 
The cDNA was then amplified by single round PCR using hot start Taq DNA 
polymerase kit (Hotstar, Qiagen, UK) to minimize amplification of non-specific 
product. The PCR consisted 15 minutes incubation at 95oC to activate the Taq 
polymerase followed by 35 cycles each consisting of denaturation at 94 oC for 
30seconds, primer annealing at 60oC for 30 seconds and extension at 72oC for 1 minute.  
The PCR reaction was set up as follows: 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Volume	  	  
HotStar  Mix                  25.0 
Forward Primer    2.50 
Reverse Primer    2.50 
H20     18.75 
cDNA     1.25 
TOTAL    50.0µl 
 
Primer pairs were designed using the online program Primer 3 (http://frodo.wi.mit.edu/) 
and 3 sets designed as shown in Table 4.1.   
 
Table	  4.1	  MAdCAM-1 Oligonucleotide Primers (f1,f3,f5-forward,r2, r4,r6-reverse) 
 
Primer	  
Amplicon Size 
(base pairs) 
Primer Sequence (5’-3’) 
MAdCAMf1 
MAdCAMr2 
117 
5’-GAGAAGTGATCCCAACAGGC-3’ 
5’-AGAGGTGATACGTGGGCAAG-3’ 
MAdCAMf3 
MAdCAMr4 
 
240 
5’-CAGCTCCTTGTGTACGCCTT-3’ 
5’-CTCTGTCACCCTGAACAGCA-3’ 
MAdCAMf5 
MAdCAMr6 
 
143 
5’CGGGCCGCAGCGTCCTCAC-3’ 
5’TCCCCCTGTGAAAGCAAAAT-3’ 
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4.1.3.3  Gel electrophoresis  
 
Analysis of the PCR product was carried out by agarose gel electrophoresis. A 1.5% 
agarose gel in TBE buffer (0.89M Tris, 0.89M Boric acid, 0.02M EDTA) was prepared 
by melting the agarose in TBE in a microwave oven. After cooling to 50oC 5µl of 
ethidium bromide solution (0.05µg/ml) was added and the gel cast in the perspex mould 
with a gel comb for well formation. After the gel had set, it was placed in the 
electrophoresis tank submerged in TBE buffer and the comb removed. 5µl of PCR 
product was mixed with 1µl gel loading buffer (15% Ficoll, 0.06% Bromophenol Blue, 
30mM Tris/EDTA pH8.0). The PCR samples and appropriate MW markers were added 
to the wells and the gel electrophoresed at 10V/cm until the dye front had migrated 4/5 
the length of the gel. The gel was then visualised by trans-illumination with UV light in 
a UVP EpiChem II Gel Documentation System (UVP Laboratory Products, USA) and a 
digital image acquired.  
 
4.1.3.4	   Gel	  extraction	  of	  PCR	  DNA	  	  
 
The DNA amplicon was extracted from the agarose gel using QIAquick Gel Extraction 
Kit (QIAGEN, UK). The DNA fragment was excised from the agarose gel three 
volumes of Buffer QG were added to 1 volume of gel. This was incubated at 50 0C for 
10 minutes until the gel slice had completely dissolved. To increase the yield of DNA 
fragments one volume of isopropanol was added and mixed thoroughly. The mixture 
was loaded onto a QIAquick spin column and centrifuged for 1minute at 13000 rpm. 
The flow-through was discarded and a further 0.5 ml of Buffer QG Buffer was added 
and centrifuged for a further 1 minute to remove all traces of agarose. 0.75 ml of Buffer 
PE was added to the column and centrifuged again for 1minute at 13,000 rpm. The 
flow-through was discarded and the column centrifuged for an additional 1minute at 
13,000 rpm to ensure complete removal of wash buffer. The column was placed into a 
clean 1.5ml-microcentrifuge tube and the DNA eluted with 30µL 10mM Tris pH 7.4. 
The DNA was stored at -20oC until used. 
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4.1.3.4	   	  DNA	  sequencing	  	  
 
The amplicon was directly sequenced using forward and reverse primers by The 
Sequencing Service (School of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big Dye Ver 3.1 chemistry and an 
Applied Biosystems 3730 automated capillary sequencer.    
 
4.1.4	   	  Results	  (figure	  4.3	  to	  4.4)	  
Human MAdCAM-1 may be extensively alternatively spliced,  creating an array of at 
least four variant forms that lack all or part of the second immunoglobulin domain, 
including all or part of the major mucin domain. Our results do not show splicing 
variants of MAdCAM-1 in histologically normal large bowel. We have demonstrated a 
single band using newly designed forward primer F1 (5’-
GAGAAGTGATCCCAACAGGC-3’) and reverse primer R2 (5’-
AGAGGTGATACGTGGGCAAG-3’) to nucleotides 980-999 and 1096-1115 
respectively, with amplification of a 117 bp product subsequently identified by 
sequence analysis (figure 4.3 and 4.4). 
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Figure 4.3 Identification of human MAdCAM-1. MAdCAM-­‐1	   cDNA	   was	   amplified	   from	  reverse	   transcribed	   human	   colon	  RNA(Sample	   1	   and	   2)	   using	   PCR	  primer	   sequences	   directed	   to	  nucleotides	  980-­‐999,1096-­‐1115	  and	  subsequent	  amplification	  of	  a	  117	  base	  pair(bp)	  product. 
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Figure	  4.4	  Electrophoretogram and sequence of human MAdCAM-1 using specific PCR 
primer sequences and amplified cDNA transcribed from RNA extracted from histologically normal large 
bowel, indicating consensus between sequenced material and MAdCAM-1 sequence information from 
GenBank.i.e presense of constitutive MAdCAM-1 in normal colon.	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4.1.5	  	  	  	  	  	  	   Discussion	  
 
We set out to develop methods to assess MAdCAM-1 expression so as to enable its 
quantification in future experiments with different  tissue samples e.g. liver . Using RT-
PCR technology our results confirm MAdCAM-1 expression in gut tissue e.g. 
histologically normal colon tissue.  
 
The conditions required for the generation of sensitive and specific RT-PCR assays 
from gut tissue samples required optimisation. There were a number of PCR optimising 
strategies that we used to alter the specificity characteristics of the PCR reaction: 
 
1. Primer design 
As well as the specific considerations relevant to the MAdCAM-1 primer design given 
in all the methods, there are some general considerations that are relevant. The two 
primers are generally 20-30 base pair long, contain a relatively balanced GC vs AT 
content (e.g. 45-55% GC) with no long stretches of one base (prevents secondary 
structures). The primary pairs should not have more than 2 adjacent complimentary base 
pairs (especially at the 3’end) to avoid primer dimer formation. 
 
2. Magnesium concentration 
The specificity of the PCR reaction can be increased by decreasing the Mg2+ 
concentration in the reaction mix. The magnesium concentration must therefore be 
optimised for an efficient PCR reaction to occur, as a concentration too low may result 
in no product forming and a concentration too high may result in a variety of unwanted 
products. 
 
3. Annealing characteristics 
The annealing temperature is particularly important in determining the specificity of the 
PCR reaction. At lower temperatures the specificity of primer binding is reduced, 
resulting in the formation of multiple non-specific products. The ideal annealing 
temperature is at or just below the melting point (Tm) of the primer/DNA hybrid i.e. 
when half of the mixture is double stranded and half dissociated. We were able to 
optimise the annealing temperature to obtain a single band on the gel, a critical 
requirement for an accurate quantification during the PCR.  
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4. Template considerations 
 The efficiency of the MAdCAM-1 PCR was also critically dependant on the presence 
of Qiagen solution Q in the PCR reaction mix. This is a solution that reduces template 
secondary structure and is particularly useful in templates with high GC content.  
 
5. Reducing nonspecific background products 
We used HotStar Taq DNA Polymerase, a modified form of Taq DNA Polymerase 
which is inactive at ambient temperatures thus reducing mis-primed products and 
primer-dimers at low temperatures. It is activated by a 15-minute incubation period at 
95oC, which was incorporated into our thermal-cycler programs.  
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4.2	  	   Experiment	  2:	  Developing	  a	  real	  time	  RT-­PCR	  method	  	  	  
to	  quantify	  MAdCAM-­1	  mRNA	  in	  gut	  and	  liver	  tissue	  
 
4.2.1	  	   	   Introduction	  -­	  Real	  time	  PCR	  	  
4.2.1.1	  	   Quantitation	  
 
There is a quantitative relationship between the relative amounts of starting target 
sample and PCR product at any given cycle number. Real time PCR aims to estimate 
the amount of input DNA by real time monitoring of the accumulation of amplicons 
during the reaction. Traditional PCR is measured at the End-Point (plateau), while Real 
Time PCR collects data in the exponential growth phase combining the amplification 
and detection into one step. The detection of amplicons is generally measured using a 
fluorescent based methodology and the first point at which the fluorescence rises above 
background in related to the amount of target DNA. This value is referred to as the 
cycle threshold or Ct, so the sooner a signal is generated i.e. a lower Ct the greater the 
starting DNA.  
 
There are many different chemistries which have been utilised for the detection of 
amplicons most of which are based on fluorescence and instruments have been 
developed which are able to carry out the PCR reaction and accurately measure the 
fluorescence of each sample at the end of each cycle. Popular among detection methods 
are DNA binding dyes, hybridization probes, hydrolysis probes, Molecular Beacons and 
Scorpion probes. In this study I have used methodology based on SYBR Green, a DNA 
binding dye which benefits from being relatively inexpensive and easy to set up.  
 
SYBR Green emits fluorescence when bound to DNA and as the DNA accumulates 
then the signal increases and is proportional to the concentration. The DNA binding is 
non-specific and therefore can also bind to other non-specific DNA species which are 
present and or accumulating during the PCR from sources such as Primer-Dimers, 
contaminant DNA or misannealed primers. For this reason careful optimization of the 
PCR conditions is required in order to avoid false positive signals. Each PCR run was 
accompanied by a melt curve analysis which identifies the Tm or dissociation 
temperature of the amplicon. Well optimized reactions with no contaminants should 
give a single peak for Tm.  
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Quantification of the amount of starting material (target DNA) in the qPCR reaction and 
by inference the amount of mRNA in the sample may be determined by absolute or 
relative methods. In this study we used absolute quantitation where known standards are 
used to generate a standard curve. The standard curve of Ct versus log input DNA is 
plotted which gives a linear relationship. The unknowns are derived from this based on 
their Ct values. 
 
The gene expression data requires normalisation to correct for sample to sample 
variation in terms of cell number, RNA quality, etc. The real time PCR results are 
normalized against a control gene which is expressed constantly in different tissue 
types, throughout development and irrespective of treatment. Generally housekeeping 
genes e.g. GAPDH, β-actin or ribosomal RNA are used for this purpose. In this study 
18S rRNA was used to normalize the real time PCR data. 
 
 
4.2.2	  	   	   Quantitation	  of	  Mouse	  tissue	  MAdCAM-­1	  mRNA	  by	  Real-­
Time	  RT-­PCR	  
 
4.2.2.1	  	   Isolation	  of	  Total	  RNA	  from	  mouse	  tissue	  
 
A variety of tissue samples (including  brain, colon, heart, lung, liver, ileum and spleen)  
were obtained from CALB/Rk strain mice. The  CALB/Rk mouse strain was used as 
this was the most accessible and easily available. The mouse experiments were  
performed once.  
  
The samples were cut into small pieces (approx 20mg), snap frozen in liquid nitrogen 
immediately after removal, and stored at -80oC until use. Total RNA was isolated using 
the Qiagen RNeasy Mini Kit (QIAGEN Ltd, Crawley, UK) using the manufacturer’s 
instructions. Briefly, frozen tissue was powdered in a pestle and mortar under liquid 
nitrogen and transferred to a microcentrifuge tube to which 600µl of lysis buffer was 
added. The lysate was then homogenised by repeatedly passing through a 21 G needle 
attached to a sterile syringe during which the high molecular DNA is sheared. The 
homogenate was then cleared by centrifugation at maximum speed in a microcentrifuge, 
the supernatant transferred to a new tube, and 600µl of 70% ethanol added. The RNA 
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was bound to the silica-gel based membrane by centrifugation of the lysate through the 
RNeasy spin column and contaminants removed by several wash spins. The RNA was 
then eluted into sterile microcentrifuge tubes in 50µl of RNase-free water and stored at -
80oC. 
4.2.2.2	  	   Reverse	  Transcription	  
 
cDNA was prepared using the Sensiscript Reverse Transcription kit (Qiagen Ltd, 
Crawley, UK). 10µl of RNA was added to 10µl reaction mix containing 1x RT buffer, 
0.5mM dNTP’s, 10µM random hexamer primers, 40U RNaseOUT (Invitrogen, UK), 
and 1µl M-MLV reverse transcriptase. The reaction was incubated at 37oC for 60 
minutes and finally heated at 93oC for 5 minutes to inactivate the enzyme. 
 
4.2.2.3	  	   Quantitative	  Polymerase	  Chain	  Reaction	  
 
Primers RTMC1 (5’-GACACCAGCTTGGGCAGTGT) and RTMC2 (5’-CAGCAT 
GCCCCGTACAGAG) designed as described for qualitative PCR were used for real-
time quantitation of MAdCAM-1 mRNA utilizing Sybr Green reagents. A standard 
curve was included in each run comprising DNA copies of the PCR product in the range 
103 – 108 per reaction. Reaction conditions were: 5µl DNA, 1x buffer, 5mM MgCl2, 
0.2mM dNTP’s, 1µM each Primer, Sybr Green (1/75000), 1U Platinum Taq DNA 
polymerase (Invitrogen, UK) in a final volume of 25µl. Thermal cycling and data 
acquisition was carried out on a Rotor-Gene RG-3000 (Corbett Research, Mortlake, 
Australia) using the following conditions: 95oC for 15 minutes; 44 cycles of 94oC 30 
seconds, 60oC 30 seconds, 72oC 60 seconds. Melt curve analysis was carried out 
between 50oC - 99oC. All samples were analysed in duplicate. Standard curves were 
constructed by regression analysis and unknowns calculated using Rotor-Gene software. 
Sample copy numbers were normalized for 18S RNA by carrying out real-time RT-PCR 
on each sample as described using 18S RNA primers 
(sense,5’GTATTGCGCCGCTAGAGGTG;anti-sense, 
5’CTGAACGCCACTTGTCCCTC) and comparative amounts calculated against a 
standard RNA included in each run. Normalized copies were calculated by dividing 
measured values by comparative 18S RNA value. Relative expression could then be 
determined by comparing the normalised copies. 
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4.2.3	   	   	  Results	  (table	  4.2,	  figure	  4.5)	  
 
We used real time PCR to quantify the levels of mouse MAdCAM-1 per unit 18S 
ribosomal RNA in a variety of murine tissue samples. There was increased constitutive 
expression of MAdCAM-1 in spleen and ileum with relatively poor expression in liver 
and heart. 
 
  A B C D E 
 Mouse     
 TISSUE 
MAdCAM-1 
COPIES 
RELATIVE 18S 
RNA 
CORRECTED 
MAdCAM-1 
RELATIVE 
EXPRESSION 
MAdCAM-1 
1 Brain 314 0.71 442 0.42 
2 Colon 207 1.26 164 0.16 
3 Heart 25 4.6 5.4 0.005 
5 Lung 508 3.55 143 0.14 
6 Liver 148 2.35 63 0.06 
7 Ileum 671 0.64 1048 1 
8 Spleen 5215 1 5215 5 
 
 
Table	   4.2	  Real time RT-PCR methodology to quantify levels of mouse MAdCAM-
1/18S RNA expression in different mouse tissues. The	  results	  have	  been	  expressed	  	  	  as	  the	  ratio	  of	  MAdCAM-­‐1/18S	  (n=1)	  
 
                
 
Figure	  4.5	  Relative expression of MAdCAM-1 in mouse tissues. The	  highest	  level	  of	  MAdCAM-­‐1	  expression	  was	  observed	  in	  splenic	  and	  ileum	  tissues	  with	  the	  lowest	  	  	  in	  heart	  samples	  and	  relatively	  weaker	  MAdCAM-­‐1	  levels	  in	  brain,	  colon,	  lung	  and	  liver(n=1)	  
BRAIN     COLON    HEART      LUNG        LIVER      ILEUM  SPLEEN  
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4.2.4	   	   	  Discussion	  
 
The ability to effectively quantify MAdCAM-1 in tissues has thus far been challenging, 
hindering significant progress to explore its modulation. The results from our first series 
of experiments in this chapter confirm the ability to detect and quantitatively assess 
MAdCAM-1 mRNA in normal mouse tissues.  
 
Using real-time PCR the relative expression of MAdCAM-1 in normal murine tissues 
showed it to be raised in spleen and ileum compared with relatively low levels in the 
heart and liver. The constitutive expression of MAdCAM-1 in histologically normal 
mouse tissues has previously been described using semiquantitative 
immunohistochemical data. In support of this, MAdCAM-1 transcripts have previously 
been described, expressed predominantly in the small intestine, mesenteric lymph 
nodes, colon, spleen, pancreas and brain. 
 
There is greater expression of MAdCAM-1 in the mouse spleen from our experiments 
compared to the other organs. This  confirms its importance in this organ. Unfortunately  
whilst these experiements show differences in the expression of  mouse MAdCAM-1 in 
different organs, the mouse experiments were only performed once and different 
numbers of tissue samples from the same organ were not used. The  natural limitations 
of reproducibility are clear and unfortunately time constraints did not allow repeat.  
 
It is noteworthy to report that high endothelial venules are constitutively absent in the 
spleen; expression has been described from immunohistochemical and electron 
microscopy analysis to be immunolocalised to the cells in the marginal zone between 
red and white pulp where expression is restricted to the sinus lining cells close to the 
lymphoid white pulp (Kraal et al. 1995). Specifically, MAdCAM-1 plays a critical role 
in the organisation of the marginal sinus around the splenic white pulp nodules. This 
may be a pre-requisite for unimpaired migration and segregation of B and T cells to and 
within the spleen i.e. proper trafficking of cells from the marginal zone to the white pulp 
particularly after a microbial challenge. Steiniger et al (2001)  reported that fibroblasts 
with an unusual phenotype located in the perifollicular zone, the outer marginal zone 
and the T-cell zone of the splenic white pulp are immunoreactive to MAdCAM-1. Each 
of the latter studies were carried out with two different monoclonal antibodies anti-
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MAdCAM-1 mAb 10A6 and 10G3 developed by  the Briskin group  laboratory has the 
ability to detect MAdCAM-1 in frozen sections but poorly (or not at all) in formalin 
fixed sections. Thus, the intriguing expression of MAdCAM-1 on fibroblasts, which 
have not previously been known to express MAdCAM-1, might suggest that these 
monoclonal antibodies cross-react with an unrelated determinant. However, it has also 
been reported that MAdCAM-1 is expressed by NIH 3T3 fibroblasts following 
activation with TNFα. The epitope recognised by the 314G8 monoclonal antibody may 
be labile in the spleen, duodenum and colon, but this seems unlikely given that the 
314G8 mAb recognises MAdCAM-1 in paraffin-embedded sections. A possible 
explanation is that MAdCAM-1 is alternatively spliced at specific anatomic sites, such 
that different functional domains are represented. Thus, MAdCAM-1 in the colon, 
duodenum, and on fibroblast-like splenic cells may represent differentially spliced 
forms that lack the first immunoglobulin domain of MAdCAM-1 and hence are not 
recognised by the 314G8 monoclonal antibodies.  
 
We observed MAdCAM-1 to be poorly expressed in mouse brain tissue.  MAdCAM-1 
expression has been reported in astrocytes surrounding blood vessels in lesions from 
animals displaying chronic relapsing experimental autoimmune encephalomyelitis 
(EAE), where it appears to play a contributory role in the progression of chronic EAE 
and is a potential therapeutic target for the treatment of demyelinating disease e.g. 
multiple sclerosis. Functional blockade of MAdCAM-1 has been shown to effectively 
prevent the development of a progressive, non-remitting form of EAE. It is interesting 
to note that treatment with anti-VCAM-1, anti-MAdCAM-1 and anti-ICAM-1 
antibodies induced a more rapid remission than the anti-MAdCAM-1 treatment alone 
(Karwar et al 2000). 
 
Lung Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for 
recruitment of mast cell progenitors to the inflamed lung. The lung is an important 
tertiary lymphoid organ and many lung diseases are associated with disordered lung 
immunity. Unlike the gut, α4β7 (binding to MAdCAM-1) the molecular pathways 
controlling lymphocyte migration to the lung are unclear.  
 
A distinctive and important observation arising from immunohistochemical analysis and 
real time data is the faint expression of MAdCAM-1 in the normal liver. This is likely to 
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reflect its inactive role in normal liver. Additional mRNA analysis by Northern blot or 
in situ hybridization would also be useful in validating the presence of MAdCAM-1 
mRNA in liver tissue. An interesting possibility could be that this MAdCAM-1 exists in 
a non-functional state. Under inflammatory conditions, a conformational change and 
increased expression results in increased functional MAdCAM-1 that leads to the 
recruitment of lymphocytes to liver tissues. It is plausible that MAdCAM-1 is present in 
normal liver where it exists with a divergent structural folding. This divergent could 
explain the relatively low expression of MAdCAM-1 detection. 
 
As MAdCAM-1 is a marker of high endothelial venules which are induced at 
chronically inflamed sites, tissue MAdCAM-1 could be a useful immunological marker 
diagnostically in monitoring and therefore managing the progression of a variety of 
major chronic inflammatory diseases with which it is linked, either alone, or in 
combination with other soluble adhesion molecules. Therefore, increased levels of 
circulating MAdCAM-1 as outlined earlier could be a marker for the presence or 
progression of chronic inflammatory disease (Leung et al 2004). 
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4.3	  	   	   Development	  and	  use	  of	  a	  Real	  Time	  PCR	  assay	  to	  
quantify	  MAdCAM-­1	  mRNA	  in	  human	  disease	  	  	  
 
4.3.1	  	   	   Isolation	  of	  Total	  RNA	  from	  human	  tissue	  
 
Fresh liver tissues n=20 (4 normal, 3 PBC cirrhosis, 3 PSC cirrhosis, 2 ALD cirrhosis, 1 
autoimmune hepatitis, 2 cryptogenic cirrhosis, 2 secondary biliary cirrhosis, 2 non-
cirrhotic portal hypertension, 1 fulminant liver failure (secondary to paracetmaol 
overdose and treated with GCSF) were cut into small pieces (50-100 mg), snap frozen 
in liquid nitrogen immediately after removal and stored at -80oC until use. Total RNA 
was isolated using the Qiagen RNeasy Mini Kit (QIAGEN Ltd, Crawley, UK) as 
described previously. The RNA was stored at -80oC until use.  
 
4.3.2	  	   	   Reverse	  Transcription	  
 
cDNA was prepared using the Sensiscript Reverse Transcription kit (Qiagen Ltd, 
Crawley, UK). 10µl (approximately 50ng) of RNA was added to 10µl reaction mix 
containing 1x RT buffer, 0.5mM dNTP’s, 1µM random hexamer primers, 1U RNase 
Inhibitor and 1µl Sensiscript reverse transcriptase. The reaction was incubated at 37oC 
for 60 minutes and finally heated at 95oC for 5 minutes to inactivate the enzyme. cDNA 
was stored at -20oC until use. 
 
4.3.3	   	   	  Quantitative	  Polymerase	  Chain	  Reaction	  
 
Primers MAdCAM F5 and R6 designed as described for qualitative PCR were used for 
real-time quantitation of MAdCAM-1 mRNA utilizing Sybr Green reagents. A standard 
curve was included in each run comprising DNA copies of the PCR product in the range 
103 – 108 per reaction. Reaction conditions were: 5µl cDNA, 1x buffer, 5mM MgCl2, 
0.2mM dNTP’s, 1µM each Primer F5 and R6, Sybr Green (1/75000), 1U Platinum Taq 
DNA polymerase (Invitrogen) in a final volume of 25µl. Thermal cycling and data 
acquisition was carried out on a Rotor-Gene RG-3000 (Corbett Research, Mortlake, 
Australia) using the following conditions: 95oC for 15 minutes; 44 cycles of 94oC 30 
seconds, 60oC 30 seconds, 72oC 60 seconds and a melt curve between 50oC - 99oC. All 
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samples were measured in duplicate. Standard curves were constructed by regression 
analysis and unknowns calculated using Rotor-Gene software.  
 
Sample copy numbers were normalized for 18S RNA by carrying out real-time RT-PCR 
on each sample as described using 18S RNA primers (sense, 
5’GTATTGCGCCGCTAGAGGTG; anti-sense, 5’CTGAACGCCACTTGTCCCTC) 
and comparative amounts calculated against a standard RNA included in each run. 
Normalized copies were calculated by dividing measured values by comparative 18S 
RNA value.  
 
We initially set out to verify the accuracy of real time PCR in measuring MAdCAM-1 
DNA levels.  We can duplicate samples on serial dilutions of standard MAdCAM-1 
DNA to establish the reproducibility  and accuracy (figure 4.6 and 4.7) of the assay. 
The assay for the standard 18s internal controls had previously been verified by Oswell, 
Southampton, UK. We tested standard concentrations of 18S RNA in number of PCR 
reactions provided by the manufacturer to verify the accuracy of the 18S internal 
controls prior to testing our samples. To establish the accuracy of this real time PCR 
protocol in quantifying MAdCAM-1DNA we used the biogene software to generate a 
standard curve for serial dilutions (figure 4.7). 
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4.3.4	  	  	  	  	  	  	  	  	  Results	  (figure	  4.6	  to	  4.8	  and	  table	  	  4.3)	  
 
I used real time PCR to quantitify levels of MAdCAM-1 mRNA  perunit 18S ribosomal 
RNA in our liver samples.There were varying levels of MAdCAM-1 expression in the 
human liver tissues from a a range of liver diseases, grouped into  normal liver,  
cirrhotic liver explants, non-cirrhotic portal hypertension   and  fulminant liver failure 
(secondary to paracetamol overdose treated with GCSF). The latter case was associated 
with the  highest MAdCAM-1 level recodered with the lowest levels of MAdCAM-1 
expression in autoimmune hepatitis  related cirrhosis.  
There was significant upregulation of MAdCAM-1 expression in the cirrhotic liver 
(n=14) p<0.011 as  compared to normal  liver (n=4) 
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a Human MAdCAM-1 = 108 copies/reaction 
b Human MAdCAM-1 =  107 copies/reaction  
c Human MAdCAM-1 = 106 copies/reaction 
d Human MAdCAM-1 = 105 copies/reaction 
e Human MAdCAM-1 = 104 copies/reaction  
f Human MAdCAM-1= 103 copies/reaction 
g PCR Negative Control=water 
 
Figure	   4.6	   The fluorescence profile for the standard concentrations of 
Human MAdCAM-1 DNA using real time PCR. The	   fluorescence	   profile	  follows	  the	  classical	  sigmoidal	  shape	  (reproducibility)	  and	  a	  serial	  drop	   in	  threshold	  Ct	  value	  representing	  each	  dilution	  (log	  10).	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Figure	   4.7	   A standard curve was generated for the serial dilutions of 
MAdCAM-1. The	  blue	  dots	  (MAdCAM-­‐1)	  are	  standards	  and	  reds	  are	  the	  unknowns.	  
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
 
 
 
 
PATIENT DIAGNOSIS 
COPIES MAdCAM-1 
mRNA/unit 18S RNA 
MEAN ± SE 
COPIES MAdCAM-1 
1 NORMAL  4.7X106 
2 NORMAL 9.3X106 
3 NORMAL 0.32X106 
4 NORMAL 0.083X106 
3.6X106 ± 2.18X106 
5 
SECONDARY 
BILIARY CIRRHOSIS 
2.2X106  
6 
NON CIRRHOTIC 
PORTAL 
HYPERTENSION 
1.1X106  
7 
CRYPTOGENIC 
CIRRHOSIS 
65X106 
8 
CRYPTOGENIC 
CIRRHOSIS 
19X106 
42X106 ±  23X106 
9 
FULMINANT LIVER 
FAILURE SECONDARY 
TO PARACETAMOL 
OVERDOSE TREATED 
WITH GCSF 
23000X106  
10 AIH CIRRHOSIS 0.064X106  
11 ALD CIRRHOSIS 67X106 
12 ALD CIRRHOSIS 11X106 
13 ALD CIRRHOSIS 64X106 
14 ALD CIRRHOSIS 21X106 
41X106 ± 14.5X106 
15 PSC CIRRHOSIS 34X106 
16 PSC CIRRHOSIS 41X106 
17 PSC CIRRHOSIS  21X106 
32X106 ± 5.9X106 
18 PBC CIRRHOSIS 2.3X106 
19 PBC CIRRHOSIS 17X106 
20 PBC CIRRHOSIS 5.6X106 
8.3X106 ± 4.5X106 
Table	  4.3	  Human hepatic  MAdCAM-1 cDNA assay from normal liver tissues and 
from a range of liver conditions(Total n=20).  
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Figure	  4.8	  Expression of MAdCAM-1 mRNA in the human liver as 
determined by real-time PCR. The figure shows significant upregulation of MAdCAM-1 
in cirrhotic liver (n=14) p<0.011 as  compared to normal  liver(n=4). 
 
 
 
 
 
 
 
 
 
 
  NORMAL         CIRRHOSIS 
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4.3.5	  	   	   Discussion	  
 
The expression of MAdCAM-1 has previously been reported in human livers in a 
variety of liver diseases which are linked to IBD e.g. PSC and AIH. Our aims in this 
section was to  confirm our findings from MAdCAM-1 immunohistochemistry and 
determine whether MAdCAM-1 is expressed in the liver as  mRNA was examianed 
specifically looking to see if detection was possible  in both normal and diseased livers. 
I  found sequence analysis of mRNA from a normal liver revealed complete alignment 
with the MAdCAM-1 gene provided by GeneBank validating the presence of 
MAdCAM-1. Additional mRNA by Northern blot or insitu hybridisation would also 
have been useful in validating the presence of MAdCAM-1 in human liver tissue as 
would MAdCAM-1 protein using Western Blot analysis.  
 
Our current experiments thus far, from chapter 2 and 4 have demonstrated our ability to  
detect and effectively quantify MAdCAM-1 in fresh human tissues e.g. liver. Using real 
time analysis (qPCR), I have shown the significant upregulation of MAdCAM-1 mRNA 
in advanced liver disease(p<0.011), confirming the findings from my  
immunohistochemical analysis. Specifically, in the  immunohistochemical work from 
Chapter 2, I found  no evidence of MAdCAM-1 in non-cirrhotic portal hypertension, 
normal liver and pre-cirrhotic PBC, HCV. This compares to my findings of  MAdCAM-
1 upregulation,  in cirrhotic liver disease from  immunohistochemistry and confirmed by 
real time PCR. Unfortunately,  whilst further liver tissues samples at different  disease 
stages for PBC and HCV i.e. pre-cirrhosis were not available to allow MAdCAM-1 real 
time measurement, there was no doubt of its absence in the pre-cirrhotic 
immunohistochemical studies and upregulation in the cirrhosis. We  hypothesise that 
the pre-cirrhotic real time samples would have shown relative paucity in MAdCAM-1 
RNA,  with a rising trend in expression compared from normal tissues. Clearly, this 
would be important future work to study this. 
 
It was worthy of note that the lowest levels of MAdCAM-1 expression in human liver 
was found in autoimmune hepatitis  related cirrhosis, albeit in one sample. This level 
was even lower than those taken from normal liver tissues. Whilst drug history from the 
autoimmune explant was not available, it is certainly possible that this patient is likely 
to have been on immunomodulatory drugs e.g prednisolone and/or azathiporine at the 
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time of orthotopic liver transplantation. The level of MAdCAM-1 may therefore reflect 
the downregulation effect from immunosuppression. 
  
It is clear from our experiments (table 4.3) that MAdCAM-1 is present constitutively in 
normal human liver, all be it in relatively small quantities, where it probably exists with 
a divergent structural folding. This contrasts with the mouse real-time analysis where 
we found almost nonexistent levels of MAdCAM-1(table 4.2 and figure 4.5). This 
divergence in human MAdCAM-1 could explain the relatively low expression levels  of 
MAdCAM-1 in some studies (Grant et al 2002 using monoclonal antibodies) and 
absence in others (Ala et al, using polyclonal antibodies). Currently, the epitope where 
the monoclonal antibody binds is not known, but as it acts as a function-blocking 
antibody it is likely that it recognises an epitope in either of the two extracellular 
domains. In the normal liver setting the non-functional folded state cannot support 
lymphocyte recruitment, where as in inflammatory conditions the local release of TNFα  
could induce further expression of MAdCAM-1.It is possible that another stimulatory 
agent(s) e.g. chemokines  in combination with the already expressed MAdCAM-1 
acquires a functional confirmation, thus being allowed to recognise leukocyte-integrin 
recognition and binding. There would certainly be merit in exploring this further. 
Specifically, additional protein nuclear magnetic resonance spectroscopy (NMR) and X-
ray crystallography experiments would provide important topographical details and 
folding of the ligand – binding domains of the MAdCAM-1 protein in not only basal but 
also inflammatory conditions.  
 
The goal of most quantitative RT-PCR methods is to use PCR product yield as a 
measure of relative differences in mRNA template abundance. As the efficiency of the 
RT reaction has been assumed to be constant, the quantitative capacity of the PCR has 
been the prime focus of debate. Early on the chapter, the feasibility of the quantitative 
PCR was questioned because of two theoretical constraints. Firstly, given the 
exponential nature of the process small tube variations in efficiency would grossly 
affect the field yield of the PCR products. Secondly, the PCR product yield would not 
only provide a valid measure of template input during the exponential phase of 
amplification. The development of competitive PCR methods allows investigators to 
address such theoretical concerns experimentally. To date the pre-requisites to allow 
quantitative RT-PCR appear to be: 
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1. PCR product yield is determined using the exponential phase of amplification 
(figure 4.6).  
2.  A standard curve demonstrates the range over which PCR product yield provides 
a measure of mRNA input (figure 4.7). 
 
We have already discussed the importance of MAdCAM-1 in Chapter 2 having shown 
`immunohistochemical upregulation in end stage liver disease. The real-time PCR 
protocol with the appropriate samples allowed us to show a significant  MAdCAM-1 
mRNA  upregulation in human cirrhotic livers (figure 4.8). 
 
It is interesting to note the GCSF treated patient from paracetamol induced fulminant 
liver failure was associated with the highest MAdCAM-1 levels (table 4.3). Whilst this 
is an isolated case it certainly allows us to postulate the aetiologies. The effect of 
MAdCAM-1 is unlikely to be secondary to the acute liver failure per se, as we have 
previously shown the absence of MAdCAM-1 in earlier stages and grades of liver 
disease. Certainly, the direct effect of GCSF on adhesion molecules is not well 
described. We can hypothesize that GCSF leads to the upregulation of TNFα, which as 
we have previously shown may induce the expression on MAdCAM-1.  
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5.1	   	   	  Background	  
 
The hypothesis underlying this chapter is that MAdCAM-1 is amenable to modulation, 
an ability which can be confirmed by quantification. The expression of MAdCAM-1 is 
achieved using an in vitro model as described in Chapter 3. Interactions can be 
prevented by reducing or masking expression of leukocyte antigens, vascular adhesion 
molecules, or both. Experimentally, in animals and man, both approaches have been 
tried. Following the positive therapeutic effect of anti-α4, (Podolosky et al 1993) α4β7 
(Hesterberg D et al 1996) or β7 (Kanai T et al 2003) antibodies against leukocyte 
integrins in experimental colitis,  humanised monoclonal antibody natalizumab to α4 
integrin IgG4 in active Crohn’s disease showed therapeutic benefits in controlled trials 
(Targan et al 2007). In respect of reducing adhesion molecule expression, as discussed 
above there are a number of adhesion molecules that are upregulated in diseased bowel-
e.g. E-Selectin, ICAM-1 and our own findings from MAdCAM-1 (Briskin et al 1997) 
(Ala et al 2003) and the particular attraction of MAdCAM-1 as a target due to its 
mucosal specificity has been discussed. In particular, an anti-MAdCAM-1 antibody has 
been used in experimental colitis with some therapeutic effect (Kato S et al 2000). 
 
Whilst we have discussed the use of blocking antibodies, the use of such agents, 
particularly on repeated occasions, has potential disadvantages associated with 
sensitization to foreign proteins (even with extensively humanised antibodies) or the 
development of anti-idiotype responses.  An alternative strategy is the prevention of the 
synthesis of endogenous proteins, which can be specifically achieved by the use of 
antisense oligonucleotides. Indeed, the potential application of this general approach has 
already been explored in Crohn’s disease, using antisense to the vascular adhesion 
molecule ICAM-1 (Yacyshyn   et al 1998) (Yacyshyn   et al 2002). Here, the results 
were negative for efficacy and therapeutic value, though the general safety of the 
approach was demonstrated in patients with IBD.  We have already commented that we 
believe ICAM-1 is a less appropriate target than MAdCAM-1.  Thus, the specific 
hypothesis underlying this chapter is that modulation of MAdCAM-1 expression may be 
achieved and can be subsequently quantified.  
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5.2	  	   	   Experiment	  1:	  Effect	  of	  modulating	  MAdCAM-­1	  using	  
an	  in	  vitro	  model	  	  
5.2.1	  	   	   Introduction	  
 
Having established our endothelial cell culture model there is potential to investigate the 
effects of modulating MAdCAM-1 expression on SVEC 4-10 cells. Therefore, our cell 
culture model has important implications relating to both clinical applications and the 
mechanism for studying MAdCAM-1 expression. I have already shown the effect of 
TNFα stimulation and quantifying this endothelial expression. Our aim is to follow a 
logical sequence from our in vitro cell culture work, which began with a dose response 
experiment studying the effects of TNFα on a monolayer of endothelial cells. This 
system was developed to study the effect of stimulation with other pro-inflammatory 
agents such as bacterial endotoxin LPS, and IL-1β. As a result, subsequent inhibition of 
MAdCAM-1 expression may also be achieved as a potential therapy, by designing 
strategies and testing them in vitro. TNFα has already been shown in Chapter 1 to 
stimulate the transcription of genes encoding endothelial cell adhesion molecules 
including E-selectin, ICAM-1 and VCAM-1. Specifially,  we have found maximal 
MAdCAM-1 to occur at  a dose of 20ng/ml as the target dose of choice for TNFα 
following stimulation of SVEC4-10 endothelial cells.  
 
We have chosen to modulate MAdCAM-1 in view of our own interesting observations 
from chapter two on the expression of MAdCAM-1 in the liver (Ala et al 2003), gut 
(Ala et al 2002) and pancreas. Previously, our laboratory chose to modulate E-selectin 
expression because as we have already shown, using plasma levels, tissue 
immunohistochemistry, and in vivo studies in patients using radiolabelled antibodies, 
that E-selectin is strongly upregulated in active but not inactive ulcerative colitis and 
Crohn’s disease. (Bhatti et al 1998). Potential strategies include administration of 
steroids, mesalasine, anti-inflammatory cytokines such as IL-10 (which may act 
directly, or indirectly via inhibition of pro-inflammatory cytokines) and the use of 
specific agents e.g. anti-sense oligonucleotide sequences (Anti-S) to inhibit expression 
of MAdCAM-1. 
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These observations will explore the hypothesis that the ability of endothelial cells to 
express MAdCAM-1 in response to different pro-inflammatory stimuli (bacterial 
endotoxin LPS, IL-1β, and TNFα). can be consistantly quantified and that this system 
could then be further developed to investigate inhibition of MAdCAM-1 expression as a 
potential therapy. We shall then be in a position to design strategies to downregulate 
MAdCAM-1 expression, and test them in vitro.  
 
5.2.2	  	   	   Methods	  
 
Our aim was to follow a logical sequence from our in vitro cell culture work,  building 
on the study of the effects of TNFα on a monoloayer of SVEC 4-10 cells. I utilised the 
in vitro model already  developed and described  in chapter 3. The SVEC 4-10 cells 
were seeded at 20,000 cells/cm2 and used immediately after confluency. I stimulated the 
cells for 24hrs with IL-1(1-100ng/ml), LPS(1-500ng/ml) and made comparisons with a 
fixed dose of 20ng/ml of TNFα, which I have already shown to have given maximal 
surface expression of MAdCAM-1 in dose dependant studies. The endothelial 
monolayers were pre-treated with Dexamethasone(0.001-1.00mM), 5-aminosalicylic 
acid(1uM-2mM of 5-ASA), hydrocortisone(0.001-10mM), interleukin-10(1-100ng/ml).  
prior to transfection with TNFα. In MAdCAM-1 induction assays, the endothelia were 
treated with IL-10 (20 ng/ml), dexamethasone (10µm) or 5-ASA (400µm),  1 hour prior 
to TNFα (20ng/ml) stimulation. The percentage inhibition of MAdCAM-1 was 
calculated having taking into account the negative control and the observed values of 
the flourscence intensity. Values are mean ± standard error. Data were analysed by one-
way ANOVA. Significance was set at p < 0.05. All data were the mean of  three 
experiments. 
 
5.2.3	   	   	  Results	  (figure	  5.1	  to	  5.3)	  
 
The first experiments were  a simple series of dose response studies  to study  the effects 
of stimulating a monolayer of SVEC4-10 cells with LPS, IL-1 compared to 20ng/ml 
TNFα for 24 hours. As expected, there were greater variations in responses with co-
culture  IL-1 and LPS compared to the dose reponse study of TNFα already established 
in chapter 3. The greatest inhibition of MAdCAM-1 was observed with Hydrocortisone 
(Figure 5.2). 
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Figure 5.1 The dose response studies on the effect  of stimulating a monolayer of 
SVEC4-10 cells with Interleukin 1L-1β(1-100ng/ml) or  LPS (1-500ng/ml) compared 
to 20ng/ml TNFα over a 24hr period. (n=9). Like LPS, there are also variations in doses of IL-
1β . There  were greater variations in responses with  LPS doses, compared to the dose response study of 
TNFα already established in chapter 3.  
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Figure	   5.2	  The effect of different doses of dexamethasone and hydrocortisone on 
mouse SVEC4-10 cells pre-stimulated with 20ng/ml mouse TNFα in vitro (n=9) and 
results expressed as mean ± S.D. The	   results	   are	   shown	   as	   percentage	   inhibition	   of	   TNFα.	  There	  is	  a	  dose	  dependant	  increase	  in	  MAdCAM-­‐1	  inhibition	  using	  hydrocortisone	  at	  cencentrations	  varying	   from	   0.001mM	   to	   10mM.	   The	   effect	   from	   Dexamethasone	   is	   less	   predicatable	   however,	  	  with	   the	   highest	   concentrations	   (1mM	   Dexamethasone)	   leading	   to	   over	   40%	   inhibition	   in	  MAdCAM-­‐1	   expression(p<0.01)	   and	   the	   greatest	   inhibition	   with	   10mM	   of	   Hydrocortisone	   at	  98%(p<0.001)	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In the next set of experiments (Figure 5.3) I characterised the effects of IL-10 and 5-
ASA. I assessed if IL-10 at five different doses between 1ng/ml and 100ng/ml affects 
inhibition of MAdCAM-1. I also determined if 5-ASA at five different doses between 
1µM and 2Mm had an effect. I found whilst the effect of 1L-10 was dose dependant, the 
overall inhibition of MAdCAM-1 was not significant, although lower doses of IL-
10(1ng/ml) appeared to have slightly greater levels of inhibition of MAdCAM-1. The 
effect of 5-ASA on MAdCAM-1 inhibition was more substantive with the greatest level 
of inhibition being demonstrated by a dose of 2mM(p<0.05) 
 
                                   
 
Figure	  5.3	  The effect of 5-ASA and IL-10 on SVEC4-10 endothelial cells stimulated 
with 20ng/ml TNFα in vitro(n=9). Pre-­‐incubation	   of	   monolayers	   with	   5-­‐ASA	   and	   IL-­‐10,	  prevented	  TNFα	  induced	  MAdCAM-­‐1	  expression	  to	  varying	  extents.	  Whilst	  there	  was	  no	  evidence	  of	  a	  significant	  effect	  of	  MAdCAM-­‐1	  with	  dose	  related	  IL-­‐10,	  there	  was	  still	  a	  degree	  of	  inhibition	  using	  5-­‐ASA	  (p<0.05)	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5.2.4	   	   	  Discussion	  
 
We have shown that mouse endothelial cells express MAdCAM-1 upon stimulation 
with pro-inflammatory cytokines TNF-α, LPS and  IL-1 to varying degrees. The 
expression can be  consistently quantified. We have seen a consistent dose dependant 
increase in MAdCAM-1 with TNFα contrasting with greater variations in responses 
with co-culture  IL-1 or LPS. It is for this reason that TNFα was used to stimulate the 
SVEC-40 cells for further study into modulating the expression of MAdCAM-1.This 
system  has  further been developed to show that modulation of MAdCAM-1 can be 
effectively achieved. In particular, we demonstrated  that glucocorticoids e.g. 
hydrocortisone, and 5-ASA cause the most significant  effect on MAdCAM-1 
expression.  
 
In our in vitro model, whilst MAdCAM-1 expression was certainly downregulated with 
IL-10 and dexamethasone, it was  not so to  a signifiant level (Ala et al 2003). There 
was a step wise dowregulation of IL-10 (100ng/ml to 10ng/ml). Curiously, the greatest 
percentage of MAdCAM-1 inhibition being achieved with the small doses of IL-10 
(10ng/ml).  It is therefore  likely that  the clinical efficacy of these agents  can be related 
to the direct  affects on MAdCAM-1, whilst IL-10 may promote MAdCAM-1 
independent effects on IBD. These findings appear to be  in contrast to the study by 
Oshima et al (2001a),  showing that 1L-10 can exert significant therapeutic activity in 
IBD with reduced TNFα-induced MAdCAM-1 protein, mRNA and also a functional 
lymphocyte adhesion. However, in these experiments neither 5-ASA, sulphasalazine, 
nor 6-MP blocked MAdCAM-1 induction.  
 
The biology of IL-10 is highly complex. It is a regularity cytokine which inhibits both 
antigen presentation and subsequent pro-inflammatory cytokine release e.g. 1L-1, 1L-6, 
1L-12, IFN-α, TNFα and the chemokine IL-8. Finally, IL-10 induces the production of 
cytokine inhibitors, such as 1L-1 receptor antagonist and the release of soluble TNFα 
receptors. The pivotal role played by IL-10 within the mucosal immune system is 
demonstrated by the chronic ileitis that develops in gene-targeted interleukin-10 knock-
out mice and by its therapeutic efficacy in animal models of colitis. However, the 
therapeutic efficacy of IL-10 in patients with Crohn’s disease is less clear cut. In vitro 
studies have shown that exogenous 1L-10 will down-regulate the enhanced pro-
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inflammatory cytokine release from lamina propria mononuclear cells isolated from 
patients with Crohn’s disease (Schreiber et al 1995) 
 
Direct immunoregulatory effects exerted by the 5-ASA include the delicate balance of 
pro-inflammatory mechanisms during active inflammation as seen in inflammatory 
bowel disease. Such effects are the inhibition of peripheral and intestinal B lymphocyte 
immunoglobulin secretion and inhibition of pro-inflammatory cytokine production and 
their binding to receptors. Some of these immunoregulatory effects appear to be 
mediated by an inhibition of the activation of the nuclear factor kappa B (NFκB) 
transcription factor family by steroids and5-ASA. Activation of NFκB appears to be 
pivotal for the sustained upregulation of inflammation molecule expression in many 
inflammatory diseases. It seems, therefore, most likely that the enormous therapeutic 
potency of steroids, as well as the anti-inflammatory properties of 5-ASA, are not 
achieved by a single action of the drug. 
 
There have been other agents which have been shown to attenuate modulatory effects 
on MAdCAM-1 expression and therefore have a therapeutic use in IBD. Most notably 
here they include melatonin but which have have been pre-stimulated with lower doses 
of TNFα e.g. 1ng/ml, over 24 hours (Sasaki et al 2002) . This affect may have 
therapeutic activity thorough its ability to inhibit NFκB dependent induction of 
MAdCAM-1. 
 
Nitric oxide is a key modulator of adhesion molecule expression in both acute and 
chronic inflammatory states. Specifically both reactive oxygen and nitrogen metabolites 
participate in regulating adhesion molecule expression in response to TNF-α with the 
ability to influencing the course of inflammatory bowel disease. Nitric oxide can 
function both as an oxidant or antioxidant depending on the availability of reactive 
oxygen species.  It has been reported that inhibition of endothelial nitric oxide synthases 
(using the non-selective NOS inhibitor L-NAME), induces endothelial adhesion 
molecules (ICAM-1 and VCAM-1) in human umbilical vein cell culture. In a study by 
Oshima et al (2001b), the investigators show how MAdCAM-1 expression in cultured 
endothelial cells is altered by NO donors and by NO synthase inhibitors. The study 
explains the affect of cytokines and NO-modifying agents which control adhesion of 
α4β7-expressing mouse lymphocytes in response to TNFα stimulation. It was observed 
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that both a short and long-acting NO donor significantly reduce TNF-α-induced 
expression of MAdCAM-1 expression in lymphatic endothelial cells. The effects of NO 
donors appear to reflect their ability to prevent the nuclear translocation of NFkB and as 
we have discussed in Chapter 4, the MAdCAM-1 promoter is strategivcally positioned 
for this action by its inherent NFkB binding sites, which are necessary to induce 
MAdCAM-1 expression.  
 
Despite the clinical problems associated with blocking antibodies, they have been used 
in clinical practise to varying extents. Future experiments using our invitro cell culture 
model to study the effect of using MAdCAM-1 antibodies and its α4β7 receptor woud 
be the next logical step in exploring this further. 
 
 
 
5.3	  	   	   Experiment	  2:	  Modulating	  mouse	  MAdCAM-­1	  
expression	  using	  speciifc	  antisense	  oligonucleotides	  	  
 
5.3.1	   	   	  Introduction	  
 
I  have described that the use of blocking antibodies, particularly on repeated occasions 
has potential disadvantages associated with sensitisation of foreign proteins (even with 
humanised antibodies) or the development of anti-idiotype responses. An alternative 
strategy is the prevention of the synthesis of endogenous proteins by the use of anti-
sense oligonucleotides. Indeed, the potential application has already been explored in 
Crohn’s disease, using antisense to the vascular adhesion molecule ICAM-1 (Schreiber  
et al 2001) (Yacyshyn  et al 2007). Here the results were negative for therapeutic value, 
although the safety of the approach was demonstrated in patients with IBD. We have 
already commented that we believe ICAM-1 is a less appropriate target than 
MAdCAM-1. The specific hypothesis is that antisense oligonucleotides can be targeted 
to MAdCAM-1 to allow modulation of its expression. 
 
Antisense oligonucleotides (Anti-S) are sequences of nucleotides targeted at the 
messenger RNA (mRNA) which then prevents the production of protein (Crooke et al 
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1999). They have the potential to specifically turn off the production of any protein in 
cells which may be used for therapeutic gain, in contrast to the majority of agents 
currently in use which modulate the activity of specific proteins involved in 
inflammation and immune regulation. 
 
Several strategies are available to regulate gene expression using oligonucleotides. 
Antisense therapy is different to gene therapy, in that the target is mRNA rather than the 
specific gene of interest. Anti-S drugs exert their effect by two separate mechanisms: 
5.3.1.1	  	   Binding	  to	  complementary	  mRNA	  
 
Knowledge of the targeted sequence and steric interference with mRNA binding shows 
that inhibition of key steps in mRNA processing or function are important in anti-sense 
therapy e.g. 5’-capping, splicing, and initiation of translation (Walton et al 2002) 
(Mahara et al 2003). 
 
5.3.1.2	  	   Utilization	  of	  Rnase	  H	  
 
Rnase H is a family of ubiquitous enzymes that cleave the mRNA strand of the DNA-
RNA heterodimer formed during normal DNA transcription, leaving the Anti-S intact 
and allowing released oligonucleotides free to bind to other target mRNA’s (Galarneau 
et al 2005) 
 
5.3.1.3	  	   Intracellular	  Anti-­S	  degradation	  
 
A number of nucleases exist naturally within cells to breakdown native DNA/RNA. 
Several strategies have been used to help prevent degradation of Anti-S. The first Anti-
S to enter clinical trials were phosphorothioate oligodeoxynucleotides (Ghosh et al 
1993) (Dagle 1991), which differ from normal oligonucleotides by the substitution of a 
sulphur atom for one of the non-bridging oxygen atoms at each of the phosphodiester 
linkages.  
 
Chemical modifications to Anti-S have been shown to increase stability in biological 
systems, specificity to potential targets and reduced level of toxicity (De Mesmaeker  et 
al 1995) (Sanghvi et al 1993). Such modifications are mostly to the backbone, sugar 
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moiety or base of the nucleotide. However, some modifications reduce the subsequent 
action of Rnase H. Perhaps the most promising modification involves the 2’ position of 
the ribose ring to form the 2’-O-(2-methoxy) ethyl (2’- MOE) moiety (Prakash et al 
2002) (Prakash et al 2004) (Vickers 2003) this modification has shown significantly 
improved pharmacological profiles in vitro, when compared to phosphorothioate 
oligonucleotides. Clinical experience with MOE oligonucleotides has so far revealed 
some dose limiting toxicities but also increased potency, prolonged duration of action 
and a lack of neutralising antibody production, which allows repeated administration 
(Geary et al 2001). 
 
5.3.1.4	  	   Non-­antisense	  effects	  	  
 
The advantages conferred by chemical modifications are offset by important non-
antisense activities e.g. immune stimulation such as B-cell proliferation and inhibition 
of viral entry into cells (Boggs et al 1997).  Confirmation of the biological effects of 
Anti-S critically relies upon differentiating specific from non-specific antisense effects. 
This includes the use dose-response, time course experiments and evaluating effects on 
functionally related and structurally distinct proteins whilst employing housekeeping 
gene products. Furthermore, specific sequences associated with non-specific effects 
such as C-G pairs and G-quartets should be avoided in designing Anti-S. It is not known 
whether the response elicited by Anti-S is due to the interaction of Anti-S with its target 
RNA, or other nucleic acids/proteins. 
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5.4	   	   	  Methods	  
	  5.4.1	   	   Generation	  and	  design	  of	  antisense	  oligonucleotides	  	  	  
 
The following antisense oligonucleotides were generated and designed: 
 
MAdCAM-1 ANTISENSE 1   5’AGGATGGATTCCATGCCTGC 3’ (40-21) 
 
MAdCAM-1 ANTISENSE 2  5’GTTCACCTGGAAGGACTGTCCT3’ (107-86) 
 
MAdCAM-1 ANTISENSE 3  5’TCTGTACACTGCCCAAGCTG3’(234-215) 
 
MAdCAM-1 ANTISENSE 4  5’ATCCTGCAGCTGGTCACTCT3’ (864-843) 
 
SCRAMBLED OLIGO’S       5’GCCTGGTCGCACAGATGTAT3’  
 
  
Phosphorothioate oligonucleotides were synthesized using phosphoramidite chemistry, 
purified by high-performance liquid chromatography, and lyophilised to dryness before 
use (Oswel Research Products, Southampton, UK). The specificity of sequences of 
oligonucleotides used in this study were checked by using BLAST analysis.  
 
We initially designed a 20 mer phosphorothioate oligonucleotide spanning the 
translation initiation codon of mouse MAdCAM-1, 5’AGGATGGATTCCATGCCTGC 
3’ (40-21), which would also target known alternative splicing variants of MAdCAM-
1’s mucin domain. 5’GTTCACCTGGAAGGACTGTCCT3’(107-86) to target the 3 -
untranslated sequences immediately 3  to the translation termination codon, 
5’TCTGTACACTGCCCAAGCTG3’(234-215) to the 3 -untranslated region, 
5’ATCCTGCAGCTGGTCACTCT3’(864-843) to target the 3 -untranslated sequences 
immediately 3  to the polyadenylation signal and 5’GCCTGGTCGCACAGATGTAT3’ 
as a scrambled oligonucleotide.  
  
Initially a fully phosphorothioated oligonucleotide (molecular weight 6453.0518mono-
isotropic and average 6455.88) (Oswel) was obtained. We  used  a concentration of  
250nmol/l mixed with lipofectin, to pretreat near confluent SVEC4-10 cells prior to 
stimulation with TNF-alpha. A scrambled oligonucleotide was used as negative control. 
These initial experiments were carried out to confirm the effectiveness of this specific 
Anti-S; if down regualtion was not achieved then further experiemnts were to be 
performed including the use of fluorinated oligonucleotides to confirm cell pernetration. 
In all, a total of four different 20-mer oligonucleotides were synthesized as described. 
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To minimise the potential non-specific toxicity observed with phosphorothioate 
oligonucleotides we used oligonucleotides with a normal phosphodiester backbone and 
two terminal phosphorothioate linkages at the 3’ and 5’ terminal. The oligonucleotide 
was purified by high-performance liquid chromatography and analysed by mass 
spectrometry.  
 
5.4.2	  	   	   Oligonucleotide	  treatment	  
 
The SVEC4-10 cells were seeded on to the gelatin coated 8 chamber wells as described 
in chapter 4 and grown to near confluence. Cells were treated with oligonucleotides by 
first washing in a serum free medium. Opti-MEM containing 10ug/ml 
DOTAMA/DOPE solution was added to the cells followed by the indicated 
concentration of oligonucleotides. The cells were incubated for 4 hours at 37 degrees 
and the medium was replaced by normal growth medium. TNF-alpha was added 0-4 
hours after removal of serum-free medium. To determine whether Anti-S could inhibit 
MAdCAM-1 expression, SVEC4-10 cells were incubated with MAdCAM-1 antisense 
oligonucleotides and then stimulated with TNFα.  
	  
5.4.3	  	   	   Oligonucleotide	  Uptake	  in	  endothelial	  cells	  
 
The need to achieve adequate intracellular concentrations of Anti-S has led to the use of 
extremely large amounts of Anti-S (up to 100µmol/L) in some in vitro studies 
(Manoharan et al 1992). To target intracellular RNA sequences, Anti-S should ideally 
traverse cellular membranes easily but in fact they do this rather poorly due to their low 
lipid solubility, and inherent negative charge. They appear to enter cells via adsorptive 
and fluid phase endocytosis (Loke  et al 1989). The identity of cell membrane proteins 
implicated in binding Anti-S is unclear, although a number of heparin binding proteins 
e.g. fibroblast growth factors, vascular endothelial growth factors have been implicated, 
suggesting that Anti-S may be preferentially taken up by activated leukocytes 
(Pirruccello et al 1994) (Hawley et al. 1996). Thus, following the stability in biological 
medium and their weak intracellular penetration, colloidal drug carriers 
e.g.nanoparticles have been useful in the delivery of Anti-S (Zhu 2004). It has been 
shown that oligonucleotides associated to nanoparticles appear to be protected against 
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degradation thus improving Anti-S stability (Arnedo 2002) Also, the use of cationic 
lipids to facilitate delivery of Anti-S in tissue culture have allowed experiments to be 
performed with concentrations of less than 1 micromol/L (Zhi 2004), allowing entry 
into different types of cells effectively and efficiently, thus avoiding aptameric effects. 
 
The lack of effect of some Anti-S may be explained by poor distribution inside the cell. 
In order to be active, Anti-S should be delivered to the nuclei of cells. The 
oligonucleotides used in the experiments were labelled with fluorescein isothiocyanate 
(FITC) at the 5’end in order that the uptake of oligonucleotides could be confirmed by 
fluorescence microscopy. All of the oligonucleotides were phosphorothioated.  I 
attempted to improve the intracellular distribution of the anti-S by transfection with 
lipofectin. I also used varying concentrations of antisense oligonucleotides to study its 
effect on MAdCAM-1 inhibition. 
 
5.4.4	  	   	   Quantifying	  the	  effect	  of	  different	  oligonucleotides	  and	  
varying	  concentrations	  on	  MAdCAM-­1	  expression	  	  
The SVEC4-10 cells were seeded onto gelatin coated 96 well plates as described in 
chapter 4. To determine if varying the concentration of the different Anti-S compounds 
could effectively influence MAdCAM-1 expression, SVEC4-10 cells were incubated 
with different MAdCAM-1 antisense oligonucleotides, including scrambled negative 
control antisense oligonucleotides of the same length and then stimulated with TNFα  
and TNF peptide. Prior to analysis of results the background fluorescence was 
subtracted from all values. The experiments were performed on six occasions.  
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5.5	  	   	   Results	  	  (figure	  5.4	  to	  5.5)	  
 
Using the gelatin coated 8 chamber wells  at 12 hours the Anti-S mostly exhibited a dot 
like appearance with most fluorescence detected in vesicles without significant 
cytoplasmic or nuclear diffusion of the ASO. There was clear uptake and intracellular 
localisation of antisense oligonucleotide (Antisense 1, 2, 3, 4). Figure 5.4 depicts the 
intracellular localisation of the these antisense oligonucleotides, proving that all  cross 
the plasma membrane with the potential to exert their effects.  
 
Fluorescence microscopy results from the cells transfected with lipofectin coupled 
FITC-Anti S indicated that the oligonucleotides internalisation with the ideal 
oligonucleotides /lipofectin ratio (0.5uM oligonucleotides and 15ug/L lipofectin) 
promoted a diffuse staining of the nucleus and cytoplasm. We found that when the 
oligonucleoitide/lipofectin ratio increased the oligonucleotides uptake assumed a 
vesicular pattern. The green staining is due to the strong fluorescence observed in the 
agglomeration of vesicles, which resemble the Golgi complex.  
 
 
Using the 96 well plates, I  studied the effect of varying concentration of MAdCAM-1 
antisense oligonucleotides of the same length. The experiments were performed on 6 
occasions. The only oligonucleotides to show significant inhibition of MAdCAM-1 
expression were AS1 2ug (p<0.05) and AS4 2ug (p<0.005), with 2ug AS3 nearer the 
limit of significance at p<0.06 (figure 5.5). The other concentrations of the same 
oligonucleotides, both concentrations of AS2 and the scrambled antisense 
oligonucleotides showed no major inhibitory activity. In most cases, higher doses of 
antisense oligonucleotides appeared to achieve lesser favourable MAdCAM-1 inhibition 
statistics (all numbers have blank subtracted).  
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Figure	   5.4:	   Uptake and intracellular localisation of antisense oligonucleotide            
(Antisense 1, 2, 3).  The	   diagram	   depicts	   the	   intracellular	   localisation	   	   of	   the	   	   antisense	  oligonucleotides	  with	  the	  ability	  to	  cross	  the	  plasma	  membrane	  so	  as	  to	  exert	  their	  effects.  
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Figure	  5.5	  The effect of Antisense Oligonucleotides on MAdCAM-1 expression. This 
graph shows the inhibition of MAdCAM-1 expression by various antisense oligonucleotides 
with a scrambled antisense oligonucleotide included as a control. The experiments were 
performed on 6 occasions. The only oligonucleotides to show significant inhibition of 
MAdCAM-1 expression were AS1 2ug (p<0.05) and AS4 2ug (p<0.005), with 2ug AS3 nearer 
the limit of significance at p<0.06. The other concentrations of the same oligonucleotides, both 
concentrations of AS2 and the scrambled antisense oligonucleotides showed no major inhibitory 
activity. 
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5.6	   	   	  Discussion	  
 
At the time of our initial observations this was the first study to report the effects of 
antisense on MAdCAM-1. We designed and tested antisense molecules in an in vitro 
setting, assessed effective penetration and efficacy at modulating the expression of 
MAdCAM-1. 
 
We have seen that in order to maintain activity, antisense oligonucleotides should 
ideally be delivered to the nuclei of cells. The apparent lack of effect of some antisense 
oligonucleotides may be explained by poor distribution within cells. Specifically, we 
found the successful uptake and intracellular localisation of our antisense 
oligonucleotides targeted to MAdCAM-1 (Antisense 1, 2, 3, 4) within endothelial cells 
i.e. the ability of these antisense oligonucleotides to negotiate the plasma membrane of 
these appeared to be effective. It is widely accepted that most cell types efficiently 
exclude oligonucleotides in vitro and require specific delivery systems, such as cationic 
lipids, to enhance uptake and subsequent antisense effects. One of the fundamental 
problems associated with antisense technology is that of delivery of oligonucleotides 
into the intracellular compartments of intact cells in vitro. Uptake generally proceeds by 
incorporation of exogenously applied antisense effectors into endocytotic vesicles. The 
ideal Anti-S agent should therefore maintain stability and cellular penetration whilst 
retaining hybridizing capabilities. We hypothesised that observed biological effects in 
our antisense experiments had been as a result of antisense effects or non–sequence 
specific effects.  
 
Phosphorothioated oligonucleotides were utilised due to their stability in cells and 
tissues. Specifically, this involves the substitution of sulphur for a non-bridging oxygen 
(at each phosphorus in the oligonucleotide chain), which retains the charge and 
solubility of the phosphodiester oligomer, as well as its crucial ability to hybridise with 
target mRNAs but is much more resistant to degradation by intracellular nucleases.   
 
Very high concentrations (usually ≥ 20 µM) of naked oligonucleotides have been 
reported to be required for “antisense” efficacy i.e. without carrier. At such high 
concentrations, tremendous non–sequence specific activity will be seen at least in part 
because of the adsorption of the oligonucleotides to cell-surface heparin-binding 
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proteins. Therefore, the delivery of such naked oligonucleotides should be avoided and 
any putative evidence for antisense effects obtained in this manner is thought to be 
highly suspect. Oligonucleotides may be delivered instead using any one of a number of 
commercially available carriers, including the cationic lipids, Lipofectin, Lipofectamine 
2000 (both, Life Technologies Inc., Grand Island, New York, USA), and Cytofectin 
(Glen Research, Herndon, Virginia, USA), as well as polyamines. Surprisingly, we 
found there was little effect of lipofectamine on the delivery of antisense 
oligonucleotides into our cells. 
 
I explored the effect of appropriate controls using endothelial cell lines stimulated with 
TNFα peptides. These are capable of binding TNF-alpha under physiological conditions 
and can include but are not limited to portions of TNF-alpha receptor and/or portions or 
structural analogs of anti-TNF antibody antigen binding regions or variable regions.  I 
found no significant effect on endothelial cell stimulation with TNF-alpha peptides.  
 
I further explored the effect of antisense oligonucleotides on MAdCAM-1 expression. 
After performing the experiments on six occasions and using different antisense 
oligonucleotides (including scrambled controls) our study showed a reduction in 
fluorescence using AS1–AS4 (figure 5.5). Specifically, there were significant 
differences on MAdCAM-1 expression between the various antisense oligonucleotides 
and their concentrations. In particular, the only oligonucleotides to show significant 
inhibition of MAdCAM-1 expression were AS1 2ug (p<0.05) and AS4 2ug (p<0.005) 
with 2ug AS3 nearer the limit of significance at p<0.06. The other concentrations of the 
same oligonucleotides, both concentrations of AS2 and the scrambled antisense 
oligonucleotides showed no major inhibitory activity. I found the greatest MAdCAM-1 
inhibition was obtained with relatively low dose antisense concentrations.  This 
intriguing observation is different to our expected outcome from higher concentrations 
leading to increased efficacy of antisense products.   
Since my original novel observations (Ala et al 2003), Goto et al  (2006) reported in 
vivo antisense therapy using mouse MAdCAM-1 targeting the translational initiation 
codon. Unlike my own experiments utilising the more representative endothelial cell 
line SVEC4-10 cells, these authors used b.End.3 cells stimulated with TNFα. Among 
the 5 oligonucleotides tested, including the control, MAd 19 reproducibly demonstrated 
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the strongest inhibitory effect on TNFα induced MACAM-1 expression, which reached 
an average of only 17.3% of MAdCAM-1 expression with MAdCAM-1 in 3 
independent experiments, compared to our experiments showing relatively higher levels 
of TNFα inhibition with levels of MAdCAM-1 varying from 24% to 39%.  These 
authors chose  MAd 19 for further evaluation of its efficacy in vivo and went on to 
inject  antisense MAdCAM-1 oligonucleotides into mice at 1.5 mg/kg/day for seven  
consecutive days from the first day of a trinitrobenzene sulfonate(TNBS) enema. 
MAdCAM-1 antisense oligonucleotides significantly suppressed the development of 
TNBS colitis clinically and histopathologically compared with controls. 
Immunohistochemistry and semi quantitative reverse-transcription polymerase chain 
reaction of the colon tissues revealed that MAdCAM-1 protein and mRNA expression 
were lower in antisense-treated mice than in controls. MAdCAM-1 antisense treatment 
reduced the number of α4β7+ lymphocytes in the inflamed colonic mucosa suggesting 
that antisense suppression of MAdCAM-1 can attenuate recruitment of lymphocytes 
bearing α4β7+  integrin to the inflamed colon. The accumulation level of FITC-
labelled oligonucleotides found in the colon from TNBS-treated mice was higher than 
that from normal mice, indicating that inflammation appeared to promote the 
accumulation of oligonucleotides in the colon.  
These results fit with the studies on ICAM-1 by Bennett et al  (1997) and others,   
supporting  the use antisense therapy for IBD (Rijcken et al 2002). Taken together, 
these results are compatible with those of previous studies using an anti-MAdCAM-1 
(Kato et al 2000) or anti-α4-specific antibody in experimental colitis (Lee et al 2005).  
It is possible since our own set of antisense oligonucleotides achieved higher levels of 
antisense modulation than those used by Goto et al (2006). 
I have demonstrated that administration of antisense oligonucleotides can inhibit 
MAdCAM-1 in SVEC4-10 cells,  with the ability to significantly suppress its 
expression in the inflamed gut at both mRNA and protein levels, allowing simultaneous 
suppression in the development of wasting disease and histological inflammation in 
TNBS-induced colitis. There exists at least 2 levels of possible silencing effects of 
antisense oligonucleotides either at the transcriptional or posttranscriptional level; the 
former targets the AUG translation initiation codon, thereby interrupting ribosome 
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activity by masking the ribosome recognition site of MAdCAM-1; the latter is RNase H 
activation, which degrades the RNA strand of an RNA-DNA heteroduplex. 
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6.1	  	   	   Role	  and	  expression	  of	  MAdCAM-­1	  in	  tissues	  
 
Following the initial description of MAdCAM-1 by Briskin et al in 1993, there have 
been relatively few articles published related to the subject, compared with other 
adhesion molecules such as VCAM-1 and ICAM-1. This is probably due to the 
expression of MAdCAM-1 being apparently limited to relatively fewer tissues, paucity 
of in vitro systems in which to study MAdCAM-1 and the apparent lack of evidence 
implicating MAdCAM-1 with any disease process other than IBD.  
 
The work in this thesis has characterised MAdCAM-1 expression in tissues and cell 
culture systems. The data presented here confirms the expression of MAdCAM-1 using 
a variety of techniques developed in our laboratory including immunohistochemical 
methods, cytofluorometry, RT-PCR and quantitative real-time RT-PCR technology. 
Using these techniques, I confirmed the presence of MAdCAM-1 and quantified its 
expression in mouse cell lines (SVEC4-10) and tissues from both murine and humans.  I 
developed a reproducible in vitro model which was used to study factors governing 
MAdCAM-1 expression. In particular, using this system I explored the concept of 
modulating MAdCAM-1 expression by a variety of agents including anti-sense 
oligonucleotides targeted to mouse MAdCAM-1. I showed using 
immunohistochemistry that MAdCAM-1 is absent in the normal human liver and 
upregulated in end stage chronic liver disease, where it immuno-localises mainly to the 
peribiliary plexus and lymphoid aggregates. However, using Real Time PCR analysis I 
found evidence apparently contradicting these initial set of observations. Specifically, I 
found MAdCAM-1 to be  present constitutively in normal human liver, albeit in 
relatively small quantities and  upregulated in end stage liver disease. In the setting of 
IBD, I confirmed MAdCAM-1 expression and upregulation in active disease from 
paraffin fixed tissues and further extended this observation to show its localisation 
within the transmural wall in chronic Crohn’s disease, an observation later validated by 
Arihiro et al 2002, using monoclonal antibodies. 
 
The expression and upregulation of MAdCAM-1 on chronically inflamed endothelia 
especially high endothelial venules, is consistent with the hypothesis that MAdCAM-1 
has a key role in recruitment of lymphocytes during inflammatory processes. In addition 
to the expression of MAdCAM-1 on vascular endothelium MAdCAM-1 was also 
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detected on immune cells with the morphology of dendritic cells. Having performed 
double staining techniques we  found focal staining  with S100, CD68 and CD21 but 
these  did not correspond to the pattern seen for MAdCAM-1. Expression of 
MAdCAM-1 has been reported on the dendritic processes within human Payer’s patches 
(Briskin et al 1997). Such hepatic expression could serve as a signal for retention α4β7 
lymphocytes in the liver. It is interesting to note that isolated follicular dendritic cells 
have been reported to express VCAM-1 and could present an antigen clustering with 
α4β1 and LFA-1 expressing B cells, leading to maturation and differentiation of B cells 
into memory cells (Freedman 1990). Thus, if MAdCAM-1 is expressed on dendritic 
cells with in the liver then it might have the same function but ultimately may play a 
broader role than just acting as an addressin in chronic liver disease. 
 
We found the distinct absence of MAdCAM-1 on the hepatocytes of all the liver tissues 
we examined. This contrasts with the findings of Grant et al (2001) where in some 
samples there was weak MAdCAM-1 immunoreactivity localised to the hepatocyte 
cytoplasm. However, MAdCAM-1   has been demonstrated to be integral in the 
progression of Type 1 diabetes mellitus in the NOD mouse, having also shown to be 
expressed not only on the endothelia but also epithelial cells of the choroid plexus in 
chronic relapsing experimental autoimmune encephalomyelitis (Faveeuw et al 1994) 
(Steffen et al 1996) which supports lymphocyte adhesion. We can postulate that in the 
observations by Grant et al that hepatocyte MAdCAM-1 may also have this role. There 
are no published studies reporting the expression of MAdCAM-1 on hepatocytes. It is 
also plausible that since hepatocytes take up molecules by pinocytosis and endocytosis 
and can engulf other cell types, so MAdCAM-1 within the hepatocyte might be a 
reflection of uptake and degradation of protein produced from other cells.  
 
Our original hypothesis was that MAdCAM-1 acts as a local addressin at different sites 
using the vessel endothelium e.g. PBP, HEV crucial for lymphocyte egress and effective 
in re-circulatory pathways to areas of inflammation, such as those around bile ducts and 
lamina propria which I have described in Chapter 2. The possibility that this egress 
occurs in capillaries is interesting because this lymphocyte-endothelium interaction 
could occur in low velocity flow states. In agreement with previous studies Hillan et al 
(1999) using polyclonal antibodies and Grant et al (2001) using monoclonal antibodies 
we detected MAdCAM-1 in a variety of liver disease associated with IBD e.g. PSC, as 
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well as in non IBD associated liver disease (HCV, ALD, PBC), although in normal liver 
MAdCAM-1 was undetectable by immunostaining which contrasted with its significant 
RNA expression in end stage liver disease, not just limited to PSC. The real time PCR 
protocol with the appropriate samples allowed us to show for the first time a trend that 
MAdCAM-1 mRNA is upregulated in human cirrhotic livers. Sequence analysis of 
cDNA from a normal liver revealed complete alignment with the MAdCAM-1 gene 
sequence thus validating the presence of MAdCAM-1. Constitutive mouse MAdCAM-1 
was present in normal liver although this was at a relatively lower level. Despite the 
strong data from increased mRNA in human and mouse tissue work and the 
immunohistochemical data from human MAdCAM-1 we were disappointingly 
unsuccessful in detecting MAdCAM-1 protein in Western blot studies of stimulated 
SVEC4-10 cells, even when reversing the monoclonal with polyclonal anti-MAdCAM-
1 during the immunoprecipitation phase of the experiments or  using alternative 
SVEC4-10 cells  from The Alexander Group (Oshima et al 2001).  
 
It is interesting to note from chapter 4 that the GCSF treated patient from paracetamol 
induced fulminant liver failure was associated with the highest recorded MAdCAM-1. 
The effect of MAdCAM-1 was unlikely to be secondary to acute liver failure shown by 
the absence of MAdCAM-1 in earlier stages and grades of liver diseases. Clearly more 
samples are required to make a satisfactory statistical conclusion. We can hypothesize 
that GCSF leads to TNFα which may induce expression of MAdCAM-1. Our 
established in vitro model in future studies is well placed to test this hypothesis  
 
6.2	  	   	   Other	  observations	  on	  MAdCAM-­1	  
 
Since our earlier observations describing the expression of MAdCAM-1 on SVEC4-10 
cells, there have been further reports confirming our findings and exploring other cell 
lines linked with MAdCAM-1 expression (Ando et al 2005). These groups have studied 
colon microvascular endothelium cell line MJC-1. This technique has involved cloning 
microvascular endothelial cells from primary colon cultures using ImmortoMice whose 
cells express a temperature-sensitive SV40 large T antigen, H-2Kb-tsA58 mice. They 
found that in vitro MAdCAM-1 can be induced on colon endothelial cells by TNFα 
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stimulation and may represent a useful model to study microvascular injury in the 
murine large intestine.  
 
It is off interest to note that the MAdCAM-1 gene and its protein expression has also 
been shown to be expressed in primary cultures of human intestinal microvascular 
endothelial cells (HIMEC) which have not previously been demonstrated in human 
umbilical vein endothelial cells. Similar to ICAM-1 and E-selectin expression, 
MAdCAM-1 gene expression in HIMEC is upregulated by inflammatory cytokines e.g. 
TNF-α, IL-1, or LPS activation. However, in contrast to ICAM-1 or E-selectin 
expression, MAdCAM-1 mRNA and protein expression in HIMEC is dependent on 
culture duration and/or cellular density. This suggests a prominent role for cell-cell 
interaction among these endothelial cells on the surface expression of MAdCAM-1. In 
the studies by Ogawa et al (2005), MAdCAM-1 expression is dependent on NF-kappa 
B activation which is similar to the regulated expression of ICAM-1 and E-selectin. 
However, unlike the expression of these ubiquitous endothelial cell adhesion molecules, 
MAdCAM-1 expression is also dependant on PI3-K/Akt signaling and the degree of 
activation of this signaling pathway is directly linked to endothelial cell-cell contact. 
These data suggest that PI3-K/Akt is involved in the gut-specific differentiation of 
HIMEC, which contributes to the expression of MAdCAM-1. Thus, density-dependant 
activation appears to reflect a PI3-K mediated Akt activation, which is maximal at 
higher cell densities and therefore related to particular phases of inflammation, with 
relatively higher levels of MAdCAM-1 in the chronic inflammatory state which is 
typical of IBD. 
 
Therefore, the ability of MAdCAM-1 to be induced by inflammatory stimuli is 
increased by cell-cell contact and may be reciprocally regulated compared to other 
endothelial adhesion molecules. There are several possible implications of such 
regulation suggesting that the differentiation of gut specific endothelial cells is governed 
by different factors. Firstly, there may be repeated cycles of angiogenesis accompanying 
the extensive intestinal tissue remodeling during inflammation. Secondly, adhesion 
molecule expression as a characteristic of culture differentiation is controlled not only 
by the number, but also the type of cell-cell junctional contacts which are proportional 
to cell densities. These factors control cytoplasmic second messages and affect cell 
responses to cellular signaling. The demonstration of MAdCAM-1 in isolated human 
181 
 
microvascular endothelial cells has previously been limited. It is possible that the 
factors responsible for prolonged culture duration and increased cell densities in 
HIMEC monolayers necessary for the demonstration of MAdCAM-1 gene and protein 
expression may be have been partly responsible for the previous challenges in its 
detection. 
 
Particular variants of MAdCAM-1 gene transcription may affect structure and 
expression of the MAdCAM-1 protein. A number of single nucleotide polymorphisms 
(SNP’s) have recently been described in the human MAdCAM-1 gene (Bowlus et al 
2006). Reports on the analysis of SNP’s in PSC patients compared to ulcerative colitis 
with healthy controls were published exploring the frequency of polymorphisms in 
MAdCAM-1 and ICAM-1 variants. There was no difference found  in the frequency of 
seven alleles between any of these groups,  concluding that neither the specific variants 
of ICAM-1 e.g. G241R nor the K469E, play a role in PSC development suggesting that 
the lack of polymorphism within this gene is associated with these two diseases.  
 
It has been hypothesised that MAdCAM-1 contributes to the recruitment of donor T 
cells into the mucosal tissues of recipients after allogeneic hematopoietic stem cell 
transplantation (aHSCT). Supporting this hypothesis was an important study 
demonstrating the relationship between selected SNPs of the MAdCAM-1 gene and the 
development of serious complications following aHSCT (Ambruzova Z et al 2009). 
Specifically, three MAdCAM1 gene single nucleotide polymorphisms (rs758502 C/T, 
rs2302217 A/G, rs3745925 G/T) were genotyped by polymerase chain reaction in 
Czech HLA-identical donor-recipient aHSCT pairs. Specifically, MAdCAM-1 
rs2302217 AA homozygous recipients developed chronic GVHD more frequently than 
patients with other genotypes These workers went onto demonstrate that MAdCAM-1 
rs2302217 AA genotype in recipients was not only an independent factor associated 
with the development of acute Graft Versus Host Disease (GVHD) but also decreased 
overall survival, suggesting that MAdCAM-1 gene polymorphisms may be associated 
with the risk of developing chronic GVHD and thereby affecting  mortality related to 
aHSCT. 
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6.3	   	   Detection	  of	  MAdCAM-­1	  expression	  in	  fluids	  	  
 
Circulating soluble forms of cell adhesion molecules including ICAM-1 and VCAM-1 
have been shown to be elevated in inflammatory, infectious and malignant diseases. 
Levels of these soluble cellular adhesion molecules reflect cellular expression and have 
been shown to correlate with disease activity and may provide useful markers to 
monitor and confirm the results of therapy.  
 
Leung et al (2004) developed the first ELISA model for soluble MAdCAM-1 in body 
fluids.  The group demonstrated the presence of MAdCAM-1 in the serum and urine of 
healthy individuals, at similar levels to ICAM-1 and VCAM-1. As we have discussed in 
chapter 1 some soluble cellular adhesion molecules are thought to be released from the 
cell-surface by proteolytic cleavage, whilst others are secreted as alternatively spliced 
forms lacking a transmembrane domain,  or even anchored to the cell surface by a 
glycosyl-phosphatidyl-inositol protein and which could be released by phosphatidyl-
inositol-specific phospholipase C.  
 
6.4	   	   Potential	  of	  imaging	  MAdCAM-­1	  expression	  in	  
inflammation	  
 
Targeting MAdCAM-1 so as to non-invasively image Crohn’s ileitis underlies its 
importance in diagnosing and monitoring disease activity. Using a novel intravascular 
ultrasound contrast agent targeting MAdCAM-1 in experimental small bowel 
inflammation, there is potential not only for the detection but quantification of intestinal 
inflammation. An image-enhancing ultrasound (US) contrast agent, consisting of 
encapsulated gaseous microbubbles (MB) was developed specifically to bind mucosal 
MAdCAM-1 (Bachmann et al 2006). MAdCAM-1-targeted MB were tested for binding 
specificity on MAdCAM-1 protein and TNFα stimulated SVEC4-10 endothelial cells 
using a combination of  (i) in vitro flow chamber assay, for their ability to detect and 
quantify ileitis by intravital microscopy and (ii) trans-abdominal ultrasound. 
Specifically, the authors used conjugated rat anti-mouse antibodies detecting 
MAdCAM-1 to the external surface of lipid-shelled MB to produce a targeted contrast 
agent for use with ultrasound to detect experimental ileitis. Therefore, the targeted 
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imaging strategy presented here forms the basis of pursuing similar technologies that 
have the potential to provide a cost-effective, non-invasive means to improve the 
diagnosis, clinical care, and management of patients with IBD. 
 
6.5	   	   MAdCAM-­1	  as	  a	  therapeutic	  target	  
 
MAdCAM-1 remains an important target to modulate and different strategies have been 
described which are capable of modulating its expression. It still remains to be shown 
whether the effect of modulation can be translated effectively and efficiently for clear 
therapeutic benefit. As the pathways in controlling the expression of MAdCAM-1 
become better characterised future strategies will clearly need to be developed to focus 
on new therapeutic targets.   
 
6.5.1	   	   Modulating	  MAdCAM-­1	  and	  α4β7	  axis.	  
 
The ability to modulate adhesion molecule expression by means of monoclonal 
antibodies may have potential for therapeutic benefit. The results of a placebo-
controlled study assessing the effects of monoclonal antibodies against α4 integrin e.g. 
Natalizumab (Biogen Idec), in patients with mild to moderately active Crohn’s disease 
demonstrated that the reduction in Crohn’s disease activity index, and the proportion of 
patients achieving remission at week two, was significantly higher in patients receiving 
Natalizumab than in those treated with placebo (Ghosh S et al 2003). In a pilot study, 
administration of Natalizumab resulted in clinical improvement in 6 out of 10 treated 
patients with active ulcerative colitis (Gordon F et al 2002). Since Natalizumab is an 
anti-α4 (95% human–derived) monoclonal antibody, it blocks both α4β7 and α4β1 
integrins and in the process, therefore all VCAM-1 and MAdCAM-1 mediated 
leukocyte-endothelial cell interactions.  
 
Natalizumab was initially approved in 2004, for induction and maintenance of moderate 
to severe Crohn’s disease, but later on it was withdrawn from the market after three 
patients developed progressive multifocal leukoencephalopathy (Targan et al 2007, Van 
Assche et al 2005). This is a consequence of defective immune surveillance of the 
central nervous system (CNS) because α4β1 is required for T cell trafficking to the 
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CNS. Natalizumab has returned to the   market in the United States, where it is used for 
the treatment of patients with Crohn’s disease. 
 
A limitation in interpreting negative findings with monoclonal antibodies is the 
uncertainty regarding whether blocking doses are actually achieved in vivo. Target 
levels are generally based on the minimum concentration required to achieve maximal 
inhibition of leukocyte adhesion in vitro. Experience gained from open-labelled clinical 
trials indicates that blocking doses are more difficult to achieve in vivo than those 
predicted from in vitro leukocyte binding assays. Another potential limitation of 
prolonged monoclonal antibodies usage, at least in chronic models of inflammation, is 
immunogenicity. This limitation has fostered the search for alternative approaches to 
block adhesion molecule function. 
 
MLN-02 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody which blocks 
α4β7-integrin/MAdCAM-1 interaction and selectively inhibits leukocyte adhesion in the 
gastrointestinal mucosa. Fc receptor recognition and binding has been detected, thus 
eliminating complement fixation and cytokine release. In a randomised placebo 
controlled trial in 185 patients with mild to moderately active Crohn's disease treated 
with placebo, MLN-02 led to remission significantly more than placebo (Fegan et al 
2008) as was the case in patients with ulcerative colitis. In both studies, apart from one 
patient with infusion reaction and angioedema, no significant adverse events were 
noted. MLN-02 appears to be an effective therapy especially for active ulcerative colitis, 
but further trials are warranted to confirm the efficacy of MLN-02 therapy for IBD.  
 
It would be interesting to study the effect of antibodies affecting the MAdCAM-1/α4β 
described in the clinical studies e.g. Natalizumab, first generation anti-MAdCAM-1 
antibodies (MECA-367), PF-00547659 in our own in vitro model. Specifically,  we will 
study if the effects of modulation are functionally active.  
 
Using adhesion assays, the Adams laboraratory  (Miles et al 2007) have studied effects 
of blocking antibodies against the α4-, β7-, and β1-integrin subunits and L-selectin (for 
adhesion to MAdCAM-1 only), or an isotype-matched control antibody. In a series of 
antibody experiments targeted against the MAdCAM-1/α4β7, they found blockade of 
lymphocyte L-selectin had no significant effect on rolling or static adhesion on 
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MAdCAM-1 because the recombinant MAdCAM-1 was not glycosylated and therefore 
lacked L-selectin ligands. This allowed further  study of integrin-mediated adhesion 
without any specific interference from L-selectin. Blockade of α4-integrin completely 
abolished rolling and reduced static adhesion on MAdCAM-1. On the other hand, 
treatment with β7 antibodies  reduced rolling and static adhesion to minimal levels, 
whereas antibody blockade of β1-integrin had no effect on either rolling or static 
adhesion. In contrast, antibody blockade of lymphocyte α4-integrin abolished rolling on 
VCAM-1 and reduced static adhesion, whereas anti-β7-integrin had no significant effect 
on rolling or static adhesion. Blockade of the β1-integrin subunit significantly reduced 
both rolling and static adhesion on VCAM-1. Adhesion to immobilized MAdCAM-1 
was therefore α4β7 dependent, without contribution from α4β1, whereas α4β1 mediated 
rolling and static adhesion on VCAM-1.  
 
6.5.2	   	   Modulating	  MAdCAM-­1	  using	  Anti-­MAdCAM-­1	  antibodies	  
 
First generation rat anti-mouse MAdCAM-1 monoclonal antibodies e.g. MECA-367 
have unfortunately not been found to be therapeutically beneficial in human patients. 
MECA-367 binds mouse MAdCAM-1 but does not show significant affinity for the 
human MAdCAM-1 molecule. In addition to being a rat antibody it leads to an immune 
response in human patients and therefore may not be suitable for therapeutic 
intervention. Mouse monoclonal antibodies, directed against human MAdCAM-1 have 
been described (WO 96/24673) but these are also likely to be immunogenic in humans.  
 
Recently, therapeutically useful fully human anti-human MAdCAM-1 antibodies with 
specificity and affinity to human and primate MAdCAM-1 have been developed e.g. 
WO2005/067620. An inhibitor of the interaction between MAdCAM-1 and α4β7 integrin 
such as a blocking anti-MAdCAM-1 antibody, or an antibody to α4β7 integrin (MLN02, 
which is humanised Act-1, described in WO 01/078779) has been postulated to be 
useful in the treatment of IBD. However, it has now been found that inhibitors of this 
interaction including blocking antibodies to MAdCAM-1 are also useful in the 
treatment of coeliac disease and tropical sprue. Currently the use of anti-MAdCAM-1 
antibodies for the treatment of coeliac disease and tropical sprue are currently being 
explored. 
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PF-00547,659 is the first highly specific,  fully human blocking anti-MAdCAM-1 IgG2 
monoclonal antibody from Pfizer which has recently been described, identified and 
fully characterised in Phase 1 multicentre trials to study the induction and maintenance 
of remission of ulcerative colitis and Crohn’s disease (Pullen et al 2009)  (Vermeire et 
al 2009). It selectively binds to MAdCAM-1 and reduces homing of specific lineages of 
leukocytes to the gastrointestinal tract without impairing normal CNS immune 
surveillance. The study results show that single and multiple doses of PF-00547659 
were safe and well tolerated with no evidence of immunogenicity.  Thus, this reagent it 
has been suggested represents a better therapeutic approach for treatment of IBD than 
other available antibodies. Specifically, in vitro studies using functional assays by 
Pullen et al (2009) demonstrate PF-00547659 blocks the binding of MAdCAM-1 
expressing cells to lymphocyte Peyer's patch adhesion molecule integrin α4β7 (LPAM)  
and is highly  specific for cynomolgus and human MAdCAM-1 over other homologous 
cell adhesion molecules. A blocking rat anti-mouse MAdCAM mAb MECA-367 was 
also used in these in vitro experiments the role of MAdCAM in inflammatory processes. 
While there are currently no defined criteria to approve surrogate antibodies for use in 
safety testing, in vitro and in vivo pharmacological evaluation of MECA-367 to 
determine its suitability as a surrogate antibody to support the clinical development of 
PF-00547659.  
 
6.5.3	   	   Modulating	  MAdCAM-­1	  protein	  synthesis:	  applications	  of	  
oligonucleotides-­silencing	  MAdCAM-­1	  RNA	  	  
 
The modulation of the MAdCAM-1/α4β7 axis has received an enormous degree of 
interest due to its possible beneficial effects on gut and liver tissue inflammation.  I 
have shown that the expression of MAdCAM-1 in vitro can be subject to modulation by 
different agents including for the first time antisense oligonucleotides. Unfortunately, 
unpredictable interactions, toxicity and variability in silencing different target genes 
coupled with poor in vivo stability have been major drawbacks in their use as 
therapeutic agents thus far. Considerable progress however has been achieved in the 
clinical application of antisense technology. First generation Anti-S has advanced 
logically to Phase III trials in the treatment of gastrointestinal disease such as colorectal 
malignancy and IBD (van Deventer et al 2004). Whilst the above examples concern the 
use of blocking antibodies, the use of such agents, particularly on repeated occasions, as 
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we have seen has potential disadvantages associated with sensitisation to foreign 
proteins (even with extensively humanised antibodies) or the development of anti-
idiotype responses.  An alternative strategy is the prevention of the synthesis of 
endogenous proteins, which can be specifically achieved by the use of antisense RNA 
oligonucleotides. Certainly, the use of antisense oligonucleotides over in mild to 
moderately active distal ulcerative colitis, antisense inhibitor of ICAM-1 in enema 
formulation has been found to be safe and efficacious at 1,3 and 6 months following 
administration (van Deventer et al 2004). Improved antisense chemistry with second 
generation Anti-S will enhance the utilisation of antisense drugs offering the potential 
of less frequent dosing although still at the detriment of the expense of Anti-S. Careful 
assessment of future controlled studies is needed to confirm antisense mediated down 
regulation of the target proteins in a larger number of patients. A sound proof of 
principle is virtually impossible in a clinical trial because of the limitations posed by the 
lack of future controls. The potential of antisense technology depends on the design of 
multiple drugs based on our increasing knowledge of genes implicated in disease 
pathogenesis. 
 
There are other alternatives to oligonucleotides as therapy. They include silencing RNA 
(siRNA), immune modulators, and triple helix oligonucleotides.  It is possible that the 
relatively new area of RNA interference may offer better ways of silencing genes 
involved in pathogenic processes. It appears to be a more promising system than 
knockout mice because groups of genes can be simultaneously rendered ineffective.  
 
Although RNAi strategies are reliant on a high degree of specificity there are some, 
potential non-specific effects as siRNA’s may have broad and complicated effects 
beyond the selective silencing of target genes when transfected into cells.  
 
 Transfection of 21-bp double stranded siRNA regularly used to induce specific gene 
silencing also result in interferon mediated activation of the Jak-STAT signalling 
pathway and up-regulation of IFN-stimulated genes. This effect is mediated by the 
dsRNA-dependant protein kinase.  
 
The transition from an in vitro setting into an appropriate animal based model has 
remained an enormous challenge, to many workers in the field of RNAi technology. Xia 
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et al (2004) appeared to have overcome this problem by using short hairpin RNA’s 
(shRNAs). These sequences are themselves processed intracellular into siRNA’s of 
approximately 21 nucleotides.  An initial assessment of the potential use of shRNAs 
may be studied using appropriate cell culture techniques. This highlights the need to test 
many RNAi-mediating molecules in vitro so as to assess efficacy and specificity of 
RNAi. These workers studied RNA interference in the fatal brain related 
neurodegenerative condition spinocerebellar ataxia type 1 (SCA1).  In this model mice 
express a mutant SCA1 transcript in the Purkinje cells of the cerebellum and which may 
be the target of choice by RNAi. The SCA1 gene encodes a mutant ataxin-1 protein 
containing an expanded poly-glutamine repeats. An RNAi approach may offer an 
advantage by reducing gene expression. Thus, the neurotoxic effect of the mutant 
protein may therefore be restricted whilst allowing sufficient wild-type protein to 
remain for normal functioning. In this study the authors chose an AAV (adeno-
associated virus) vector because of its ability to efficiently transfect a broad range of 
cell types (particularly neurons) and express transgenes over a sustained period.  
 
Modifications to siRNA may be introduced to prolong stability in vivo as has been 
shown from observations where siRNA may be targeted to conserved sites in the 
hepatitis B virus (HBV).  
 
The transformation of siRNAs from a functional genomic tool into a new therapeutic 
modality could be assisted by effective systems for systemic administration. I postulate 
that further work on siRNA directed against MAdCAM-1 could be used to explore the 
modulation of MAdCAM-1 in this respect. Overall,  a total of 14 RNAi therapeutic 
programs have entered clinical trials in the last decade involving local/topical  delivery 
to the eye, respiratory tract and skin. No data have emerged to suggest serious adverse 
events linked to siRNA. The conduct of large phase 3 studies using siRNA  is awaited.  
6.5.4	   	   Chemokines	  and	  emerging	  relationships	  with	  MAdCAM-­1	  
and	  its	  modulation	  	  
 
Chemokines trigger α4β7and α4β1 integrin mediated adhesion to VCAM-1 and 
MAdCAM-1 through emerging pathways, a number of such critical pathways which 
have been recently identified. Specifically, the immobilised CC-chemokine ligand 
CCL25 and CCL28 are both been found to trigger α4β7 dependent lymphocyte arrest 
189 
 
on MAdCAM-1 under shear, highlighting a potential role for these chemokines in the 
arrest of lymphocytes on gut postcapillary venules. Furthermore, immobilised CCL21 
and CXC-chemokine ligand (CXCL) 12 convert rolling cell adhesion to static arrest on 
MAdCAM-1 by activating lymphocyte integrins. Thus, the α4β1/VCAM-1 and 
α4β7/MAdCAM-1 operate independently to support lymphocyte adhesion and flow. 
Chemokines which may act in concert with one set of chemokines triggering integrin-
mediated arrest and a second set of chemokine promoting motility and transendothelial 
migration. The receptor for CCL28 is CCR10; its presence on IgA secreting B cells in 
the small and large intestine is crucial and underlies the importance of CCL28 in B cell 
localisation to these sites.  
 
Another important related chemokine CXCL13 is expressed on a substantial proportion 
of HEV’s in lymph nodes and Peyer’s patches (Kanemitsu et al 2005). CXCL13 
induces B-cell adhesion to MAdCAM-1 by activating GTPase critically involved in 
α4β7 so supporting its role as an arrest chemokine for B cells in HEV’s and confirms its 
important role in B-cell entry into Peyer’s Patches as well as MLN’s. 
 
I have described earlier the effective role of chemokines CCL21 (lymph node 
associated) and CCL25 (gut-associated) as important factors responsible for activation 
of lymphocyte adhesion to MAdCAM-1 and recruiting lymphocytes. Studies by Grant 
et al (2002) show the expression of chemokine CCL25 (thymus-expressed chemokine -
TECK) to be also localised in PSC liver sinusoidal endothelium but absent in the liver 
in autoimmune hepatitis and primary biliary cirrhosis. A significant population of 
CCR9+ mucosal lymphocytes (i.e. the ligand for CCL25) has been detected infiltrating 
PSC liver tissue compared with controls and matched peripheral blood supporting the 
hypothesis of a T cell enterohepatic recirculation. The CCR9 lymphocytes also co-
express the gut homing integrin α4β7.  Therefore, CCL25 recruits CCR9+ lymphocytes 
to the liver in PSC by triggering adhesion to MAdCAM-1 and CCL25 which are 
upregulated in the liver in inflammatory liver diseases whereas previously they were 
thought to be restricted to the gut.  
 
Emerging data from the Adams laboratory suggests that in addition to its specific role 
for CCL25 in PSC, CCL21 is also involved in the critical recruitment of T lymphocytes 
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into the portal tract. Specifically CCL21 or secondary lymphoid chemokine is noted for 
its strong up regulation on CD34(+) vascular endothelium in PSC portal associated 
lymphoid tissue. In contrast CCL21 is absent from LYVE-1(+) lymphatic vessel 
endothelium. The expression of CCL21 in association with MAdCAM-1 portal tracts in 
PSC may promote the recruitment and retention of CCR7(+) mucosal lymphocytes, 
leading to the establishment of chronic portal inflammation and the expanded portal-
associated lymphoid tissue. This study provides further evidence for the existence of 
portal-associated lymphoid tissue and provides novel findings demonstrating ectopic 
CCL21 is associated with lymphoid neogenesis in human inflammatory disease. 
 
Interesting therapeutic studies in the SAMp/Yit mice where targeting CCL25 or CCR9 
have shown that this receptor/ligand is important during the early stages of induction of 
spontaneous chronic murine ileitis but not in late disease suggesting that in the late 
stage the recruitment process is less dependent on this chemokine/receptor pair (Rivera-
Nieves et al 2006). To this effect TRAFICET-EN, an orally active pharmaceutical 
CCR9 inhibitor is currently being assessed for the treatment of Crohns disease (Eksteen 
et al 2010). 
 
	  6.5.5	   	   VAP	  and	  its	  emerging	  relationship	  in	  the	  expression	  
MAdCAM-­1	  	  
 
It is clear from our in vitro experiments that TNFα is pivotal in the initiation of 
MAdCAM-1. This has of course been effectively translated by the commercial use of 
anti-TNFα antibody which successfully reduces colonic injury and expression of 
adhesion molecules in IBD. Although VAP-1 is only expressed at low concentrations 
within vessels in the non-inflamed gut, it like MAdCAM-1 is upregulated in active IBD 
(Kurkiijarvi et al 1998) (Salmi et al 1993). Unlike MAdCAM-1 the factors that regulate 
the induction of VAP-1 in gut mucosa have not been well characterised. It has however 
been reported that VAP-1 dependant signaling induces production of soluble E-selectin 
which activates neutrophil β2 integrin and induction of ICAM-1 and VCAM-1 (Lalor et 
al 2007) (Jalkanen et al 2007).  Increased levels of metabolic products released by 
catabolic activity of VAP-1/SSAO could curiously upregulate and induce functional 
expression of adhesion molecules such as MAdCAM-1, P-selectin and together with the 
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other adhesion molecules like properties of VAP-1 promote uncontrolled leukocyte 
recruitment in the gut mucosa in IBD. 
 
 
6.5.6	   	   Other	  MAdCAM-­1	  related	  targets	  	  
 
The importance of immunoglobulin A’s secretory role in the intestinal lumen has been 
described in Chapter 1. Pivotal to this function is the role of B-lymphocytes which 
proliferate and differentiate into IgA-secreting plasma cells within lymphoid organs and 
migrate directly into the intestinal lamina propria. Studies on MAdCAM-1-deficient 
mice have specifically explored the B-cell compartment of the GI-associated lymphoid 
tissue. These studies provide in vivo evidence of MAdCAM-1’s   critical role in the 
localisation and function of IgA-secreting plasma cells in the intestine (Schippers et al 
2009). The authors found that in MAdCAM-1 deficient mice the size of Peyer's patches 
is significantly reduced when compared with that of wild-type mice. This significant 
finding is detectable as early as three days post partum, indicating that MAdCAM-1 is 
not only critical for embryonic Peyer's patch development but also strategically 
positioned to facilitate recruitment of lymphocytes into these lymphoid organs at later 
stages (Salmi et al 2001a). 
 
It is intriguing to note that enteral feeding has also been found to affect MAdCAM-1 
expression. Complete MAdCAM-1 blockade reduces GALT lymphocytes to PN levels 
but the effect of chow feeding stimulus preserves IgA and early antibacterial resistance 
implying the existence of non-MAdCAM-1 mechanisms to preserve mucosal immunity. 
That is, chow does not eliminate mucosal immunity. Protection against an infectious 
challenge is preserved in spite of that blockade. Experimentally lack of enteral 
stimulation decreases GALT cell mass, reduces intestinal and respiratory tract IgA 
levels, and impairs established mucosal immunity to specific pathogens.  
 
These experiments quantify the effects of the route and type of nutrition on the 
magnitude and/or kinetics of MAdCAM-1 expression and the response of GALT cell 
populations to MAdCAM-1 blockade.  Current work demonstrates that lack of enteral 
feeding rapidly reduces expression of MAdCAM-1 responsible for directing cells into 
the PP, thereby resulting in lymphocyte depletion, which rapidly recovers with enteral 
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feeding. The cause and effect is confirmed by reducing GALT cell populations to the 
level of PN-fed mice by administering MECA-367 which blocks all MAdCAM-1. This 
blockade reduces GALT cell populations but IgA levels in the respiratory and GI tract 
are preserved with chow feeding. 
 
One recent study explored the interesting hypothesis that MAdCAM-1 is regulated via 
angiotensin II type 1 receptor (AT1R) (Mizushima et al 2010). The role of AT1R in the 
expression of MAdCAM-1 in SVEC and MJC-1 (a mouse colonic endothelial cell) was 
examined following cytokine stimulation. Whilst NF- B translocation was inhibited 
into the nucleus by these treatments, angiotensin receptor blockade  significantly 
suppressed MAdCAM-1 expression induced by TNF  but did not inhibit 
phosphorylation of p38 MAPK or of I B,  which has already been been shown to 
modulate MAdCAM-1 expression. These investigators went on to investigate in a 
murine colitis model induced by DSS. They  found that  the degree of colitis as judged  
by weight loss, histological damage and the disease activity index, was much milder in 
AT1R-/- than in wild-type mice and that the expression of MAdCAM-1 was also 
significantly lower in AT1R-/- than in wild type mice. These results suggest that AT1R 
regulates the expression of MAdCAM-1 under colonic inflammatory conditions through 
the regulation of the translocation of NF- B into the nucleus and inhibition of AT1R 
ameliorates colitis in a mouse colitis model. Therefore, AT1R might be one of the new 
future therapeutic targets of inhibition e.g. IBD, end stage liver disease via the 
regulation of MAdCAM-1.  
 
Mucosal vaccination has been shown to upregulate MAdCAM-1 expression. Using oral 
cholera vaccine, the endothelial expression of MAdCAM-1 is increased in the gastric 
and upper small intestinal mucosa after immunisation through the different local routes 
of administration compared to rectal immunisation (Lindholm et al 2004). Specifically 
the vaccine component cholera toxin B subunit (CTB) increased MAdCAM-1 
expression on endothelial cells in cultured human gastric explants, an effect which is 
mediated by TNFα. This strongly supports the involvement of MAdCAM-1 in the 
preferential homing of mucosal lymphocytes to their original site of activation. That is, 
the mucosal homing of antigen-specific lymphocytes after vaccination, which is 
dependent on a regionally increased expression of the addressin and TNFα mediates 
vaccine-induced MAdCAM-1 expression in the human gastrointestinal mucosa. 
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6.6	   	   Future	  work	  
	  	  
1. Functionality and further  MAdCAM-1 modulation 
We will determine functionality by using adhesion assays to observe the ability of gut 
and liver derived lymphocytes to bind to MAdCAM-1 under normal or inflammatory 
conditions. We will study the effect of GCSF and antibodies affecting the MAdCAM-
1/α4β7 system described in the clinical studies e.g. Natalizumab, first generation anti-
MAdCAM-1 antibodies(MECA-367), PF-00547659 in our in vitro model. Specifically, 
we will study if the effects of modulation are functionally active.  
 
2. Quantitation of MAdCAM-1 
The assay developed to measure MAdCAM-1 could be used to quantitiate expression in 
a variety of mouse and human tissues e.g. precirrhotic liver samples at different stage 
and grade of disease. The development of an ELISA would be useful for the 
measurement of secreted MAdCAM-1 in tissue lysate.  
 
3. Identifying the natural cleavage of MAdCAM-1 
By using single amino acid mutagenesis we can elucidate the ‘hot spot’ for MAdCAM-
1 and α4β7 interaction, which is critical in drug design. The options are small sequence 
specific molecule inhibitors, peptide inhibitors, molecular modelling e.g. docking 
studies, to determine the biological sequele of modulation. Further studies investigating 
the structural conformation of MAdCAM-1 in normal and diseased livers using site 
directed mutagenesis of the residues responsible for integrin recognition and binding 
might help to develop therapies targeting functionally active MAdCAM-1 thus 
diminuting the side effects when widely used pathways are blocked.  
 
4. Small interfering RNA 
We would like to design sequence specific siRNA targeted to mouse MAdCAM-1 and 
use our established in vitro model to assess penetration and effect of modulation. We 
will choose an adenovirus-associated virus vector to deliver siRNA into a colitis mouse 
model and study the affect of MAdCAM-1 inhibition within this system. 
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